The Transient Receptor Potential Vanilloid-1 Channel in Stress-Induced Astrocyte Migration by Ho, Karen W.
THE TRANSIENT RECEPTOR POTENTIAL VANILLOID-1 CHANNEL 
IN STRESS-INDUCED ASTROCYTE MIGRATION 
By 
Karen W. Ho 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Pharmacology 
December, 2014 
Nashville, Tennessee 
 
Approved by: 
David J. Calkins, Ph.D. 
Bruce D. Carter, Ph.D. 
Kevin Currie, Ph.D. 
Vsevolod V.  Gurevich, Ph.D. 
Rebecca M. Sappington, Ph.D. 
Gregg Stanwood, Ph.D. 
 
 
 
 
 
ii 
 
ACKNOWLEDGEMENTS 
 
Throughout this journey, there have been many people who have helped and guided me 
along the way.  I would like to thank my advisor, Dr. David Calkins for his commitment to 
training and mentoring.  His boundless energy, enthusiasm and passion for science have 
contributed to many of my successes.  I appreciate his trust and confidence in my abilities to give 
me the freedom to pursue my research interests.  The training and support I received from him 
are instrumental in my growth and development as a scientist.  I would also like to thank the 
members of my committee.  Dr. Gregg Stanwood, who chaired my committee, provided great 
help and thoughtful guidance throughout my graduate studies.  Dr. Seva Gurevich and his 
knowledge of receptor theory pushed me to consider different aspects of TRPV1 pharmacology.  
Dr. Kevin Currie and Dr. Bruce Carter asked great questions that gave me another perspective 
regarding TRPV1 function and signaling.  Dr. Rebecca Sappington taught me multiple 
techniques including primary cell isolations that became an integral part of my project.  She 
always provided great advice and knowledge regarding the visual system, glaucoma and TRPV1.   
 Additionally, I also benefited tremendously from the support from a wonderful team of 
researchers in the Calkins Lab.  I owe a great deal of gratitude to Dr. Wendi Lambert for her 
guidance and help throughout the years.  She was always willing to listen, help me troubleshoot 
techniques and brainstorm new ideas and approaches.  I am thankful for her knowledge and 
endless patience.  Dr. Carl Weitlauf provided me with a novel perspective on my project, data 
analysis and interpretation.  I also appreciate his guidance and advice on navigating the job 
market.  Brian Carlson provided a great deal of help with the animal work and making sure I had 
the reagents and supplies for my experiments.  Nick Ward is a fellow graduate student and a 
wonderful colleague.   I am fortunate to have worked with so many incredible people. 
iii 
 
 I am also grateful to the Pharmacology department for their strong training program, and 
the Pharmacology training grant for helping fund my research.  I am especially grateful to Karen 
Gieg, Joey Neil and Dr. Joey Barnett for their help and support.  Part of my training is also 
attributed to the Vanderbilt Eye Institute, and I appreciate the support from Vanessa Alderson.  I 
am also grateful to the Cell Imaging Shared Resource core at Vanderbilt, and my research has 
benefitted from their resources.     
 I am also thankful to the wonderful friends who have made my time in Nashville an 
exciting, interesting and fun one.  And lastly, I would like to thank my parents, Wing and Joanna 
Ho.  None of this would be possible without their infinite love and support.  I am forever 
grateful. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ............................................................................................................ ii 
LIST OF FIGURES ...................................................................................................................... vii 
ABBREVIATIONS ....................................................................................................................... xi 
Chapter 
I:   Background and Introduction .....................................................................................................1 
1.1 Astrocyte characterization .......................................................................................1 
1.2 Astrocyte function ....................................................................................................2 
1.3 Astrocytes in the retina and optic nerve ...................................................................8 
1.4 The astrocyte stress response .................................................................................12 
1.5 Relevance of astrocyte migration in disease ..........................................................17 
1.6 Cell migration ........................................................................................................20 
1.7 Components of cell migration ................................................................................22 
 Actin ....................................................................................................................23 
 Microtubules .......................................................................................................24 
 Intermediate filaments ........................................................................................25 
 Focal adhesions ...................................................................................................27 
1.8 Calcium signaling in astrocytes .............................................................................29 
1.9 The Transient Receptor Potential Vanilloid 1 Channel .........................................32 
1.10 TRPV1 pharmacology .........................................................................................33 
1.11 Structure and modulation of TRPV1 ...................................................................34 
1.12 TRPV1 in CNS function ......................................................................................36 
1.13 TRPV1 in the retina .............................................................................................38 
1.14 TRPV1, an intrinsic stress response protein in astrocytes ...................................39 
 Specific Aims ......................................................................................................39 
 
II: Characterization and Expression of the TRPV1 Channel in Astrocytes ...................................41 
2.1 Introduction ............................................................................................................41 
2.2 Methods..................................................................................................................46 
 Animals ...............................................................................................................46 
 Immunohistochemistry .......................................................................................47 
 Isolation of primary astrocytes ............................................................................48 
 Genotyping of TRPV1-/- animals .......................................................................49 
 Isolation of primary optic nerve astrocytes .........................................................51 
 Immunocytochemistry ........................................................................................52 
 Western blot ........................................................................................................53 
2.3 Results ....................................................................................................................53 
 Expression of TRPV channels in vivo in retinal astrocytes ................................53 
 Optic nerve astrocytes express TRPV1 in vivo ...................................................57 
 Primary cell cultures express astrocyte-specific genes .......................................60 
v 
 
 Astrocyte cultures express TRPV1 channel ........................................................65 
2.4 Discussion ..............................................................................................................70 
III: The Contribution of the TRPV1 Channel in Astrocyte Migration ..........................................75 
3.1 Introduction ............................................................................................................75 
3.2 Methods..................................................................................................................77 
 Scratch wound model of injury-induced migration ............................................77 
 Quantification of proliferation in scratch wound assay ......................................79 
 Quantification of astrocyte migration .................................................................80 
 Statistical analysis ...............................................................................................81 
3.3 Results ....................................................................................................................81 
 Proliferation in scratch wound assay is reduced with low serum conditions .....81 
 TRPV1 agonism has modest effects on astrocyte migration ..............................83 
 Effects of TRPV1 agonists on astrocyte proliferation ........................................89 
 Antagonism of TRPV1 reduces retinal astrocyte migration ...............................90 
 Effects of TRPV1 antagonists on astrocyte proliferation ...................................96 
 Genetic knockout of TRPV1 slightly reduces retinal astrocyte migration .........97 
 Chelation of extracellular calcium reduces astrocyte migration .......................100 
3.4 Discussion ............................................................................................................105 
 
IV: The Contribution of the TRPV1 Channel to Injury-Induced Calcium Influx .......................113 
4.1 Introduction ..........................................................................................................113 
4.2 Methods................................................................................................................115 
 Calcium imaging ...............................................................................................115 
 Quantification of calcium imaging ...................................................................116 
 Statistical analysis .............................................................................................117 
4.3 Results ..................................................................................................................118 
 Effects of TRPV1 agonists on physiological calcium levels in astrocytes .......118 
 Antagonism of TRPV1 reduces and slows calcium influx following injury ....120 
 Effects of TRPV1knockout on intracellular calcium influx with injury...........125 
 Microtubule stabilization has modest effects on intracellular calcium influx with 
injury .................................................................................................................129 
4.4 Discussion ............................................................................................................134 
 
V: TRPV1 in Cytoskeletal Remodeling of Astrocytes Following Injury ....................................139  
5.1 Introduction ..........................................................................................................139 
5.2 Methods................................................................................................................142 
 Western blots ....................................................................................................142 
 Immunocytochemistry ......................................................................................142 
5.3 Results ..................................................................................................................145 
 Effects of TRPV1antagonism on levels of proteins involved in migration ......145 
 Effects of TRPV1 antagonism on cell area and cytoskeletal components........146 
 Antagonism, but not agonism, of TRPV1 affects α-tubulin rearrangement 
following injury ................................................................................................150 
vi 
 
 Antagonism, but not agonism, of TRPV1 affects actin rearrangement following 
injury .................................................................................................................152 
 Knockout of TRPV1 has modest effects on cytoskeletal rearrangement 
following injury ................................................................................................155 
 Antagonism of TRPV1 reduces the number of focal adhesions .......................157 
5.4 Discussion ............................................................................................................158 
 
VI: Discussion and Conclusion ....................................................................................................164 
6.1 Discussion ............................................................................................................164 
6.2 Conclusion ...........................................................................................................168 
 
 
REFERENCES ............................................................................................................................169 
  
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
Figure                         Page 
1.1 General astrocyte subtypes ........................................................................................................2 
 
1.2 Common astrocyte functions .....................................................................................................3 
 
1.3 Astrocyte communication and interactions ................................................................................6 
 
1.4 Components of the blood brain barrier ......................................................................................7 
 
1.5 Retinal layers and cell types ....................................................................................................10 
 
1.6 Astrocytes distribution in the retina .........................................................................................11 
 
1.7 Astrocyte distribution in optic nerves. .....................................................................................11 
 
1.8 Astrocyte in optic nerve cross sections ....................................................................................12 
 
1.9 Triggers of astrocyte reactivity ................................................................................................14 
 
1.10 Grades of astrocyte reactivity following injury .....................................................................14 
 
1.11 Functional changes in reactive astrocytes ..............................................................................16 
 
1.12 The cytoskeleton of a migrating cell ......................................................................................22 
 
1.13 Focal adhesion dynamics in a migrating cell .........................................................................28 
 
1.14 Calcium channels and receptors in astrocytes .......................................................................31 
 
1.15 Structure of TRPV1 ...............................................................................................................35 
 
2.1 Neurodegeneration in glaucoma ...................................................................................................42 
 
2.2 TRPV mRNA in whole retinas ................................................................................................43 
 
2.3 TRPV1 mRNA in optic nerve astrocytes .................................................................................46 
 
2.4 Isolation of primary retinal astrocytes .....................................................................................49 
 
2.5 Isolation of primary optic nerve astrocytes ..............................................................................51 
 
2.6 TRPV channels in astrocytes ...................................................................................................55 
viii 
 
 
2.7 TRPV1 expression in retinal astrocytes ...................................................................................56 
 
2.8 TRPV1 expression in optic nerve head astrocytes ...................................................................59 
 
2.9 TRPV1 expression in optic nerve astrocytes ...........................................................................60 
 
2.10 Morphology of cultured Muller cells .....................................................................................61 
 
2.1l Purity of retinal astrocyte cultures ..........................................................................................63 
 
2.12 Heterogeneity of retinal astrocyte cultures ............................................................................64 
 
2.13 Purity of optic nerve astrocytes ..............................................................................................65 
 
2.14 TRPV1 expression in cultured retinal astrocytes ...................................................................67 
 
2.15 TRPV1 expression in cultured optic nerve astrocytes ...........................................................69 
 
3.1 The scratch wound assay of injury-induced migration ............................................................79 
 
3.2 Proliferation in scratch wound model ......................................................................................82 
 
3.3 Cell morphologies following CAP treatment ..........................................................................85 
 
3.4 Effects of CAP on astrocyte migration ....................................................................................86 
 
3.5 Cell morphologies following RTX treatment ..........................................................................87 
 
3.6 Effects of RTX on astrocyte migration ....................................................................................88 
 
3.7 Effects of TRPV1 agonists on astrocyte proliferation following injury ..................................90 
 
3.8 Cell morphologies following CPZ and IRTX treatments ........................................................92 
 
3.9 Effects of CPZ on astrocyte migration.....................................................................................93 
 
3.10 Effects of IRTX on astrocyte migration.................................................................................95 
 
3.11 Effects of TRPV1 antagonists on astrocyte proliferation following injury ...........................97 
 
3.12 Comparison of cell morphologies in C57 and TRPV1-/- astrocytes .....................................98 
 
3.13 Injury-induced migration in TRPV1-/- astrocytes .................................................................99 
 
3.14 Astrocyte morphologies following addition of calcium chelators .......................................102 
ix 
 
 
3.15 Effects of EGTA on astrocyte migration .............................................................................103 
 
3.16 Effects of BAPTA-AM on astrocyte migration ...................................................................104 
 
4.1 Calcium imaging quantification and analysis ........................................................................117 
 
4.2 Effects of CAP and RTX on basal astrocyte calcium levels ..................................................119 
 
4.3 Quantification of CAP and RTX on physiological calcium levels ........................................120 
 
4.4 Injury-induced calcium changes with addition of TRPV1 antagonists .................................122 
 
4.5 Real time calcium changes following injury and with TRPV1 antagonism ..........................123 
 
4.6 Quantification of calcium dynamics with TRPV1 antagonism .............................................124 
 
4.7 Calcium changes in C57 and TRPV1-/- astrocytes following injury ....................................126 
 
4.8 Real time calcium dynamics in TRPV1-/- astrocytes following injury .................................127 
 
4.9 Quantification of calcium changes in TRPV1-/- astrocytes following injury .......................128 
 
4.10 Effects of taxol on astrocyte calcium influx after injury .....................................................131 
 
4.11 Real time calcium changes after injury and with taxol treatment ........................................132 
 
4.12 Quantification of calcium dynamics with addition of taxol.................................................133 
 
5.1 Effects of fixation on the preservation of the cytoskeleton ...................................................144 
 
5.2 Effects of TRPV1 antagonism on levels of cytoskeletal and migration-related proteins 
following injury ...........................................................................................................................146 
 
5.3 Actin and tubulin expression with increasing distance from the injury .................................147 
 
5.4 Effects of TRPV1 antagonism on cell area and -tubulin and F-actin intensity ...................149 
 
5.5 Agonism of TRPV1 and subcellular localization of -tubulin ..............................................151 
 
5.6 Antagonism of TRPV1 and retraction of -tubulin ...............................................................152 
 
5.7 Agonism of TRPV1 and the subcellular localization of actin ...............................................154 
 
5.8 Antagonism of TRPV1 and retraction of actin ......................................................................154 
 
x 
 
5.9 Effects of TRPV1 knockout on the subcellular localization of -tubulin .............................156 
 
5.10 Effects of TRPV1 knockout on the localization of actin .....................................................157 
 
5.11 Effects of TRPV1 on vinculin expression following injury ................................................158 
 
6.1 Intracellular changes that occur to modulate cell migration ..................................................167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
ABBREVIATIONS 
 
 CNS  Central nervous system 
 RGC  Retinal ganglion cell 
 NFL  Nerve fiber layer 
 pNF  Phosphorylated neurofilament 
 MBP  Myelin basic protein 
 GFAP  Glial fibrillary protein 
 MTOC  Microtubule organizing center 
 TRP  Transient receptor potential 
 CAP  Capsaicin 
 RTX  Resiniferatoxin 
 CPZ  Capsazepine 
 IRTX  Iodo-resiniferatoxin 
 EPSC  Excitatory postsynaptic current 
 LTD  Long term depression 
LTP  Long term potentiation 
PBS   Phosphate buffered saline 
EGTA  Ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid 
DIC  Differential interference contrast 
DAPI   4',6-Diamidino-2-phenylindole 
SEM  Standard error of the mean 
AKAP  A-kinase anchor proteins 
BrDU   Bromodeoxyuridine 
 
* Portions of this chapter have been published previously in Ho KW, Ward NJ, Calkins DJ. TRPV1: a 
stress response protein in the central nervous system (2012) Amer J Neurodegener Dis 1(1):1-14.   
1 
 
CHAPTER 1 
 
BACKGROUND AND INTRODUCTION* 
 
1.1 Astrocyte Characterization 
The central nervous system (CNS) is comprised of neurons and glia, non-neuronal cells 
that support neurons.  Astrocytes are the main glia found in the CNS and account for 20-50% of 
the brain volume (Tower and Young, 1973).  They are distinguished by their stellate morphology 
and exist in distinct, non-overlapping domains where they can establish networks with the 
vasculature and other cell types.  Astrocytes exhibit incredible morphological and functional 
heterogeneity.  The two main classes of astrocytes are protoplasmic and fibrous (Figure 1.1). 
Protoplasmic astrocytes are found in grey matter and contain many finely branched processes, 
whereas fibrous astrocytes are located in white matter and have longer processes (Robel et al., 
2011b).  However, at least nine morphological subtypes of astrocytes have been identified across 
regions in the CNS (Emsley and Macklis, 2006).  Species-dependent differences in morphology 
also exist as humanoid astrocytes display increased complexity including a larger cell size and a 
greater number of processes than their rodent counterparts (Matyash and Kettenmann, 2010).  
Functional heterogeneity also exists amongst various astrocyte subtypes including differences in 
expression of neurotransmitter receptors, gap junction coupling and calcium signaling (Matyash 
and Kettenmann, 2010). 
 Despite their heterogeneity, astrocytes are vital in maintaining homeostasis of the 
extracellular environment and provide both metabolic and structural support to neurons.   
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Some of their main functions include providing ionic and fluid support, recycling 
neurotransmitters and serving as a metabolic and energy reserve.  Once believed to mainly 
provide support to neurons, astrocytes are increasingly recognized to have much broader 
functions from modulating synaptic activity to contributing to neurodegeneration.     
 
 
Figure 1.1.  General astrocyte subtypes.  Protoplasmic and fibrous are the main classifications of 
astrocyte subtypes.  The morphology of astrocytes in normal CNS tissue is visualized with green 
fluorescent protein under the control of an astrocyte-specific promoter.  Protoplasmic astrocytes 
are found in grey matter and possess finer, more branched processes than the fibrous astrocytes 
found in white matter.  Scale: 10 μm.  
Figure from Robel et al., 2011b and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
1.2 Astrocyte Function  
Astrocytes are coupled to other cell types and can serve as a connection between cells to 
facilitate communication. For example, astrocyte endfeet contact blood vessels while their 
processes can envelop axons of neurons, which allow astrocytes to serve as a link between 
neurons and the vasculature.  Astrocytes are also connected to astrocytes and other cell types by 
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a network of gap junctions that facilitates communication and exchange of molecules between 
cells.   
As a result of this network, astrocytes perform a variety of functions that support 
neuronal health and maintain homeostasis (Figure 1.2).  In fact, extensive communication exists 
between astrocytes and neurons.  For example, since astrocyte processes envelop neuronal 
processes and synapses, astrocytes facilitate neurotransmitter recycling and can modulate 
synaptic transmission. They also support neuronal survival by producing and releasing 
neurotropic factors, as well as providing energy substrates. Through their contact with the 
vasculature, astrocytes are also involved in maintenance of the blood-brain barrier and can 
modulate vascular dynamics in response to neuronal activity. Astrocytes are also important in 
maintaining ionic homeostasis and buffering the extracellular space through potassium buffering 
and fluid and pH regulation.   
 
 
Figure 1.2.  Common astrocyte functions.  Astrocytes have multiple supportive functions to 
maintain CNS homeostasis. 
 
During times of increased neuronal activity, the extracellular space accumulates 
excessive levels of glutamate and potassium.  If they are not removed, these compounds can 
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affect neuronal synaptic transmission and channel kinetics.  Astrocytes are responsible for 
clearing a majority of these compounds through a number of channels and transporters expressed 
on the cell surface (Figure 1.3).  In fact, about 80% of glutamate in the extracellular space is 
cleared by perisynaptic astrocytes while the remaining 20% is taken up by neurons (Parpura and 
Verkhratsky, 2012).  To take up excess glutamate, astrocytes express glutamate transporters like 
GLAST (or EAAT1) and GLT-1 (or EAAT2; Perego et al., 2000).  Glutamate is then converted 
to its precursor, glutamine via glutamine synthetase.  Glutamine is then released to neurons, 
which reconvert glutamine to active neurotransmitters.  Similarly, astrocytes also mediate GABA 
recycling, whereby GABA is first converted to glutamate and then to glutamine, which is 
recycled to neurons (Sickmann et al., 2010).  In addition to glutamate, astrocytes also mediate 
clearance of potassium.  Potassium influx into astrocytes occurs through inward rectifying 
potassium channels (Walz, 2000).  Unlike glutamate which is recycled, potassium is 
redistributed via gap junctions throughout the astrocyte network and is released into areas with 
low potassium concentrations.      
In addition to neurotransmitter recycling, astrocytes also mediate synaptic pruning of 
neurons.  Transcriptome profiling indicates astrocytes express genes involved in metabolism, 
lipid synthesis and phagocytosis (Cahoy et al., 2008).  Proteins involved in phagocytosis like 
MEGF10 and MERTK can mediate dendritic pruning by astrocytes (Chung et al., 2013).  
Astrocytes can engulf synaptic material and deletion of MEGF10 and MERTK results in an 
excessive number of synapses in retinal neurons in the dorsal lateral geniculate nucleus (Chung 
et al., 2013).  Phagocytosis of neuronal synapses and debris by astrocytes can also be mediated 
by the Draper signaling pathway and the Crk/Mbc/dCed-12 complex (Tasdemir-Yilmaz and 
Freeman, 2014). 
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Astrocytes also provide metabolic support to neurons by serving as energy reserves.  This 
concept is known as the lactate shuttle (Belanger et al., 2011).  During glutamatergic synaptic 
transmission, glutamate accumulates in the extracellular space and is transported into astrocytes 
via the Na
+
-dependent glutamate transporters.  The increased Na
+
 activates the Na
+
/K
+
-ATPase 
pump that increases ATP consumption and glycolysis.  Glycolysis is supported by the glucose 
transporter, Glut1 that facilitates uptake of glucose into astrocytes from the vasculature (Allen 
and Messier, 2013).  Once glucose is taken up by astrocytes, it can be stored as glycogen or 
converted to lactate that is then released to neurons as an energy substrate.     
Astrocytes are also coupled to blood vessels and help establish a link between neurons 
and the vasculature (Figure 1.4).  Neuronal activity can induce an increase in astrocyte 
intracellular calcium, which triggers the production of arachidonic acid in astrocytes (Strokin et 
al., 2003).  Arachidonic acid can generate prostaglandins or epoxyeicosatrienoic acids for 
vasodilation and 20-hydroxyeicosatetraenoic acid for vasoconstriction (Belanger et al., 2011).  
The endfeet of astrocytes envelop blood vessels and interact with endothelial cells that make up 
the blood brain barrier. (Figure 1.4).  The blood brain barrier can provide neurons with nutrients 
and facilitate the removal of waste products.  However, the passage of molecules into the CNS is 
restricted by tight junctions formed between endothelial cells.  This limits the influx of 
potentially harmful substances from reaching neurons and helps maintain homeostasis of the 
CNS.  Extensive communication and information exchange exist between endothelial cells and 
astrocytes (Figure 1.4; Abbott et al., 2006).  Since astrocytes also interact with neurons, they 
serve as intermediates between neurons and the vasculature.      
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Figure 1.3.  Astrocyte communication and interactions.  Astrocytes communicate with both 
neurons and blood vessels.  Neurons release glutamate that induces an increase in astrocyte 
intracellular calcium (1).  Astrocytes communicate with other astrocytes through release of ATP 
(2) and a network of gap junctions (3).  Astrocyte can provide metabolic support through 
glutamate recycling (4) and uptake of glucose (5).  Astrocytes also mediate vascular dynamics 
(6), as well as take up and release glutamate (7, 8).  
Figure from Maragakis and Rothstein, 2006 and used in accordance with Copyright Clearance 
Center’s RightsLink service.   
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Figure 1.4.  Components of the blood brain barrier.  Astrocytes are one of the cell types that 
comprise the blood brain barrier.  Astrocyte endfeet encircle endothelial cells.  Both astrocyte 
and endothelial cells release factors to facilitate communication between the two cell types.     
Figure from Abbot et al., 2006 and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
In addition to potassium and glutamate, astrocytes also regulate fluid and pH balance.  
Fluid accumulation in the brain can increase intracranial pressure and lead to tissue damage, but 
astrocytes reduce brain edema by maintaining water balance. Astrocytes express water channels 
like aquaporins, especially aquaporin 4 at their endfeet to regulate fluid redistribution (Fukuda 
and Badaut, 2012).  In addition to aquaporins, astrocyte also express the Na
+
/H
+
  and Na
+
/HCO3
-
 
transporters to regulate pH (Chesler, 2003).  For these transporters, the movement of sodium is 
coupled to transport for H
+
 or HCO3
-
 in an isoelectic exchange.  A change in pH can occur 
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through cellular respiration and activity.  If not regulated, a drop in pH can affect enzyme 
function and ion channel activity, and ultimately influence cell viability (Chesler, 2003).      
 
1.3 Astrocytes in the Retina and Optic Nerve 
Astrocytes are found throughout the CNS, including the retina and optic nerve.  In the 
retina, astrocytes are located in the nerve fiber layer where their processes envelop the axons of 
retinal ganglion cells (RGCs; Figure 1.5).  The axons of RGCs converge to form the optic nerve, 
and the axon terminals synapse in the visual cortex.  Retinal and optic nerve astrocytes both 
originate in the brain.  During development, astrocytes migrate from the brain, down the optic 
nerve and into the retina (Watanabe and Raff, 1988).  They enter the retina at the optic disk and 
migrate centrifugally to the periphery.  By secreting factors like VEGF, astrocytes provide a 
template for endothelial cells to migrate and form the developing vasculature (Dorrell et al., 
2002; Jiang et al., 1994; Ling et al., 1989; West et al., 2005).   
The macroglia of the retina are comprised of astrocytes and Muller cells.  Both cell types 
have similar functions and express similar genes.  Although less focus has been placed on retinal 
astrocytes, studies have suggested that they exhibit similar properties to astrocytes found in the 
brain.  In the retina, astrocytes are distributed across the surface where their processes surround 
RGC axons (Figure 1.6).  In the mature retina, mechanical stimulation can lead to calcium wave 
propagation in astrocytes through release of ATP to modulate neuronal activity (Newman, 2001).  
Whether the modulation is excitatory or inhibitory depends on the type of RGC being recorded, 
although glial calcium waves generally reduced firing rates of RGCs (Newman and Zahs, 1998).  
Astrocytes are also involved in angiogenesis and maintenance of the blood-retinal barrier.   
Protection and rescue of astrocytes helped revascularize the retina and prevent pathological 
  
 9 
 
neovascularization in the vitreous in a model of oxygen-induced retinopathy (Dorrell et al., 
2010).  Retinal astrocytes express aquaporin 4, suggesting they might be involved in osmosis and 
fluid redistribution (Nagelhus et al., 1998).  They also express the glutamate transporters, 
EAAT4 and GLAST, as well as glutamine synthetase suggesting that retinal astrocytes also 
mediate glutamate recycling and uptake (Derouiche and Rauen, 1995; Ward et al., 2004).  
In the optic nerve head, astrocytes are perpendicular to RGC axons and form columns 
through which the axons pass (Figure 1.7 and 1.8).  Astrocytes provide structural support to RGC 
axons by synthesizing extracellular matrix molecules such as collagen and elastin (Hernandez, 
1992; Hernandez et al., 1991).  Astrocytes can extend processes through the extracellular matrix 
and contact other cell types, including RGC axons at the Nodes of Ranvier (Butt et al., 1994; 
Hernandez, 2000).  The release of ATP and glutamate during an action potential can increase 
intracellular calcium in optic nerve astrocytes that propagates to neighboring glia (Hamilton et 
al., 2008).  Astrocytes in the optic nerve also help buffer and regulate extracellular potassium 
levels during synaptic transmission. Inhibition of glial inward rectifying potassium channels 
increases extracellular potassium accumulation and prolongs axon recovery following compound 
action potentials (Bay and Butt, 2012).      
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Figure 1.5.  Retinal layers and cell types.  Astrocytes are located in the nerve fiber layer (NFL) 
with the RGC axons.   
Figure from Calkins 2006 and used in accordance with Copyright Clearance Center’s RightsLink 
service.   
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Figure 1.6. Astrocytes distribution in the retina.  Confocal micrographs show the astrocyte 
plexus as labeled with GFAP (green) in the retina (A). Astrocyte morphologies at various 
eccentricities from the retina are shown (B).  Scale: 500µm for A; 20µm for B.  
 
 
Figure 1.7.  Astrocyte distribution in optic nerves.  Confocal micrographs show astrocyte 
distribution in mouse and monkey longitudinal optic nerve sections.  Mouse and monkey optic 
nerves are immunolabeled for phosphorylated neurofilaments (pNF; green), myelin basic protein 
(MBP; red) and glial fibrillary acidic protein (GFAP; blue) (A).  High magnification images of 
the optic nerve head are shown (B).  Scale: 100µm for A; 50µm for B.   
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Figure 1.8.  Astrocyte in optic nerve cross sections.  A schematic depicts the orientation of 
astrocyte somas and processes relative to the axon bundles of RGCs (A).  The presence of 
astrocytes surrounding axon bundles in the optic nerve is further shown (yellow arrows; B).      
Figure from Sun et al., 2013a and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
1.4 The Astrocyte Stress Response 
In addition to their physiological contributions, astrocytes also serve a variety of 
functions under pathophysiological conditions.  Following injury, astrocytes undergo a stress 
response known as reactive gliosis, which is characterized by both morphological and functional 
changes.  A variety of stressors including ischemia, infection and apoptosis can trigger gliosis 
(Figure 1.9).  Additionally, injury responses from other cells including microglia and leukocytes 
can release factors to induce astrocyte reactivity.  Excessive astrogliosis has also been implicated 
in neurodegeneration.  In Alzheimer’s disease, exposure to amyloid-β can triggers gliosis, 
leading to reactive hypertrophic astrocytes encircling the neuritic plaque (DeWitt et al., 1998; 
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Nagele et al., 2004; Rodriguez et al., 2009).  Increased astrogliosis has also been found in the 
substantia nigra, potentially contributing to the inflammatory state in Parkinson’s disease 
(Koprich et al., 2008; McGeer and McGeer, 2008; Mena and Garcia de Yebenes, 2008).  In 
glaucoma, reactive astrocytes in the retina and optic nerve are an early indication of pathology 
and contribute to axon loss (Inman and Horner, 2007; Son et al., 2010).   
One defining characteristic of gliosis is astrocyte hypertrophy, which refers to a 
thickening of astrocyte soma and processes (Figure 1.10).  Astrocyte hypertrophy can be due to 
increased expression of intermediate filaments including GFAP, vimentin and nestin.  Astrocytes 
devoid of GFAP and vimentin have shorter processes compared to wild-type astrocytes 
following cortical lesion, although the volume occupied by reactive astrocytes is similar 
(Wilhelmsson et al., 2004).  The processes of reactive astrocytes from GFAP and vimentin 
double-knockouts also appear as fine strands rather than as thick processes in a mouse model of 
Alzheimer’s Disease (Kraft et al., 2013).     
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Figure 1.9.  Triggers of astrocyte reactivity. 
Figure from Sofroniew and Vinters, 2010 and used in accordance with Copyright Clearance 
Center’s RightsLink service.   
 
 
Figure 1.10.  Grades of astrocyte reactivity following injury.  Moderate gliosis induced by 
lipopolysaccharide results in astrocytes hypertrophy.  More severe types of trauma, however, can 
lead to formation of a glial scar. 
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Figure from Verkhratsky et al., 2012 and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
 In addition to hypertrophy and glial scarring, astrocytes also undergo multiple functional 
changes (Figure 1.11).  For example, they can secrete multiple pro-inflammatory cytokines like 
TNF-α, IL-1β and IL-6 and also chemokines including RANTES and IL-8 (Dong and 
Benveniste, 2001).  These cytokines and chemokines have both beneficial and detrimental effects 
on neurons.   TNF-α is a pro-inflammatory cytokine and can reduce the length and branching of 
hippocampal neurons in vitro (Neumann et al., 2002).  It can also initiate a signaling cascade that 
leads to caspase activation and apoptosis in dopaminergic neurons (Mogi et al., 2000).  However, 
there is evidence that TNF-α might also exert neuroprotective effects (Figiel, 2008).  For 
example, TNF-α can activate NF-B to lead to transcription of anti-apoptotic genes including 
Bcl-2and cIAP2 (Tamatani et al., 1999; Wang et al., 1998).  It can also induce production of 
neuroprotective factors like NGF, GDNF and BDNF in astrocytes (Appel et al., 1997; Saha et al., 
2006).  Like TNF-α, IL-6 can be both pro- and anti-inflammatory depending on the signaling 
pathway that is activated (Scheller et al., 2011).  IL-1β, on the other hand, is regarded as a pro-
inflammatory cytokine that initiates multiple inflammatory responses (Allan et al., 2005).  
Increased levels of IL-1β have been observed in multiple neurodegenerative diseases (Luheshi et 
al., 2009).  These cytokines can activate other astrocytes as well as microglia, which further 
exacerbate reactive gliosis.  
Glial clearance of glutamate is also impacted by stress and injury.  Expression of 
glutamate transporters, EAAT1 and EAAT2 is down-regulated in astrocytes in the glial scar and 
following traumatic brain injury, leading to reduced glutamate uptake (Schreiner et al., 2013; van 
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Landeghem et al., 2006).   In models of Amyotrophic Lateral Sclerosis, reactive astrocytes 
reduce expression of glutamate transporters as well as release glutamate and nitric oxide.  Both 
actions lead to excitotoxicity and apoptosis of neurons (Barbeito et al., 2004).  Although some 
inconsistencies exist, expression of glutamate transporters in reactive astrocytes is generally 
reduced in epilepsy, stroke and other neurodegenerative diseases (Maragakis and Rothstein, 
2004).  A reduction in expression of glutamate transporters impacts the ability of astrocytes to 
clear the glutamate released during synaptic transmission, thereby contributing to neuronal 
excitotoxicity.  
 
 
Figure 1.11.  Functional changes in reactive astrocytes.  Under physiological conditions, 
astrocytes help maintain homeostasis.  Following injury, however, astrocytes can adopt 
functional changes that can be detrimental for neuronal survival. 
Figure from Heneka et al., 2010 and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
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1.5 Relevance of Astrocyte Migration in Disease 
 A moderate injury will cause astrocyte hypertrophy, but in response to more severe 
injuries, astrocytes may also migrate to the injury site.  Astrocyte migration within the CNS can 
underlie glial scar formation seen following spinal cord injury and traumatic brain injury (Di 
Giovanni et al., 2005; Yuan and He, 2013).  Glial scar formation can exert both beneficial and 
detrimental effects on neuronal survival.  For example, the scar can isolate the area of damage 
and help repair the blood-brain barrier, but it can lead to expression of extracellular matrix 
proteins like chondroitin sulfate proteoglycans that act as a barrier against axon regeneration 
(Silver and Miller, 2004).  Astrocyte motility can be influenced by matrix metalloproteinases that 
degrade the extracellular matrix.  For example, matrix metalloproteinase-9 knockouts display 
reduced astrocyte migration and decreased chondroitin sulfate proteoglycan expression and glial 
scarring following spinal cord injury (Hsu et al., 2008). Likewise, knockout of aquaporin-4 can 
also reduce motility as well as glial scarring after cortical stab injury (Saadoun et al., 2005).  In 
addition to migration, astrocytes can also affect the response of other cell types involved in glial 
scarring.  Following cortical stab injury, reactive astrocytes can secrete growth factors and 
cytokines to guide other migrating cells to the injury site (Wang et al., 2004).  However, 
astrocytes can inhibit migration of both Schwann cells and oligodendrocyte precursor cells 
through increased production of cadherins that anchor the cells and decrease their motility (Fok-
Seang et al., 1995; Wilby et al., 1999). Schwann cells and oligodendrocytes are recruited to 
myelinate the axon following injury, and reducing their migration to the damage site might 
impact nerve repair. 
In addition to glial scar formation, astrocyte migration is important in the metastasis of 
gliomas.  Gliomas account for about 70% of all brain tumors, and less than 3% of patients 
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survive five years after diagnosis (Ohgaki and Kleihues, 2005).  One reason for the high 
mortality is the invasive and aggressive nature of glioma cells.  Surgical removal of the tumor is 
usually unsuccessful, mostly because the malignant cells have already invaded the normal brain 
tissue. This leads to a recurrence of tumors usually within 1 cm of the resection site (Demuth and 
Berens, 2004).  Increased cell motility contributes to the invasiveness of gliomas.  Glioma cells 
upregulate genes that mediate migration, including genes involved in extracellular matrix 
remodeling and cell adhesion, such as matrix metalloproteinases, tenascin C, integrin and 
cadherins (Demuth and Berens, 2004).  They can also migrate long distances at speeds of up to 
100 µm/h along the surface of blood vessels with intermittent periods of proliferation in response 
to cues from the brain vasculature (Farin et al., 2006).  Migrating glioma cells have an increased 
resistance to apoptosis, thus reducing the success of chemotherapy and many cytotoxic 
treatments (Mariani et al., 2001).  These factors contribute to the invasive nature of gliomas and 
render the tumors difficult to manage.  Drugs directed against matrix metalloproteinases or 
angiogenic targets, as well as treatments including surgery, radiotherapy, chemotherapy and 
immunotherapy have not significantly increased survival rate, and prognoses for high grade 
gliomas remain poor (Demuth and Berens, 2004; Ehtesham et al., 2004; Lefranc et al., 2009).   
Astrocyte migration has also been observed in eye diseases including age-related macular 
degeneration and glaucoma.  Under physiological conditions, retinal astrocytes are localized to 
the nerve fiber layer.  However, in age-related macular degeneration and retinal detachment, 
retinal astrocytes can be found in the vitreous cavity, suggesting that they have migrated from the 
nerve fiber layer to the vitreous (Morino et al., 1990; Ramirez et al., 2001).  Ischemia can occur 
in age-related macular degeneration and results in a high metabolic need.  It has been suggested 
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that astrocytes migrate into the vitreous to help meet that metabolic demand and send nutrients to 
the retina through intercellular gap junctions (Ramirez et al., 2001). 
Glaucoma is a blinding disease that results from degeneration of the RGCs and their 
axons, and an estimated 79.6 million people will be affected by the disease by 2020 (Quigley and 
Broman, 2006).  Currently, there is no cure for glaucoma, and once vision is lost, it is nearly 
impossible to restore.  Increased intraocular pressure is one risk factor and currently the only 
modifiable factor for glaucoma.  Indeed, many glaucoma treatments attempt to lower intraocular 
pressure (Lee and Higginbotham, 2005).  Like other neurodegenerative diseases, astrocyte 
reactivity is seen in both the retina and optic nerve in glaucoma (Inman and Horner, 2007; Son et 
al., 2010).  In response to elevated hydrostatic pressure in vitro, astrocytes increase migration 
and proteolytic degradation of the extracellular matrix (Tezel et al., 2001a).  Reactive astrocytes 
in the optic nerve can migrate into the nerve bundles and occupy the spaces left by degenerating 
RGC axons (Miao et al., 2010).  Like in gliomas, genes involved in migration, including tenascin 
C, integrins, neural cell adhesion molecule, matrix metalloproteinases and myosin light chain 
kinase also show differential expression in glaucomatous astrocytes (Hernandez et al., 2008; 
Miao et al., 2010).   
Reactive astrocytes can migrate in response to injury, and can exert both beneficial and 
detrimental effects on neuronal survival.  Astrocytes can release inflammatory mediators like 
nitric oxide and TNF-but can also increase production of protective factors like brain-derived 
neurotrophic factor (Crish et al., 2013; Liu and Neufeld, 2000; Tezel and Wax, 2000).  
Astrocytes in the glial scar impede axon regeneration but can also repair the blood-brain barrier 
and isolate the area of damage to minimize the impact on healthy surrounding tissue (Silver and 
Miller, 2004).  By better understanding the mechanisms and signaling pathways that underlie 
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astrocyte migration, perhaps novel therapeutic interventions can be developed to temper glial 
scar formation, glioma metastasis and other detrimental effects of astrocyte motility. 
 
1.6 Cell Migration 
Cell migration requires a coordinated cascade involving multiple receptors, proteins and 
signaling pathways, and can essentially be divided into six general steps (Figure 1.12):  
1. Establishment of direction and polarity  
2. Protrusion of the leading edge  
3.  Attachment to the extracellular matrix 
4. Contraction of the cell 
5.  Release of the cell rear 
6.  Recycling of proteins to the front of the cell 
The first step in migration is to establish directionality.  One way polarity is created is 
through detection of a chemotactic gradient.  Cells can migrate in response to a variety of stimuli 
including growth factors, chemokines and other extracellular molecules.  For example, astrocytes 
can migrate in response to platelet derived growth factor, transforming growth factor β and the 
nucleotide UTP (Bressler et al., 1985; Morganti-Kossmann et al., 1992; Wang et al., 2005b).  
Astrocytes also express chemokine receptors CXCR4, CCR1, CCR5, and CX3CR1 that would 
enable the cell to detect chemokines and migrate (Dorf et al., 2000).  Activation of multiple 
signaling proteins, including CDC42, Par6 and PKC, can reorient the microtubule organizing 
center (MTOC) in the direction of migration to establish polarity in astrocytes (Etienne-
Manneville and Hall, 2003). 
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Upon establishing polarity, cell protrusion occurs to form the leading edge.   Cell 
protrusion is generally mediated by remodeling of the cytoskeleton.  In astrocytes, the leading 
edge is formed primarily by polymerization of microtubules radiating from the MTOC, although 
actin assembly can also modulate this process (Baorto et al., 1992; Etienne-Manneville, 2013).  
The leading edge then must contact and adhere to the extracellular matrix.  This is mediated by 
the formation of focal adhesions that link actin stress fibers to integrins, which are receptors for 
the extracellular matrix.  Astrocytes express multiple integrins including 11, 31, 51 and 
61 to bind laminin, collagen and fibronectin (Tawil et al., 1993; Tawil et al., 1994). 
Adherence to the extracellular matrix may be regulated by signaling pathways, such as the JAK-
STAT pathway with the transcription activator Stat3 (Buffo et al., 2010).  Astrocytes from Stat3-
/- mice display reduced migration and increased expression of E-cadherin, which might increase 
adhesion of cells to inhibit motility (Okada et al., 2006). 
Once the leading edge adheres to the extracellular matrix, the cell undergoes contraction.  
The contractile forces are usually generated by interactions between actin and myosin II.  
Myosin II can bind actin and move actin fibers in an anti-parallel direction (Vicente-Manzanares 
et al., 2009).  Microtubules can indirectly influence this process by modulating signaling proteins 
like RhoA, which activates myosin (Liu et al., 1998).  These contractile forces can push the cell 
forward in the direction of migration.  Once the cell has moved, it has to detach from the 
extracellular matrix.  Cell detachment is mediated by disassembly of focal adhesions while 
retraction of the cell rear is mediated by actin-myosin interactions (Broussard et al., 2008; 
Mitchison and Cramer, 1996). 
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Figure 1.12.  The cytoskeleton of a migrating cell. This schematic shows the localization of actin 
(red), microtubules (green) and focal adhesions (blue) in a migrating cell. 
From Etienne-Manneville, 2004a and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
1.7 Components of Cell Migration  
In addition to providing the structural framework of the cell and mediating normal 
cellular function, the cytoskeletal rearrangement that occurs following injury is a key driving 
force underlying migration.  The astrocyte cytoskeleton is made up of three main components: 
actin, microtubules and intermediate filaments. Each of these components plays a role in 
migration.  Additionally, a variety of receptors, proteins and signaling pathways all converge to 
mediate the cytoskeletal rearrangements that occur during migration.   
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Actin: Actin can transition between two states: monomeric (G-actin) and filamentous (F-
actin).  Actin polymerization occurs through addition of actin monomers at the barbed (+) end of 
the filament, while disassembly occurs at the pointed (-) end in an ATP-dependent process 
(Dominguez and Holmes, 2011).  The actin cytoskeleton can also undergo various modifications 
that are mediated by multiple actin binding proteins.  Actin binding proteins can facilitate 
assembly/disassembly by sequestering G-actin monomers to prevent polymerization, dissociating 
F-actin into G-actin, capping the barbed or pointed ends to prevent turnover, severing actin into 
shorter filaments and crosslinking actin to promote filament polymerization and branching (dos 
Remedios et al., 2003).     
The actin cytoskeleton mediates multiple aspects of astrocyte function.  Disruption of 
actin dynamics can reduce the propagation of calcium waves (Cotrina et al., 1998).  Similarly, 
inhibition of actin polymerization with cytochalasin D affects the morphological clustering of the 
glutamate transporter, GLT-1 to disrupt glutamate uptake and recycling (Zhou and Sutherland, 
2004).  The actin cytoskeleton is also involved in gating ion channels, including outwardly 
rectifying chloride-selective channels and calcium channels (Johnson and Byerly, 1993; Lascola 
et al., 1998).  In neocortical astrocytes, polymerization or stabilization of actin increased the 
probability of chloride channels being in the open state, which was reduced when actin 
polymerization was inhibited (Lascola et al., 1998).  Actin can also modulate voltage-gated 
calcium channels, as stabilization of actin can prolong calcium channel activity and reduce its 
inactivation (Johnson and Byerly, 1993). 
In addition to normal astrocyte function, actin has also been shown to mediate gliosis.  
Following scratch wound or stab injury, astrocytes increased expression of palladin, an actin-
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binding protein (Boukhelifa et al., 2003).  Palladin was also increased along the edge of the 
injury and correlated with increased actin assembly (Boukhelifa et al., 2003).  Addition of IL-6 
can result in actin reorganization and loss of stress fibers without affecting overall actin levels 
(John et al., 2004). Consequently, IL-6 slowed astrocyte migration following scratch injury.  
During migration, astrocytes treated with IL-6 randomly extended and collapsed their processes 
and lacked coordination, while control cells were able to protrude a process, contact the 
extracellular matrix and push forward (John et al., 2004). 
 
Microtubules: Microtubules are formed from the polymerization of α- and β- tubulin in a 
process that is dependent on GTP.  Like actin, microtubule filaments are polarized – tubulin 
monomers are usually added to the plus-end and dissociated from the slower minus-end.  When 
microtubules transition from growth to shrinkage, the process is known as catastrophe, and the 
transition from shrinkage to growth is referred to as rescue (van der Vaart et al., 2009). They can 
also undergo a process known as dynamic instability, which is characterized by rapid growth and 
disassembly. Microtubules interact with microtubule-associated proteins that stabilize and cross-
link microtubules.  Generally, microtubule-associated proteins can regulate shrinkage speeds and 
modulate the frequencies of catastrophe and rescue to promote disassembly or growth (van der 
Vaart et al., 2009).  
Microtubules can regulate a variety of cellular functions including morphology, cell 
division and intracellular transport (Nogales, 2000).  Addition of colchicine to inhibit 
microtubule polymerization reduced expression of the microtubule-associated protein, MAP-2 
and shortened astrocyte processes (Couchie et al., 1985).  Microtubule disassembly can also 
cause vimentin filaments to condense and aggregate into bundles in glioma cells (Sorci et al., 
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2000).  In addition to mediating morphology, microtubules help position the centrosome during 
cell division.  The motor protein, dynein can interact with microtubules to generate a pulling 
force that reorients the centrosome in astrocytes (Etienne-Manneville, 2004).  Microtubules are 
also involved in cellular transport, and provide the tracks for the motor proteins dynein and 
kinesin to transport membrane-bound vesicles or organelles (Goldstein and Yang, 2000).   
Similar to actin, microtubules can also regulate aspects of gliosis.  Reactive astrocytes 
have been shown to increase expression of MAP2, a protein usually found in dendrites of 
neurons (Geisert et al., 1990).   Stabilization of microtubules can reduce astrocyte reactivity, glial 
scarring and promote axon regeneration following spinal cord injury (Hellal et al., 2011).  
Addition of taxol to stabilize microtubules reduced the levels of both glycosaminoglycan and 
chondroitin sulfate proteoglycan (Hellal et al., 2011).  Following sciatic nerve injury, addition of 
taxol induced axon regeneration in dorsal root ganglion neurons and neurons from the Raphe 
spinal tract compared to the retraction observed in vehicle-treated neurons (Hellal et al., 2011).  
 
Intermediate Filaments: Intermediate filaments are a diverse group of proteins and are 
classified into five types based on amino acid sequence.  The main type found in astrocytes is 
Type III intermediate filaments which include vimentin, nestin and GFAP (Eliasson et al., 1999).  
Intermediate filaments are formed by one filament strand coiling around another to create a 
dimer.  Dimers then associate to form tetramers, and tetramers associate to form protofilaments 
which combine together to form the filament (The Cell: A Molecular Approach. 2nd edition. 
Cooper GM).  In vimentin knockout animals, astrocytes retained expression of GFAP though 
expression was lowered.  GFAP filaments were also less condensed with increased spacing 
between each filament (Eliasson et al., 1999).  Unlike GFAP, vimentin cannot form filaments 
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without associating with another Type III filament.  Examples include vimentin-GFAP and 
vimentin-nestin interactions (Eliasson et al., 1999). In cortical astrocytes, intermediate filament 
organization within the cell appears to be dependent on microtubules, as stabilization or 
depolymerization of microtubules resulted in a re-distribution of intermediate filaments and 
inhibited astrocyte process extension in the presence of dibutyryl cyclic AMP (Goetschy et al., 
1986).  Microtubule-associated proteins like MAP2 can also interact with intermediate filaments 
to regulate the movement and transport of intermediate filaments along microtubules (Chang and 
Goldman, 2004).     
Intermediate filaments form both a cytoplasmic and a nuclear network, thus connecting 
cell-to-cell junctional complexes at the plasma membrane to the nuclear matrix in order to 
modulate the dynamics and structural integrity of cells (Herrmann et al., 2007; Middeldorp and 
Hol, 2011). The cytoplasmic intermediate filament network can act to stabilize cell morphology 
and reinforce microtubules (Herrmann et al., 2007).  In astrocytes, GFAP is the major 
intermediate filament, and recent work has suggested this protein can affect a multitude of 
functions including maintenance of cell shape, astrocyte motility, proliferation and vesicular 
trafficking (Middeldorp and Hol, 2011).  GFAP can also modulate neuronal function via 
astrocyte-mediated changes in synaptic plasticity, regulation of the blood brain barrier and CNS 
myelination (Middeldorp and Hol, 2011).   
Increased expression of intermediate filaments, like GFAP, is a hallmark of astrocyte 
reactivity.  Astrocytes from vimentin/GFAP double knockout mice exhibit a reduction in 
hypertrophy and had shorter processes following cortical lesion, and this was accompanied by 
increased synaptic regeneration (Wilhelmsson et al., 2004).  In addition to mediating 
hypertrophy, intermediate filaments are involved in the transient swelling of astrocytes in 
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response to osmotic stress.  Spinal cord astrocytes that lacked GFAP swelled slower compared to 
wild-type in hypotonic or high potassium solutions (Anderova et al., 2001). Intermediate 
filaments have also been shown to mediate migration. For example in glioma cells, induced 
expression of GFAP reduced migration and elongated cell processes (Elobeid et al., 2000).   
Studies using vimentin knockout mice showed reduced migration and altered arrangement of 
actin and focal adhesions in fibroblasts (Eckes et al., 1998).  In astrocytes, nestin, vimentin and 
GFAP interact with actin to position the nucleus following scratch injury (Dupin et al., 2011).  
Astrocytes that lack either GFAP or vimentin also have reduced speed but maintained their sense 
of direction (Lepekhin et al., 2001). 
 
Focal Adhesions: To migrate effectively, a cell needs to contact and adhere to the 
extracellular matrix.  Focal adhesions help mediate this process by linking actin stress fibers to 
integrins and proteoglycans (Figure 1.13).  They are comprised of a variety of proteins including 
scaffolding proteins, GTPases and kinases.  Focal adhesions can vary in size.  Smaller focal 
adhesions, known as focal contacts, localize to the cell periphery and are regulated by the small 
GTPases CDC42 and Rac (Nobes and Hall, 1995).  Focal contacts can develop into larger 
complexes known as focal adhesions.  Focal adhesions are found both peripherally and centrally 
within a cell and are regulated by the GTPase Rho (Chrzanowska-Wodnicka and Burridge, 1996; 
Ridley and Hall, 1992).  Downstream effectors of Rho that modulate such events include PI 3-
kinase and actin binding proteins including cofilin (for review, see (Raftopoulou and Hall, 2004).  
In addition to GTPases, other proteins that modulate focal adhesions include kinases like focal 
adhesion kinase and src, and scaffold proteins such as paxilin (Frame et al., 2002; Shen and 
Schaller, 1999; Turner, 2000).   
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   Once the leading edge of the cell contacts the extracellular matrix, small focal contacts 
that contain mainly paxilin and α-actinin are established (Laukaitis et al., 2001).  Tenascin C can 
mediate this process by interacting with extracellular matrix molecules like fibronectin 
(Midwood and Schwarzbauer, 2002).  Tenascin C can also modulate focal adhesion kinase and 
RhoA, and induce loss of focal adhesions (Chung et al., 1996; Midwood and Schwarzbauer, 
2002).  Other proteins, including talin, vinculin, and focal adhesion kinase, are then recruited to 
form focal adhesions and stabilize the leading edge (Wozniak et al., 2004; Zaidel-Bar et al., 
2003).  Once focal adhesions form, they have to be disassembled to allow migration.  Src and 
calpains can modulate focal adhesion turnover.  For example, src kinase generally leads to cell 
detachment and one mechanism is through phosphorylation of integrins (Parsons and Parsons, 
1997).  The calpain proteases also lead to disassembly by cleaving proteins found in focal 
adhesions including talin and α-actinin (Bhatt et al., 2002; Dourdin et al., 2001).   
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Figure 1.13.  Focal adhesion dynamics in a migrating cell.  This diagram illustrates focal 
adhesion assembly at the leading edge, and disassembly at the cell rear.  This process is mediated 
by various proteins including calpains, Rac, Rho and CDC42.    
Figure from (Frame et al., 2002) and used in accordance with Copyright Clearance Center’s 
RightsLink Service. 
 
1.8 Calcium Signaling in Astrocytes 
Astrocytes can respond to a wide variety of stimuli with increases in calcium.  For 
example, mechanical stimulation increases intracellular calcium in retinal astrocytes (Newman, 
2001).  This increase in calcium can spread to neighboring astrocytes via both intracellular and 
extracellular pathways.  Intracellularly, inositol triphosphate (IP3) can pass through gap 
junctions and activate IP3 receptors in the endoplasmic reticulum to release calcium from 
intracellular stores (Scemes and Giaume, 2006).  In the extracellular pathway, glutamate and 
ATP are released and bind to glutamate and purinergic receptors on the plasma membrane to 
increase calcium (Scemes and Giaume, 2006).  In addition to mediating intercellular 
communication, calcium is also important for astrocytes in modulating synaptic transmission.  
Glutamate that is released into the extracellular space during neuronal synaptic activity can bind 
metabotropic glutamate receptors on astrocytes.  This leads to increased intracellular calcium and 
the subsequent release of gliotransmitters, including glutamate, ATP and D-serine to modulate 
neuronal activity.  This enables astrocytes to interact with pre- and post-synaptic neurons at the 
synaptic cleft and form a unit known as the tripartite synapse.  The tripartite synapse mediates 
the bi-directional communication between neurons and astrocytes (Perea et al., 2009).   
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Calcium signaling is an important component of the astrocyte stress response. Indeed, 
reactive astrocytes can exhibit aberrant calcium dynamics in neurodegenerative diseases 
(Agulhon et al., 2012).  Reactive astrocytes also increase expression of L-type calcium channels 
following brain injury (Westenbroek et al., 1998).  Inhibition of L-type calcium channel with the 
drug verapamil can reduce GFAP upregulation in astrocytes following cortical lesion (Klepper et 
al., 1995).   Calcium influx through L-type calcium channels also activates calpains to induce 
astrogliosis and GFAP expression following injury (Du et al., 1999).  The IP3 receptor can also 
mediate reactive gliosis as astrocytes from IP3 receptor knockouts have reduced GFAP 
expression following neocortical stab wound injury (Kanemaru et al., 2013).  In addition to 
hypertrophy, calcium increases are necessary for astrocytes to release IL-6 (Codeluppi et al., 
2014).  Also, functional voltage-gated calcium channels and ryanodine receptors are required for 
glial cell migration (Lohr et al., 2005; Matyash et al., 2002).   
In addition to gliosis, calcium is an important signaling molecule in cell migration.  A 
migrating cell can exhibit a calcium gradient that is higher posteriorly (Brundage et al., 1991).  
This calcium gradient might be important in establishing cell polarity and mediating retraction at 
the cell rear.  Calcium microdomains at the leading edge of the cell are important for turning the 
cell and creating directionality (Wei et al., 2009). The calcium binding protein, S100A4 can 
interact with myosin-IIA to mediate cell protrusion (Li and Bresnick, 2006).  Additionally, many 
proteins that regulate the cytoskeleton are contain calcium-binding sites and are, in turn, 
regulated by calcium.  For example the actin crosslinking protein, α-actinin and the actin 
severing protein, gelsolin contain two and three calcium-binding sites respectively (Lamb et al., 
1993; Noegel et al., 1987).  Focal adhesion dynamics are also modulated by calcium.  Calcium-
activated proteins like CaMKII, calcineurin and calpains can modulate focal adhesion assembly 
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and turnover (Conklin et al., 2005; Easley et al., 2008; Glading et al., 2002).  Since calcium 
mediates multiple aspects of astrocyte function during physiology and following injury, 
astrocytes express a variety of channels and receptors to regulate calcium levels (Figure 1.14).  
These calcium channels include transporters, metabotropic receptors and ligand-gated and 
voltage-gated channels.  
 
 
Figure 1.14.  Calcium channels and receptors in astrocytes.  
From Achour SB et al., 2010 and used in accordance with Copyright Clearance Center’s 
RightsLink service. 
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1.9 The Transient Receptor Potential Vanilloid 1 Channel 
One family of calcium channels expressed by astrocytes is the transient receptor potential 
(TRP) family.  TRP channels are a diverse group that regulates cation entry and contributes to a 
vast variety of physiological functions.  There are 28 mammalian TRPs, divided into 6 
subfamilies based on homology: canonical (TRPC1-7), vanilloid (TRPV1-6), melastatin 
(TRPM1-8), ankyrin (TRPA1), polycystin (TRPP1-3) and mucolipin (TRPML1-3).  All six 
members share a common structure of six transmembrane domains with a hydrophobic pore 
located between the fifth and sixth domains.  TRP channels can respond to a variety of external 
stimuli including temperature, osmolality, mechanical force, chemoattractants and ischemia 
(Christensen and Corey, 2007; Jost et al., 1992; Liu et al., 2007; Simard et al., 2007; Wang and 
Poo, 2005).  Characterized by an increased calcium flux, TRP activation has been implicated in 
many calcium-mediated events including synaptic transmission, neuronal death, axon 
pathfinding and visual transduction (Aarts and Tymianski, 2005; Clapham et al., 2001; Cui and 
Yuan, 2007; Montell, 2005; Munsch et al., 2003).   
Similar to other TRP channels, TRPV1 displays robust calcium conductance and has a 
10-fold greater selectivity for calcium versus sodium (Kauer and Gibson, 2009).  TRPV1 is 
known for its role in pain sensation where it modulates levels of intracellular calcium in 
nociceptive neurons (Caterina et al., 1997; Hagenacker et al., 2008).  Activation of TRPV1 in 
nociceptive neurons induces release of neurotransmitters and neuropeptides involved in pain 
transmission, including substance P and calcitonin gene-related peptide, thereby making TRPV1 
an attractive target for hyperalgesic drugs  (Gazzieri et al., 2007; Nakanishi et al., 2010)). 
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1.10 TRPV1 pharmacology 
 TRPV1 was first isolated as the receptor for capsaicin (CAP), the prototypical TRPV1 
agonist (Caterina et al., 1997).  Subsequent research has demonstrated that in TRPV1 knockout 
animals, capsaicin-induced activity such as nociceptive behavior, glutamate transmission, 
ethanol avoidance, wound healing and vasoconstriction is eliminated (Caterina et al., 2000; 
Ellingson et al., 2009; Keeble and Brain, 2006; Musella et al., 2009; Sumioka et al., 2014).  One 
of the most potent agonists of TRPV1 is resiniferatoxin (RTX), a plant toxin isolated from the 
plant Euphorbia resinifera.  RTX has a molecular structure similar to and recognizes the same 
vanilloid binding sites on TRPV1 as CAP, but is about 20-fold more potent than CAP 
(Raisinghani et al., 2005; Szallasi et al., 1993).  Endogenous ligands of TRPV1 include 
endocannabinoids (anandamide and N-arachidonolydopamine), lipoxygenase products, protons 
and heat. 
Capsazepine (CPZ) was one of the first competitive antagonists of CAP and RTX found. 
CPZ can block vanilloid-induced activity in multiple cell types including nociceptive neurons in 
the dorsal root ganglion, corneal epithelial cells, hippocampal interneurons and microglia (Bevan 
et al., 1992; Dickenson and Dray, 1991; Gibson et al., 2008; Kim et al., 2006; Yang et al., 
2010b)).  Iodination of a moiety on RTX led to the discovery of iodo-resiniferatoxin (IRTX), 
another TRPV1-selective antagonist.  Binding experiments revealed that IRTX is 40 times more 
potent than CPZ, and can displace vanilloid binding as well as block vanilloid-induced activity in 
neurons from the dorsal root ganglia, microglia, dopaminergic neurons and other cell types (Kim 
et al., 2006; Marinelli et al., 2003; Seabrook et al., 2002; Wahl et al., 2001).  Endogenous 
inhibitors of TRPV1 include PIP2 and adenosine (Puntambekar et al., 2004; Rosenbaum and 
Simon, 2007). 
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1.11 Structure and Modulation of TRPV1 
Structural analysis of TRPV1 indicates a compact transmembrane region and a large 
basket-like intracellular domain (Moiseenkova-Bell et al., 2008).  Figure 1.15 shows the 
structure of TRPV1.  TRPV1 contains six transmembrane domains.  The N-terminal tail has 
numerous phosphorylation sites and ankyrin repeats that serve as binding sites for calmodulin 
and ATP (Lishko et al., 2007).  The C-terminal tail has a TRP domain and binding sites for both 
calmodulin and PIP2, an endogenous TRPV1 inhibitor (Garcia-Sanz et al., 2004; Numazaki et al., 
2003; Ufret-Vincenty et al., 2011).  Within the extracellular loop domain, the amino acid 
residues Glu600 and Glu648 can regulate TRPV1 activation by protons, allowing for pH 
sensitivity (Jordt et al., 2000).  Agonist activation is also mediated intracellularly, as lipophilic 
capsaicin readily crosses the membrane to bind several sites on TRPV1 (Jung et al., 1999).  
Mutation and deletion studies have identified multiple residues critical for activation.  Deletion 
of Thr550 in transmembrane region 4 can reduce capsaicin sensitivity (Gavva et al., 2004).  
Deletion of Arg114 and Glu761 in the N- and C-termini can block capsaicin-induced currents 
without affecting its activation by heat (Jung et al., 2002).  Mutations of Tyr511 and Ser512 can 
abolish capsaicin responses, yet leave activation by heat and protons intact (Jordt and Julius, 
2002). 
Phosphorylation is also important in modulating the channel allowing for rapid responses 
to external stimuli or environmental changes.  Generally, phosphorylation sensitizes while 
dephosphorylation desensitizes the channel.  PKC phosphorylation at Ser800 reverses 
desensitization of TRPV1 from prolonged capsaicin treatment and increases the sensitivity of 
TRPV1 to agonists (Mandadi et al., 2006; Varga et al., 2006). Forskolin-mediated activation of 
PKA can decrease capsaicin-induced desensitization of TRPV1, a phenomenon that is blocked 
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by a PKA inhibitor (Mohapatra and Nau, 2003).  PKA can also reduce desensitization by direct 
phosphorylation of TRPV1 at Ser116 (Bhave et al., 2002).  In addition, PKC or PKA activation 
through stimulation of multiple receptors including the protease-activated receptor PAR2, 
bradykinin B1 and B2, purinergic P2 receptors, chemokine receptor CCL3 and endothelin 
receptors have all been shown to increase sensitivity of the channel (Amadesi et al., 2006; 
Tominaga et al., 2001; Vellani et al., 2004; Yamamoto et al., 2006; Zhang et al., 2005a).  Src 
kinase, CaMKII and PI3K can all phosphorylate TRPV1 and increase sensitivity as well (Price et 
al., 2005; Van Buren et al., 2005; Zhang et al., 2005b). On the other hand, dephosphorylation by 
calcineurin/PP2B and increases in intracellular calcium can desensitize the channel (Koplas et 
al., 1997; Mohapatra and Nau, 2005). 
 
 
Figure 1.15.   Structure of TRPV1.  TRPV1 has six transmembrane domains with the pore 
region between the fifth and sixth domains.  Binding sites for kinases, capsaicin, protons and 
other factors are shown.  
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From Ho KW et al. 2012 and used in accordance with the Creative Commons Attribution 
Noncommercial License.  
 
1.12 TRPV1 in CNS function 
TRPV1 has been shown to mediate both neuronal and glial function in the CNS (Ho et 
al., 2012).  In neurons, TRPV1 can mediate synaptic transmission and plasticity.  In substantia 
nigral and hypothalamic brain slices, capsaicin increases presynaptic calcium to enhance 
presynaptic activity and glutamate release (Marinelli et al., 2003; Medvedeva et al., 2008; 
Sasamura et al., 1998).  In addition to glutamate release, TRPV1 has also been implicated in 
dopamine release. In the ventral tegmental area, capsaicin enhances both the release of dopamine 
at the nucleus accumbens and also the firing of dopaminergic neurons (Marinelli et al., 2005).  In 
striatal medium spiny neurons and sensory neurons, TRPV1 enhances the frequency of 
glutamatergic excitatory post-synaptic currents (EPSC) that were potentiated by PKC-mediated 
decreases in desensitization (Musella et al., 2009; Sikand and Premkumar, 2007)  TRPV1-
mediated increases in EPSC frequencies have also been observed in the substantia gelatinosa, 
periaqueductal gray, medial preoptic nucleus, substantia nigra and locus coeruleus (Jiang et al., 
2009; Karlsson et al., 2005; Marinelli et al., 2003; Marinelli et al., 2002; Xing and Li, 2007). 
By modulating synaptic transmission, TRPV1 can influence synaptic plasticity and 
survival.  In hippocampal neurons, TRPV1 activation by capsaicin or 12-(S)-HPETE is necessary 
to cause long term depression (LTD) by high frequency stimulation. This effect was notably 
absent in TRPV1-null mice (Gibson et al., 2008).  As a result of this finding, the authors propose 
a model in which glutamate induces post-synaptic release of 12-(S)-HPETE into the synaptic 
cleft to activate pre-synaptic TRPV1 channels.  Activated TRPV1 subsequently decreases pre-
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synaptic glutamate release through a calcium-dependent pathway.  Another study found that in 
the dentate gyrus and in the medium spiny neurons of the nucleus accumbens, post-synaptic 
activation of TRPV1 by anandamide leads to LTD through calcium-mediated endocytosis of 
AMPA receptors (Chavez et al., 2010; Grueter et al., 2010).  In the developing superior 
colliculus, IRTX blocks the induction of tetanus-induced LTD, while RTX reduces the amplitude 
of field excitatory postsynaptic potentials (Maione et al., 2009).  In TRPV1 knockout mice, there 
is a reduction in long term potentiation (LTP) compared to wild-type mice in the CA1 region of 
the hippocampus (Marsch et al., 2007).  These previous studies indicate that TRPV1 facilitates 
LTD; however, another study found that CAP and RTX amplify LTP and suppressed LTD in the 
CA1 region of the hippocampus (Li et al., 2008). 
 In glia, spinal cord astrocyte and microglial reactivity is reduced in TRPV1 knockout 
mice in models of acute, inflammatory and neuropathic pain (Chen et al., 2009).  TRPV1 
activation by CAP can also increase both microglial and astrocyte reactivity in the trigeminal 
nucleus caudalis (Kuroi et al., 2012). However in the mesencephalon, CAP reduces microglial 
activation and production of reactive oxygen species to increase survival of dopaminergic 
neurons following 1-methyl-4-phenylpyridinium-induced toxicity in a model of Parkinson’s 
Disease (Park et al., 2012).  Treatments of CAP can up-regulate bradykinin B1, a receptor 
involved in nociception and inflammation, as well as IL-1β levels in rat spinal cord microglia 
(Talbot et al., 2012).  Addition of cannabidiol can also increase phagocytosis by brain and spinal 
cord microglia, a process that could be reduced with addition of CPZ (Hassan et al., 2014).  
TRPV1 activation, however, can induce microglial apoptosis by increasing intracellular calcium 
and release of cytochrome C (Kim et al., 2006).  
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 In addition to microglia, TRPV1 can also mediate astrocyte function.  In a mouse model 
of Amyotrophic Lateral Sclerosis, transplanted neural stem cells can reduce astrocyte activation 
by releasing endogenous ligands of TRPV1 to activate the channel (Nizzardo et al., 2014).  
TRPV1 is also expressed in astrocytes, mainly in thick cellular processes, in the sensory 
circumventricular organs, where channel activation can increase c-fos expression (Mannari et al., 
2013).  Cortical astrocytes also express TRPV1 to mediate changes in current induced by low pH 
through an influx of sodium rather than calcium (Huang et al., 2010).  Additionally, TRPV1 
expression is also found in astrocytes in the spinal cord, hippocampus and retina (Doly et al., 
2004; Leonelli et al., 2009; Sun et al., 2013).       
 
1.13 TRPV1 in the Retina 
During retinal development, TRPV1 is expressed in the retinal neuroblastic layer and can 
modulate cellular apoptosis (Leonelli et al., 2009).  TRPV1 inhibition with CPZ can reduce 
apoptosis in the retina of newborn rats without affecting cell division (Leonelli et al., 2011).  In 
the mature retina, TRPV1 is expressed in multiple retinal cell types including neurons (RGCs, 
photoreceptors), interneurons (amacrine cells), endothelial cells and glia (astrocytes and 
microglia) (Leonelli et al., 2009; Sappington and Calkins, 2008; Sappington et al., 2009; Zimov 
and Yazulla, 2004, 2007).  TRPV1 activation has both beneficial and detrimental effects on 
retinal neuronal function.  In RGCs, TRPV1 activation with CAP can reduce cell loss following 
intravitreal injections of N-methyl-d-aspartic acid (Sakamoto et al., 2014).  Deletion of TRPV1 
exacerbates deficits in RGC anterograde transport as well as axon loss in a model of optic 
neuropathy (Ward et al., 2014).  Similarly, a neuroprotective role for TRPV1 has been suggested 
following ischemia-reperfusion of the retina – addition of CPZ reduces the neuroprotective effect 
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of anandamide, an endogenous TRPV1 ligand (Nucci et al., 2007).  However, TRPV1 activation 
has also been shown to mediate neurodegeneration. Capsaicin treatment in retinal explants can 
increase nitric oxide levels and induce RGC apoptosis (Leonelli et al., 2013).  TRPV1 also 
contributes to apoptosis of the RGCs by increasing intracellular calcium following exposure to 
elevated hydrostatic pressure (Sappington et al., 2009).  
In retinal glia, TRPV1 can modulate reactivity.  For example, injection of CPZ reduces 
Muller glial reactivity and GFAP expression in the retina following axotomy (Leonelli et al., 
2010).  Likewise, TRPV1 antagonism can reduce NF-κB translocation and IL-6 secretion in 
microglia following exposure to elevated hydrostatic pressure (Sappington and Calkins, 2008). 
 
1.14 TRPV1, an Intrinsic Stress Response Protein in Astrocytes 
Decades of research have established the importance of calcium in mediating astrocyte 
function and cell motility.  TRPV1 is a cation channel with a high calcium permeability and is 
known to be expressed in retinal astrocytes (Leonelli et al., 2009).  Previous studies performed 
by our lab have determined that TRPV1 is part of the intrinsic stress response of RGCs (Ward et 
al., 2014), but the function of the channel in the astrocyte stress response is unknown.  Because 
of the importance of calcium in astrocyte function and reactivity, the objective of this project is 
to determine the contribution of TRPV1 to astrocyte function following injury.  My central 
hypothesis is that TRPV1 influences astrocyte stress response by modulating migration, calcium 
influx and cytoskeletal dynamics in response to injury.  The specific aims of this project are: 
 
Aim 1:  Determine the contribution of TRPV1 activation to astrocyte migration.  My 
working hypothesis is that mechanical injury activates TRPV1 to contribute to astrocyte 
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migration.  Using the scratch wound assay as a model of injury-induced migration, I will 
measure whether astrocyte motility is modulated by (a) TRPV1 agonists and antagonists, (b) 
genetic knockout of TRPV1 and (c) chelation of intracellular and extracellular calcium.   
 
Aim 2: Quantify the contribution of TRPV1 to calcium influx following injury.  My working 
hypothesis is that TRPV1 modulates calcium levels in astrocytes following injury.  Using 
calcium imaging and the scratch wound model, I will measure (a) the influx of calcium following 
injury, and if calcium levels are influenced by (b) TRPV1 pharmacological agents and (c) 
genetic knockout of TRPV1.  
 
Aim 3: Determine the effects of TRPV1 modulation on cytoskeletal dynamics in response to 
injury. My working hypothesis is that TRPV1 modulates cytoskeletal dynamics in astrocytes 
following injury.  Using immunocytochemistry and confocal microscopy, I will visualize 
changes in the actin and tubulin cytoskeleton in astrocytes following (a) scratch injury, (b) with 
addition of TRPV1 agonists and antagonists and (c) genetic knockout of TRPV1.   
 
 
 
 
 
 
* Portions of this chapter have been published previously in Ho KW, Lambert WS and Calkins DJ.  
Activation of the TRPV1 cation channel contributes to stress-induced astrocyte migration (2014) Glia 
62(9):1435-51. 
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CHAPTER II 
 
CHARACTERIZATION AND EXPRESSION OF THE TRPV1 CHANNEL IN 
ASTROCYTES* 
 
2.1 Introduction 
 Neurodegeneration is the progressive loss of structure or function of neurons. While 
neuronal dysfunction and death are fundamental to neurodegeneration, the role of glia in this 
process is still being elucidated (Gionfriddo et al., 2009; Sappington et al., 2006; Tezel et al., 
2001b). To better understand the mechanisms of neurodegeneration and the neuron-glia 
interactions that mediate this process, the Calkins Lab uses the retinal neuron, RGCs as the 
prototypical neuron.  RGC somas are located in the retina, while their axons comprise the optic 
nerve and their axon terminals synapse in the brain.   The retina and optic nerve are part of the 
CNS and are readily accessible for experimental manipulation.  Various disease states including 
ischemia, optic neuropathy, excitotoxicity, traumatic injury and mechanical stress have all been 
modeled in the eye (Calzada et al., 2002; Downs et al., 2008; Gionfriddo et al., 2009; 
Levkovitch-Verbin, 2004).  Glaucoma, a group of optic neuropathies that involves the 
degeneration of RGCs and their axons, exhibits a pathology similar to other neurodegenerative 
diseases (Howell et al., 2013; Nickells et al., 2012).  The pathogenesis in glaucoma occurs in a 
distal to proximal fashion, with loss of anterograde transport at the central projection sites as one 
of the earliest signs of dysfunction and loss of RGC bodies as one of the end stages of 
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degeneration (Calkins, 2012; Crish et al., 2010).  Other neurodegenerative outcomes in glaucoma 
are shown in Figure 2.1, further demonstrating the practicality of the eye as a model tissue for 
CNS neurodegeneration. 
 
 
Figure 2.1 Neurodegeneration in glaucoma.  Pathogenesis displays a distal-to-proximal 
progression, and exhibits outcomes similar to other neurodegenerative diseases. 
Figure from Calkins, 2012 and used in accordance with Copyright Clearance Center’s 
RightsLink service.   
 
 Previous work in our lab examining neuronal and glial responses to injury suggests that 
the TRPV1 channel may play a key role in glaucomatous neurodegeneration. In the retina, 
TRPV1 is found in neurons including photoreceptors and RGCs, interneurons like amacrine 
cells, and glia including astrocytes and microglia (Leonelli et al., 2009; Sappington and Calkins, 
2008; Sappington et al., 2009; Zimov and Yazulla, 2004, 2007). Using quantitative PCR, we 
have shown that whole mouse retinas express TRPV1 and other TRPV channel family members 
(Figure 2.2). Expression of TRPV5 was not detected, possibly because the assay used did not 
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detect splice variants in the retina or that retinal expression is below the limit of target detection 
for this assay (Flicek et al., 2014). Using immunohistochemistry, we localized TRPV1 protein to 
microglia and RGCs within the retina, demonstrating expression that is diffuse throughout the 
RGC soma and more punctate in the dendrites and axons (Sappington et al., 2009).  In microglia 
exposed to elevated hydrostatic pressure to mimic glaucomatous stress, we found that TRPV1 
mediates the translocation of NF-B to the nucleus and release of IL-6 (Sappington and Calkins, 
2008).  More recently, we have shown that TRPV1 is neuroprotective to RGCs in an animal 
model of glaucoma.  Deficits in anterograde transport and axon loss in response to increased 
intraocular pressure are greater in TRPV1-/- animals compared to wild-type, strongly suggesting 
TRPV1 is part of an intrinsic stress response within the retina and optic nerve (Ward et al., 
2014). 
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Figure 2.2.   TRPV mRNA in whole retinas.  C57BL/6 whole retinas express TRPV channel 
mRNA.  Bar graph shows mRNA expression of the TRPV family normalized to GAPDH in 
mouse retinas. 
Similar to RGCs and microglia, astrocytes undergo a stress response known as reactive 
gliosis in disease and following injury.  Reactive astrocytes are hypertrophic, demonstrating 
increased expression of intermediate filaments, as well as increased proliferation, migration, 
extracellular matrix remodeling and cytokine secretion. In age-related macular degeneration, 
reactive astrocytes within the retina can phagocytose RGCs as well as migrate from their location 
in the nerve fiber layer into the vitreous (Ramirez et al., 2001).  Retinal astrocytes also become 
reactive in glaucoma, where they increase expression of GFAP but do not proliferate (Inman and 
Horner, 2007).  They also reduce IL-6 secretion and increase expression of TNF-both of 
which modulate RGC survival (Sappington et al., 2006; Tezel et al., 2001b).  Proteomic-based 
analysis showed retinal astrocytes upregulate inflammatory mediators such as NF-B as well 
(Tezel et al., 2012).  
Astrocytes in the optic nerve also undergo gliosis and increase expression of intermediate 
filaments following injury or disease (Son et al., 2010).  Reactive astrocytes contribute to 
remodeling of the optic nerve head through release of extracellular matrix proteins.  In 
glaucomatous tissue, astrocytes increase expression of both neural cell adhesion molecule, a 
protein involved in cell anchoring, and collagen (Morrison et al., 1990; Ricard et al., 2000).  
Levels of integrins and glycosaminoglycans and the synthesis of matrix metalloproteinases are 
altered as well (Agapova et al., 2001; Morrison, 2006; Tezel et al., 1999).  In response to 
elevated hydrostatic pressure, optic nerve astrocytes can also increase migration and degrade the 
extracellular matrix as they move (Tezel et al., 2001a).  In addition to extracellular matrix 
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remodeling, reactive astrocytes might also be involved in inflammatory responses.  Like in the 
retina, astrocytes in the optic nerve upregulate production of TNF-α, which induces expression of 
nitric oxide synthase (Yuan and Neufeld, 2000).   
Since astrocytes in both the retina and optic nerve can undergo a stress response in 
diseases like glaucoma and age-related macular degeneration, we wanted to determine if TRPV1 
mediates an intrinsic stress response in these glial populations as it does in RGCs.  TRPV1 
expression has been shown in rat retinal astrocytes, but its expression in astrocytes in other 
species or in optic nerve has not been determined (Leonelli et al., 2009).  Preliminary work in 
our lab demonstrated expression of TRPV1 mRNA in mouse optic nerves using fluorescent in 
situ hybridization (Figure 2.3).  In young (3 month) and older (9 month) optic nerves, TRPV1 
message was found in astrocyte somas and either colocalized with GFAP or was surrounded by 
GFAP.  While these results suggest optic nerve astrocytes express TRPV1, mRNA expression 
does not necessarily mean a functional protein is expressed.  Therefore, to further investigate 
whether TRPV1 mediates an intrinsic stress response in retinal and optic nerve astrocytes, I 
wanted to determine if retinal and optic nerve astrocytes express this protein.  This chapter will 
describe the expression of TRPV1 protein in retinal and optic nerve tissue, the isolation and 
characterization of retinal and optic nerve astrocyte cultures, and the expression of TRPV1 
protein in these cultures. 
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Figure 2.3.  TRPV1 mRNA in optic nerve astrocytes.  Fluorescent in situ hybridization show 
that TRPV1 mRNA (red) is found in GFAP-positive (blue) optic nerve astrocytes (arrowheads) 
in 3 month and 9 month mouse optic nerves.  mRNA was absent in tissue labeled with sense 
TRPV1.  Axons are labeled with phosphorylated neurofilaments (green).  Scale: 20 µm.     
 
2.2  Methods  
Animals 
All animal procedures were approved by the Vanderbilt University Medical Center 
Institutional Animal Care and Use Committee.   Adult (1-month-old) male Trpv1−/− (B6.129X1-
Trpv1
tm1Jul
/J) mice, which were created on a C57BL/6 background, were obtained from Jackson 
Laboratories and age-matched C57BL/6 mice were obtained from Charles River Laboratories 
(Wilmington, MA). Timed-pregnant Sprague-Dawley rats were also obtained from Charles River 
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Laboratories.  Animals were maintained in a 12 hour light/dark cycle with standard rodent chow 
available ad libitum as described (Crish et al., 2010; Sappington et al., 2010).  
 
Immunohistochemistry   
Perfused optic nerves or retina from Sprague-Dawley rats, C57 mice or Macaque 
monkeys were washed in phosphate-buffered saline (PBS) and blocked with 5% normal serum 
with 0.1% Triton-X 100 in PBS for 2 hours at room temperature.  Tissue was then placed in 
primary antibody solution containing 3% normal serum, 0.1% Triton X-100 in PBS for least 4 
days at 4˚C.  The following primary antibodies and dilutions were used: TRPV1 (for rat, Novus 
Biologicals, Littleton, CO, 1:1000; for mouse, Neuromics, Edina, MN, 1:100), TRPV2 
(Alomone Labs, Jerusalem, Israel, 1:200), TRPV3 (Alomone Labs, Jerusalem, Israel, 1:200), 
TRPV4 (Alomone Labs, Jerusalem, Israel, 1:200), TRPV5 (Alomone Labs, Jerusalem, Israel, 
1:200), TRPV6 (Santa Cruz Biotechnology Inc, Dallas, TX, 1:200), glial fibrillary acidic protein 
(GFAP; EMD Millipore, Billerica, MA 1:500), phosphorylated neurofilament (pNF, SMI-31, 
Sternberger Monoclonal, Baltimore, MD, 1:1,000).  Tissue was then washed with PBS and 
placed into the appropriate DyLight-conjugated secondary antibodies (Jackson Immunoresearch, 
West Grove, PA 1:150) with 1% normal serum and 0.1% Triton X-100 in PBS overnight at 4˚C.  
Samples were washed with PBS and then coverslipped with Fluoromount–G (SouthernBiotech, 
Birmingham, AL).  Confocal images were captured using an Olympus FV-1000 inverted 
microscope. 
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Isolation of primary retinal astrocytes 
Primary astrocytes were isolated with immunomagnetic separation as previously 
described (Figure 2.4; Sappington et al., 2006).  Retinas from post-natal day 1 to 3 Sprague-
Dawley rats were harvested in DMEM/Glu plus 5% glucose (Corning Cellgro, Manassas, VA) 
and then centrifuged at 70 x g for 6 min.  The tissue was then dissociated with 1 mg/mL papain 
and 0.005% DNase at 37˚C for 15 minutes, followed by mechanical trituration.  The cells were 
centrifuged at 250 x g for 8 minutes, and then incubated with a mouse anti-astrocyte antibody 
that recognizes a 180-200 kDa protein on the astrocyte cell surface (Leinco Technologies, St. 
Louis, MO, 4 µg/mL) for 10 minutes on ice to isolate astrocytes. Cells were centrifuged and 
incubated with 20 μL anti-mouse IgM microbeads (Miltenyi Biotec, Auburn, CA).  Cell 
suspensions were centrifuged again, and then loaded onto pre-equilibrated magnetic columns 
(Miltenyi Biotech) and allowed to flow through.  The columns were washed with DMEM/Glu 
plus 5% glucose, and then eluted.  Isolated cells were seeded onto poly-D-lysine-coated (Sigma-
Aldrich, St. Louis, MO, 0.01mg/mL) T25 flasks and grown until confluent in astrocyte media 
[DMEM/F12 (Mediatech, Inc. Manassas, VA), 1X G5 supplement (Life Technologies, Grand 
Island, NY) and 0.1% gentamicin (Life Technologies, Grand Island, NY) plus 10% FBS 
(Mediatech, Inc. Manassas, VA)].  Media was changed the day after seeding and then every 
other day.  Once confluent, cells were passaged with 0.25% trypsin/2.21 mM EDTA (Mediatech, 
Inc. Manassas, VA) and then seeded onto poly-D-lysine-coated wells to be used for experiments. 
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Figure 2.4.  Isolation of primary retinal astrocytes.  Retinal astrocytes were isolated with 
immunomagnetic separation.  Postnatal retinas were dissociated.  Astrocytes were identified with 
a cell-specific antibody, followed by a magnetic secondary antibody.  The cell suspension was 
placed in column with magnetic beads.  Labeled cells were retained and non-labeled cells were 
washed out.  Labeled cells were then washed and eluted.   
 
Genotyping of TRPV1-/- animals 
The TRPV1-/- mouse was generated from a germ-line mutation that resulted from a 
deletion of an exon encoding part of the fifth and all of the sixth transmembrane domains, which 
include the pore-loop region.  The background for the TRPV1-/- are C57BL/6, which were used 
as controls, and mice were genotyped prior to use (Caterina et al., 2000).   Ear clippings (3 mm x 
3 mm) were collected, and DNA was extracted with the DNeasy Blood and Tissue Kit (Qiagen, 
MD).  DNA concentration was determined with a NanoDrop 8000 (Thermo Scientific, 
Wilmington, DE), and then used in a PCR reaction.  Each PCR reaction contained the following: 
2.5 μL 10X PCR Buffer (Life Technologies, Grand Island, NY), 0.75 μL 50 mM MgCl2 (Life 
Technologies, Grand Island, NY), 0.5 μL 10 mM dNTP mix (Promega, Madison, WI), 0.5 μL of 
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each primer (10 μM working stocks; Integrated DNA Technologies, Coralville, IA), 0.1μL 
Platinum Taq polymerase (Life Technologies, Grand Island, NY), 40 ng of extracted template 
DNA, and the correct amount of DNase/RNAse free water to bring the reaction volume to 25 μL.  
The primers used were recommended by Jackson Laboratories for detection of the TRPV1-/- 
gene truncation.  Two forward primers were used to distinguish between wild-type (Jackson 
Laboratory, Bar Harbor, Maine, oIMR1561; 5' CCT GCT CAA CAT GCT CAT TG 3') and 
knockout (Jackson Laboratory, Bar Harbor, Maine, oIMR0297; 5' CAC GAG ACT AGT GAG 
ACG TG 3') gene products.  Both forward primers shared a reverse primer (Jackson Laboratory, 
Bar Harbor, Maine, oIMR1562; 5' TCC TCA TGC ACT TCA GGA AA 3').  Wild-type animals 
yield a product size of 984 bp and TRPV1-/- animals results in a product size of 600 bp.  
GAPDH gene was used as positive control with the following primers: forward (5’ TTG GCA 
TTG TGG AAG GGC TC 3’) and reverse (5’ TGC TGT TGA AGT CGC AGG AGA C 3’) to 
produce a 363 bp product.  PCR reactions were performed using a Mastercycler gradient 
thermocycler (Eppendorf AG, Hamburg, Germany) with the following cycling steps: 
Step 1: Denaturing: 94ºC for 3 minutes 
Step 2: Denaturing: 94ºC for 30 seconds 
Step 3: Annealing: 65ºC for 1 minute 
Step 4: Extension: 72ºC for 1 minute 
Step 5: Repeat steps 2-4 40 times 
Step 6: Extension: 72ºC for 2 minutes 
Step 7: Finish, holding reactions at 4ºC 
The PCR products from this reaction were then used as template DNA for a second PCR reaction 
using the same steps described above.  This was necessary because one round of PCR did not 
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yield enough product for detection on an agarose gel.  The second PCR reaction used 2.5 to 3.0 
μL of template DNA from the first round PCR and the same reagents and primers.  Products 
from the second round of PCR were separated on a 1.5% agarose gel with addition of ethidium 
bromide.  Gels were imaged on a Gel Doc XR+ (Bio-Rad, Hercules, CA) gel reader with the 
expected following products: GAPDH 363 bp for a positive control (data not shown), C57 984 
bp, TRPV1-/- 600 bp.  
 
 Isolation of primary optic nerve astrocytes 
To isolate optic nerve astrocytes, both optic nerves from a mouse were dissected and 
minced with a razor blade as previously described (Figure 2.5; Lambert et al., 2001).  Tissue was 
then placed into a well of a 24-well plate coated with 0.1mg/mL poly-D-lysine in astrocyte 
media with 10% FBS.  Over time, astrocytes migrate out from the optic nerve explants and 
proliferate.  Once confluent, cells were passaged with 0.25% trypsin/2.21 mM EDTA and then 
seeded onto poly-D-lysine-coated T25 flasks.  The cells were placed in serum-free astrocyte 
media to reduce the viability of other cell types including oligodendrocytes and microglia, and to 
increase purity of the astrocyte cultures.  The cultures were placed into full astrocyte media with 
10% FBS the following day and allowed to proliferate. 
 
Figure 2.5.  Isolation of primary optic nerve astrocytes.  Astrocytes were isolated from optic 
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nerve explants.  Astrocytes will migrate from minced optic nerve tissue.  Cell purity was 
increased with subsequent passaging of cells and incubation in serum-free media. 
 
Immunocytochemistry 
Cultured astrocytes were fixed with 4% paraformaldehyde in PBS for 20 minutes.  Cells 
were washed in PBS and blocked with 5% normal serum with 0.1% Triton-X 100 in PBS for 2 
hours at room temperature.  Cells were then placed in primary antibody in a solution containing 
3% normal serum, 0.1% Triton X-100 in PBS overnight at 4˚C. The following primary 
antibodies and dilutions were used: glutamine synthetase (GluSyn, Santa Cruz Biotechnology, 
Dallas, TX, 1:250), ionized calcium binding adaptor molecule 1 (Iba-1, Abcam, Cambridge, MA, 
1:400), phosphorylated neurofilaments (pNF, SMI-31, Sternberger Monoclonal, Baltimore, MD, 
1:1,000), GFAP (EMD Millipore, Billerica, MA 1:500), nestin (Santa Cruz Biotechnology, 
Dallas, TX, 1:200), myelin basic protein (MBP, Novus Biologicals, Littleton, CO, 1:500), 
TRPV1 (Novus Biologicals, Littleton, CO, 1:1000).  The next day cells were washed with PBS 
and incubated with appropriate DyLight-conjugated secondary antibodies (Jackson 
Immunoresearch, West Grove, PA 1:150) in 1% normal serum and 0.1% Triton X-100 in PBS 
overnight at 4˚C.  Cells were washed with PBS, counterstained with DAPI (1:100, Molecular 
Probes, Eugene, OR), and then washed with PBS before being coverslipped with Fluoromount–
G (SouthernBiotech, Birmingham, AL).  Confocal images were captured using an Olympus FV-
1000 inverted microscope. 
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Western Blot 
Protein lysates were collected from primary astrocytes in RIPA buffer [50 mM Tris-HCl, 
150 mM NaCl, 5 mM EDTA, 0.2 mM sodium vanadate, 1% NP-40, 0.1% SDS, 0.5% sodium 
deoxycholate, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Roche, Basal, 
Switzerland)].  Protein concentration was determined with the bicinchoninic acid protein assay 
kit (Thermo Scientific, Wilmington, DE).  Samples (40µg) were prepared with addition of 
protein loading buffer (Li-Cor Inc., Lincoln, NE) and 10% β-mercaptoethanol (Sigma, St. Louis, 
MO), and denatured at 70˚C for 5 minutes.  Samples were then separated by SDS-PAGE in 4% 
to 20% gradient Tris-glycine precast gel (Bio-Rad, Hercules, CA) following the Western blot 
protocol from Li-Cor Inc.  Blots were incubated in primary antibodies: TRPV1 (Novus 
Biologicals, Littleton, CO, 1:2000), GFAP (EMD Millipore, Billerica, MA 1:5,000), β-actin 
(Life Technologies, Grand Island, NY, 1:2000).  Proteins were detected using IRDye 680 or 
IRDye 800CW secondary antibodies, Odyssey Blocking Buffer and a Li-Cor Odyssey Infrared 
Imaging System (Li-Cor Inc., Lincoln, NE) following manufacturer’s protocol. 
 
2.3 Results 
 
Expression of TRPV channels in vivo in retinal astrocytes 
 The TRPV family of ion channels is comprised of six members. We have shown 
expression of TRPV family members 1 to 4 and 6 in whole retina using quantitative PCR.  Other 
groups have found that retinal astrocytes express TRPV1 but not TRPV2 or TRPV4 (Leonelli et 
al., 2009; Ryskamp et al., 2011).  To determine which TRPV family members are expressed 
specifically in retinal astrocytes, I performed immunochemistry on mouse retinal whole mounts 
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(Figure 2.6).  While quantitative PCR demonstrated that whole retinas expressed TRPV mRNA, 
immunochemistry elucidates the expression and localization of TRPV protein in retinal 
astrocytes.  Consistent with previous results, TRPV2 and TRPV4 was not detected in retinal 
astrocytes (Figure 2.6; Leonelli et al., 2009; Ryskamp et al., 2011).  I found that retinal 
astrocytes express TRPV1, TRPV5 and TRPV6, all of which colocalized with GFAP, but 
TRPV2, TRPV3 and TRPV4 expression was absent.  TRPV1 and TRPV5 demonstrated diffuse 
labeling throughout the cell soma (filled arrowheads) and processes (arrows), while TRPV6 
appeared to have greatest expression in astrocyte processes with weak expression in astrocyte 
cell somas.  TRPV1, TRPV5 and TRPV6 were also present in the RGC somas, which are located 
in the retinal ganglion cell layer beneath astrocytes.  Astrocytes did not express TRPV2, TRPV3 
or TRPV4.  TRPV2 was found in RGC somas and axons, while TRPV4 was expressed in both in 
RGC somas as well as in the endfeet of Muller cells (arrowheads).  TRPV3 was not expressed by 
either RGCs or astrocytes in mouse whole mount retinas (Figure 2.6).               
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Figure 2.6. TRPV channels in astrocytes.  Confocal micrographs show expression of TRPV1, 
TRPV2, TRPV3, TRPV4, TRPV5 and TRPV6 (green; A-F) in mouse retinal whole mounts.  
Astrocytes are positive for GFAP (red).  TRPV expression and colocalization with GFAP is 
present in astrocyte soma (filled arrowheads) and processes (arrow) and Muller cell endfeet 
(arrowheads).  Scale: 10 µm. 
 
 Since the primary retinal astrocyte cultures I used for my in vitro studies are isolated 
from rat retinas, I was interested in further characterizing the expression of TRPV1 in rat retinal 
astrocytes.  Immunochemistry and confocal micrographs indicate that rat retinal astrocytes 
express TRPV1 (Figure 2.7A and 2.7B).  Like in mouse, TRPV1 is diffusely expressed 
  
 56 
 
throughout astrocyte soma (filled arrowheads) and processes (arrows).  The channel is also found 
in RGC somas and axons, where is colocalizes with pNF (Figure 2.7A).  High magnification 
images and orthogonal views demonstrate discrete areas of colocalization between TRPV1 and 
GFAP in astrocytes in both rat and mouse (Figure 2.7B and 2.7C). 
 
 
Figure 2.7.  TRPV1 expression in retinal astrocytes. Whole-mounted rat (A, B) and mouse (C) 
retinas demonstrate TRPV1 labeling (green) throughout processes (arrows) and somas 
(arrowheads) of GFAP-positive astrocytes (red). Phosphorylated neurofilaments (pNF) label 
RGC soma (blue).  Higher magnification and orthogonal views (B, C) show discrete 
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colocalization of TRPV1 within GFAP-labeled astrocyte processes (yellow puncta). Scale: 10 
μm (A and B); 5 μm (C). 
 
Optic nerve astrocytes express TRPV1 in vivo 
The optic nerve is comprised of axons from RGC, and is believed to be an initial site of 
injury in glaucoma, our lab’s disease of interest (Morgan, 2000; Quigley et al., 1981).  Increased 
intraocular pressure is believed to target the optic nerve head and optic nerve, leading to axon 
degeneration and apoptosis of RGCs (Weber et al., 2008).  In glaucoma, as well as diabetic 
retinopathy, astrocyte reactivity in the optic nerve has been observed prior to overt changes 
within the brain or retina and is one of the earlier signs of pathogenesis (Fernandez et al., 2012a, 
b; Hernandez, 2000; Son et al., 2010).  To determine if TRPV1 may mediate an intrinsic stress 
response in optic nerve astrocytes, my in vitro studies utilized cultures of primary optic nerve 
astrocytes.  However, prior to those studies I first had to characterize TRPV1 expression in 
mouse, rat and monkey optic nerve head and optic nerve tissue (Figure 2.8 and 2.9).   
 In mouse optic nerve head, TRPV1 expression was observed in discrete pockets in 
GFAP-positive astrocytes, while axonal expression appeared more diffuse (Figure 2.8).  In 
contrast, TRPV1 expression in rat optic nerve head astrocytes appears more diffuse than in the 
mouse optic nerve head, although areas of discrete TRPV1 labeling are still observed (arrows).  
Axonal expression of TRPV1 in the rat optic nerve head was similar to mouse.  Intense areas of 
TRPV1 labeling that did not colocalize with GFAP and did not appear to be within RGC axon 
bundles were also observed in rat optic nerve head tissue. In monkey optic nerve head, TRPV1 
was extensively colocalized with GFAP.  Of the three species examined, monkey optic nerve 
head demonstrated higher astrocyte TRPV1 expression than mouse or rat. 
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Within the optic nerve proper, TRPV1 expression in mouse was localized to discrete 
pockets in GFAP-positive astrocytes, similar to what was observed in the optic nerve head 
(Figure 2.9). Colocalization of TRPV1 and GFAP appeared within axonal bundles. Axonal 
expression of TRPV1 in mouse optic nerve appeared more punctate than in the nerve head.  This 
staining pattern suggests TRPV1may localize at the Nodes of Ranvier.  In rat optic nerve 
astrocytes, TRPV1 expression appeared diffuse and moderately colocalized with GFAP. 
Colocalization of TRPV1 and GFAP appeared concentrated along axonal bundles more so than 
within the bundles.  Diffuse TRPV1 expression was also observed in monkey optic nerve 
astrocytes, and colocalization with GFAP appeared more concentrated along axonal bundles with 
very little astrocyte TRPV1 expression within axon bundles. TRPV1 protein also appeared in the 
somas of non-GFAP positive cells (arrowheads), indicating possible expression in 
oligodendrocytes (Figure 2.9).          
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Figure 2.8.  TRPV1 expression in optic nerve head astrocytes.  Mouse, rat and monkey optic 
nerve heads are immunolabeled for TRPV1 (green) and GFAP (red).  TRPV1colocalizes with 
GFAP (arrows).  Dotted lines denote the axons of RGCs. Scale: 20 µm (A); 10 µm (B).  
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Figure 2.9.  TRPV1 expression in optic nerve astrocytes.  Mouse, rat and monkey optic nerves 
are immunolabeled for TRPV1 (green) and GFAP (red).  TRPV1colocalizes with GFAP (arrows) 
but is also observed in non-GFAP positive cells (arrowheads).  Dotted lines denote the axons of 
RGCs. Scale: 20 µm (A); 10 µm (B).  
 
Primary cell cultures express astrocyte-specific genes 
Since TRPV1 is expressed in retinal and optic nerve astrocytes in vivo, I was interested in 
characterizing the channel’s expression in vitro in isolated primary astrocytes.  I was able to 
isolate and culture three primary astrocyte populations: post-natal rat retinal astrocytes, adult 
C57 wild-type optic nerve astrocytes, and adult TRPV1-/- optic nerve astrocytes.  The formation 
of the extracellular matrix and the presence of Muller cells in adult retinas make isolating retinal 
astrocytes more difficult.  There is increased cell death and decreased cell viability as well the 
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presence of Muller cells.  Also, the mouse retina is smaller than rats and would require twice the 
number of animals to produce similar cell numbers.  Therefore, optic nerve rather than retinal 
astrocytes were isolated from adult mice. 
Purity of the retinal astrocyte primary cultures was assessed with immunocytochemistry 
using antibodies against proteins expressed by glia and neurons present in the retina: glutamine 
synthetase (macroglia), Iba-1 (microglia) and pNF (neurons; Figure 2.10).  Both astrocytes and 
Muller cells express glutamine synthetase, however the two cell types differ based on 
morphology.  Muller cells are more fibrous and elongated while astrocytes are more globular and 
amoeboid shaped (Figure 2.10 and 2.11; Hicks and Courtois, 1990). 
 
 
Figure 2.10.  Morphology of cultured Muller cells. Phase-contrast images show Muller cells 
after 4 days in culture (A) or 2 passages (B). DIC images showing retinal astrocytes in culture 
(C)  Arrow indicates a dividing cell.  
Figure from Hicks and Courtois, 1990 and used in accordance with Copyright Clearance 
Center’s RightsLink service.   
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Isolated retinal astrocytes do not express Iba-1 or pNF, indicating the absence of both 
microglia and neurons respectively, in the culture (Figure 2.11). My isolated rat retinal cultures 
express GFAP, further validating their astrocyte identity (Figure 2.12).  The astrocyte cell 
population is heterogeneous, as shown by the range of morphologies as well as patterns of GFAP 
expression.  While the cells are generally amoeboid shaped, some cells have well defined 
processes.  Cell size also varies within the same culture.  In some astrocytes, GFAP is 
filamentous and expressed throughout the cell, while in others labeling appears diffuse.  The 
intensity of GFAP labeling also varied; some cells had uniform labeling throughout while others 
had intense labeling in the perinuclear area and less intense labeling in the cell processes (Figure 
2.12).            
The purity of optic nerve cultures from C57 and TRPV1-/- mice was also determined 
using immunohistochemistry with antibodies for optic nerve glia:  GFAP and nestin for 
astrocytes, myelin basic protein (MBP) for oligodendrocytes and Iba-1 for microglia (Figure 
2.13).  Cells isolated from C57 and TRPV1-/- optic nerve explants expressed both GFAP and 
nestin, suggesting these cells are astrocytes (Figure 2.13A and 2.13B).  Both intermediate 
filaments were expressed throughout the astrocytes, and while GFAP expression was more 
diffuse, nestin labeling was more filamentous. Expression of Iba-1 or MBP was not observed in 
my optic nerve cultures, indicating the absence of microglia and oligodendrocytes, respectively 
(Figure 2.13C and 2.13D).   
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Figure 2.11.  Purity of retinal astrocyte cultures.  Confocal micrographs show that retinal 
astrocytes express glutamine synthetase but not Iba-1 or pNF (A).  Muller cells also express 
glutamine synthetase, while microglia express Iba-1 and RGCs express pNF (green; B).  Scale: 
20µm.  Muller cell image courtesy of D’anne Duncan in Rebecca Sappington’s lab. 
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Figure 2.12.  Heterogeneity of retinal astrocyte cultures.  Astrocyte cultures are labeled with 
GFAP (red), and DAPI (blue) identifies the nucleus (A). Arrows indicate well defined processes.  
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Asterisks indicate different cell sizes in same culture.  The variations in GFAP distribution 
throughout astrocytes is shown in B.  Scale: 20 m. 
 
 
Figure 2.13.  Purity of optic nerve astrocytes.  Isolated cells express GFAP and nestin.  Optic 
nerve astrocytes isolated from C57 and TRPV1-/- mice are positive for GFAP (green; A) and 
nestin (green; B), but do not express the oligodendrocyte marker, myelin basic protein (MBP; C) 
or the microglial marker, Iba-1 (D).  Nuclei are labeled with DAPI (blue).  Scale: 50 m. 
 
Astrocyte cultures express TRPV1 channel 
After validating the purity of my primary astrocyte cultures, I wanted to determine the 
pattern of TRPV1 expression in vitro.  Immunocytochemistry showed that in rat retinal astrocyte 
cultures, GFAP labeling was filamentous throughout the cell body and processes, while TRPV1 
exhibited more punctate and diffuse labeling (Figure 2.14A).  Merged confocal images indicated 
that the two proteins have discrete areas of co-localization.  Higher magnification images were 
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then taken to allow for better visualization to discern the finer details of TRPV1 and GFAP 
expression. The filamentous expression of GFAP and the more diffuse punctate pattern of 
expression for TRPV1 are highlighted (Figure 2.14B).  Orthogonal views indicate that TRPV1 
and GFAP maintained distinct areas of expression but co-localization occurred in discrete 
pockets within the soma and processes in isolated astrocytes, much like the pattern seen in 
astrocytes from rodent retinal whole mounts (Figure 2.7 and 2.14).  Western blots from these 
primary cultures further confirmed the presence of TRPV1 and GFAP protein in rat retinal 
astrocytes (Figure 2.14C).  Full-length TRPV1 has a molecular weight of 90 to 113 kDa due to 
glycosylation states (Sappington et al., 2009).  We detected four TRPV1 isoforms in our 
astrocytes, similar to those found in neuroblastoma cells (Lilja et al., 2007) with the band below 
75 kDa having been specifically reported in astrocytes (Huang et al., 2010; Lilja et al., 2007).   
The bands present in the GFAP Western blot have molecular weights of about 55 and 60 kDa, 
and likely represent different splice isoforms or phosphorylation or glycosylation states of GFAP 
(Korolainen et al., 2005; Tura et al., 2009). 
Next, I was interested in characterizing the expression of TRPV1 in primary optic nerve 
astrocytes (Figure 2.15A).  Immunolabeling for GFAP in both C57 and TRPV1-/- astrocytes was 
diffuse and punctate throughout the cell.  TRPV1-/- astrocytes appeared to have more perinuclear 
GFAP labeling.  This was in contrast to rat retinal astrocytes which exhibited more filamentous 
GFAP expression (Figures 2.14 and 2.15A).  Similar to retinal astrocytes, TRPV1 expression 
was diffuse in C57 optic nerve astrocytes and localized to both the soma and processes.  As 
expected TRPV1 label was absent in TRPV1-/- optic nerve astrocytes (Figure 2.15A).  Knockout 
of the TRPV1 gene was confirmed with genotyping (Figure 2.15B).  Using primers near the 
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deletion site and a common reverse primer yielded a gene product at 984 bp in C57 mice and 
product at 600 bp in TRPV1-/- mice.  GAPDH was used as a positive control (data not shown).  
 
 
Figure 2.14.  TRPV1 expression in cultured retinal astrocytes. Cultures of primary rat retinal 
astrocytes (A) expressing GFAP (red) demonstrate diffuse TRPV1 labeling (green). Higher 
magnification and orthogonal views (B) demonstrate patches of TRPV1 (green) or GFAP (red) 
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label as well as colocalization (B; yellow). Western blot analysis (C) shows expression of 
TRPV1 and GFAP in cultured astrocytes; β-actin is shown as loading control. Bands for TRPV1 
include the expected weight near 100 kDa, a 75 kDa isoform, and a lower weight doublet 
specific for astrocytes. Scale: 10 μm (A); 5 μm (B). 
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Figure 2.15.  TRPV1 expression in cultured optic nerve astrocytes .  Cultures of primary optic 
nerve astrocytes from C57 and TRPV1-/- mice (A) express GFAP (red).  TRPV1 (green) is 
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expressed by C57 optic nerve astrocytes but is absent in TRPV1-/- astrocytes.  Scale: 20 m.  
Genotyping (B) confirms that TRPV1-/- mice have a deletion in the TRPV1 gene as shown by 
the different-sized  PCR products generated using DNA from C57 and TRPV1-/- mice. L: 100 bp 
ladder (top gel), 1 kb ladder (bottom gels). neg: negative control (water added in place of DNA).   
 
2.4 Discussion 
 Astrocytes in the retina and other parts of the CNS are known to express TRPV1 (Huang 
et al., 2010; Leonelli et al., 2009; Mannari et al., 2013; Sun et al., 2013).  Here, I show that 
retinal astrocytes express TRPV1, TRPV5 and TRPV6 channels (Figure 2.6A, E and F).  TRPV5 
and TRPV6 are more calcium-selective than TRPV1 (den Dekker et al., 2003), but their function 
in astrocytes is unknown.  The expression of TRPV2 in astrocytes depends on the astrocyte 
population studied.  Cerebellar astrocytes express TRPV2, which can be activated by 
temperature > 50˚C and the lipid, lysophosphatidylcholine to increase intracellular calcium levels 
(Shibasaki et al., 2013).  In contrast, TRPV2 expression has not been shown in retinal astrocytes  
(Leonelli et al., 2009).  Consistent with that study, TRPV2 expression was not detected in my 
retinal astrocytes (Figure 2.6).  Similar to TRPV2, the expression of TRPV4 also varies across 
astrocyte populations.  Although retinal astrocytes do not express TRPV4 (Figure 2.6D;  
Ryskamp et al., 2011), TRPV4 is found in astrocytes in the cortex and hippocampus (Bai and 
Lipski, 2010; Benfenati et al., 2007; Butenko et al., 2012).  Less is known about TRPV3 in 
retinal astrocytes.  In addition to TRPV channels, astrocytes in the brain also express TRPA1, 
which modulates astrocyte calcium levels and TRPC1-6, which are involved in store-operated 
calcium entry and calcium regulation (Beskina et al., 2007; Grimaldi et al., 2003; Malarkey et 
al., 2008; Miyano et al., 2010; Shigetomi et al., 2012).  Expression of TRPA and TRPC channels, 
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however, has not been studied in astrocytes in the retina or optic nerve.  Since astrocytes are 
important in mediating neuronal function and synaptic transmission, and calcium is a key 
signaling molecule, it would be interesting to profile the expression and localization of other 
TRP channels in astrocytes.   
TRPV1 localized to astrocyte cell bodies and processes identified by GFAP co-label in 
both mouse and rat whole-mounted retina (Figure 2.6 and 2.7). Retinal ganglion cells labeled 
with pNF also express TRPV1 (Figure 2.7), consistent with previous work (Leonelli et al., 2010; 
Sappington et al., 2009).  Higher magnification images and orthogonal views show discrete 
pockets of colocalization of GFAP and TRPV1 in astrocyte cell bodies and processes in both 
mouse and rat (Figure 2.7).  This is similar to the expression pattern seen in retinal cultures, 
which also exhibited punctate localization of TRPV1 and GFAP (Figure 2.14).  Other groups 
have found that TRPV1 is punctate and more concentrated in astrocytes in the perivascular area 
in retinal sections (Leonelli et al., 2009).  TRPV1 expression in the astrocyte cytoplasm and in 
the endfeet that contacts the vasculature has also been seen in vivo in the spinal dorsal horn, 
temporal cortex and hippocampus (Doly et al., 2004; Sun et al., 2013).   In the sensory 
circumventricular organs, however, TRPV1 has higher expression in the thick astrocyte 
processes than in the finer ones (Mannari et al., 2013).  Within both retina and optic nerve 
primary astrocytes cultures, TRPV1 was diffusely expressed throughout the astrocyte soma and 
processes (Figure 2.13 and 2.14).  This expression pattern was similar to cultured cortical 
astrocytes, where TRPV1 expression was extensive in the membrane and cytoplasm, but was 
more limited in the processes (Huang et al., 2010).  
In the optic nerve head and optic nerve tissue, TRPV1 expression in astrocytes was 
generally more punctate than in the retina and appeared to be species-dependent (Figure 2.9).  
  
 72 
 
TRPV1 either localized to discrete areas within astrocytes (mouse) or was diffusely expressed 
throughout astrocytes (rat and monkey). The punctate expression of TRPV1 observed in some 
optic nerve astrocytes has also been seen in astrocytes in the spinal dorsal horn and brain tissue 
(Doly et al., 2004; Huang et al., 2010).  Extensive co-labeling with GFAP was observed in 
monkey optic nerve head astrocytes compared to mouse or rat (Figure 2.9).  The optic nerve head 
architecture is different and more complex in monkeys than in rodents, which might account for 
the differences in expression pattern.  The antigenicity of TRPV1 might also be different 
between monkey and rodents and resulted in greater antibody recognition. There is also vast 
heterogeneity in astrocytes within different tissues.  Across regions in the CNS, astrocytes can be 
classified into as many as nine groups (radial, Bergmann glia, protoplasmic, fibrous, velate, 
marginal glia, perivascular, ependymal and tanycytes) based on morphology (Emsley and 
Macklis, 2006).  Comparing TRP expression amongst the different types of astrocytes within the 
CNS could help elucidate the role of these channels in normal glial function.   
 Species differences also exist between primate and rodent astrocytes.  Astrocytes from 
human tissue are more complex than rodents.  Human protoplasmic astrocytes are 2.6 times 
greater in diameter and have 10 times more GFAP-positive processes than rodents (Oberheim et 
al., 2009).    Because human astrocytes are larger and more complex, the number of synapses an 
astrocyte can cover is also greater - 270,000 to 2 million synapses compared to 20,000 to 
120,000 synapses for rodents (Oberheim et al., 2009).  Calcium wave propagation in human 
astrocytes is also 4 times faster than rodents (Oberheim et al., 2009).  Additionally, two novel 
astrocyte subtypes exist in primates that are not present in rodents: interlaminar and varicose 
projection astrocytes.  Interlaminar astrocytes are found in cortical layer 1 and are characterized 
by one to two long columnar processes in addition to several shorter processes that radiate from 
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the soma (Colombo, 1996; Colombo et al., 1995; Oberheim et al., 2009).  Varicose projection 
astrocytes are present in layers 5-6, and have a feature of one to five long, evenly spaced 
processes radiating from the soma (Oberheim et al., 2009).  This suggests that astrocytes are 
fundamentally different in terms of morphology and function depending on species.  Even within 
the same species, multiple subtypes exist which further emphasizes the heterogeneity of 
astrocyte populations. 
 Astrocyte properties can also differ between mouse and rat.  In a scratch wound model, 
rat astrocytes demonstrated higher expression of GFAP and increased proliferation following 
injury when compared to mouse astrocytes (Puschmann et al., 2010).  Rat astrocytes also exhibit 
higher mRNA and protein levels for GFAP, nestin and vimentin than mouse astrocytes under 
basal conditions in vitro (Ahlemeyer et al., 2013).  Following 28 days in culture, levels of the 
glutamate transporters, GLAST and GLT-1 decreased in mouse but not rat astrocytes 
(Ahlemeyer et al., 2013). These data suggest that astrocytes, while similar in mouse and rat, are 
fundamentally different in the expression of certain genes and in their response to injury.  
   In the optic nerve, two subtypes of astrocytes (type 1 and type 2) have been identified 
based on antigenicity and morphology.  Type 2 astrocytes can bind tetanus toxin and the 
antibody for A2B5, a cell surface ganglioside, while Type 1 astrocytes usually do not (Raff et al., 
1983). Type 1 astrocyte can be further divided into Type 1A and 1B based on their expression of 
neural cell adhesion molecule (NCAM).  Type 1A astrocytes express GFAP, but not NCAM or 
A2B5 while Type 1B express both GFAP and NCAM but not A2B5 (Kobayashi et al., 1997).  
Type 1B is the main astrocyte in the optic nerve head, while Type 2 astrocytes make up more 
than 65% of the optic nerve (Kobayashi et al., 1997; Miller et al., 1985).  Type 1 astrocytes are 
morphologically similar to protoplasmic astrocytes while Type 2 are more like fibrous astrocytes 
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(Miller and Raff, 1984).  Since optic nerve cultures were isolated from adult mice, both astrocyte 
subtypes would be present.  Since Type 1 and Type 2 astrocytes can be distinguished with the 
antibody A2B5, it would be interesting to immunolabel for A2B5 to determine the percentage of 
each subtype present in the optic nerve cultures.   Furthermore, co-immunolabeling for A2B5 
and TRPV1 can be done to determine if there are differences in expression of TRPV1 between 
the two subtypes.   
 Subtypes of astrocytes have also been found in retina.  In primates, two morphological 
classes of astrocytes have been determined: elongated and stellate (Ogden, 1978).  Elongated 
astrocytes have processes that are parallel to the axon bundles and without vascular contact, 
while processes of stellate astrocytes form contacts with the vasculature (Ogden, 1978).  In rabbit 
retina, however, three subtypes have been identified: class A, B and C (Robinson and Dreher, 
1989).  Class A astrocytes are perivascular and coupled with the vasculature.  Class B do not 
contact either the vasculature or axons, and Class C mainly associate with axons (Robinson and 
Dreher, 1989).  Less is known about retinal astrocyte subtypes in rodents, and one possible 
experiment would be to classify the different astrocyte morphologies present in rodent retina 
using immunolabeling with astrocyte markers including GFAP, S100β and glutamine synthetase.      
 Astrocytes from different regions of the eye and across different species exhibit a high 
degree of heterogeneity.  Although both retinal and optic nerve astrocytes express TRPV1, 
expression patterns vary from diffuse to punctate and discrete pockets depending on location and 
species.  This chapter established the presence of TRPV1 protein in retinal and optic nerve 
astrocytes both in vivo and in vitro.  Subsequent chapters will examine the role of TRPV1 in an 
intrinsic stress response in astrocytes.   
 
 * Portions of this chapter have been published previously in Ho KW, Lambert WS and Calkins DJ.  
Activation of the TRPV1 cation channel contributes to stress-induced astrocyte migration (2014) Glia 
62(9):1435-51. 
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CHAPTER III 
 
THE CONTRIBUTION OF THE TRPV1 CHANNEL IN ASTROCYTE MIGRATION* 
 
3.1 Introduction 
Astrocytes distribute widely across the CNS and provide both metabolic and structural 
support to neurons as part of normal physiology.  For example, by establishing networks with the 
vasculature and with other glia, astrocytes contribute to the exchange of ions and small 
molecules to maintain homeostasis and facilitate cell-cell communication (Giaume et al., 2010).  
Astrocytes can also modulate synaptic transmission between neurons through potassium uptake, 
neurotransmitter recycling, and the release of gliotransmitters such as glutamate and ATP 
(Hamilton and Attwell, 2010; Wang et al., 2012).  In response to neuronal stress or injury, 
astrocytes undergo reactive hypertrophy of the cell soma and processes (Sofroniew, 2009; 
Sofroniew and Vinters, 2010).  These morphological changes are associated with an upregulation 
and redistribution of cytoskeletal proteins, including GFAP and actin.   
Along with changes in morphology, reactive astrocytes undergo a series of functional 
changes, including increased motility. Astrocyte migration within the CNS can underlie glial scar 
formation in spinal cord injury and traumatic brain injury, and can be both beneficial and 
detrimental to neurons (Hsu et al., 2008; Saadoun et al., 2005; Silver and Miller, 2004).  In 
addition to injuries, astrocyte migration is also important in the metastasis of gliomas, which 
account for about 70% of all brain tumors (Ohgaki and Kleihues, 2005).  Glioma cells are 
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particularly invasive and aggressive, leading to high mortality rates for patients.  Increased cell 
motility contributes to this invasiveness, as glioma cells upregulate genes that mediate migration, 
cell adhesion and extracellular matrix remodeling (Demuth and Berens, 2004; Farin et al., 2006; 
Mariani et al., 2001).  Astrocyte migration has also been observed in eye diseases including age-
related macular degeneration and glaucoma (Miao et al., 2010; Morino et al., 1990; Ramirez et 
al., 2001).  In age-related macular degeneration and retinal detachment, retinal astrocytes can 
migrate from their location in the nerve fiber layer to the vitreous (Morino et al., 1990; Ramirez 
et al., 2001).  In glaucoma, astrocytes in the optic nerve can become reactive and migrate into the 
nerve bundles (Miao et al., 2010).  And like in gliomas, glaucomatous astrocytes have 
differential expression of genes involved in migration and extracellular matrix remodeling 
(Hernandez et al., 2008; Miao et al., 2010).  
 Migration is a stress response of astrocytes following injury, and this motility can be both 
beneficial and harmful to neurons (Demuth and Berens, 2004; Ehtesham et al., 2004; Fok-Seang 
et al., 1995; Lefranc et al., 2009; Ramirez et al., 2001; Wang et al., 2004; Wilby et al., 1999).  By 
better understanding the mechanisms that mediate astrocyte migration, novel therapeutic 
interventions can be developed to temper glial reactivity to improve pathological outcomes 
associated with injury and disease.   
 Astrocyte migration is mediated by a variety of signaling pathways and involves 
cytoskeletal proteins and proteins that mediate adhesion, cell polarity and extracellular matrix 
remodeling (Laczko et al., 2007; Milner et al., 1999; Ogier et al., 2006; Osmani et al., 2006; 
Raftopoulou and Hall, 2004; Ricard et al., 2000). Calcium is a key signaling messenger and can 
regulate many of these pathways.  Astrocytes are known to express a number of potent Ca
2+
 
modulators, including TRPV1 (Chen et al., 2009; Doly et al., 2004; Ho et al., 2012; Huang et al., 
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2010; Mannari et al., 2013).  Since retinal and optic nerve astrocytes express TRPV1 (Chapter 2; 
Leonelli et al., 2009), we asked whether this channel could play a role in mediating astrocyte 
migration in response to injury.  We induced migration of isolated retinal astrocytes using a 
scratch wound assay and examined how modulation of TRPV1 activation with subunit-specific 
agonists (CAP and RTX) and antagonists (IRTX and CPZ) affected the rate of migration. We 
also examined the rate of migration in astrocytes isolated from the optic nerve head of C57BL/6 
mice and TRPV1 -/-  mice following scratch injury.  
 
3.2 Methods       
Scratch wound model of injury-induced migration 
To test astrocyte migration following injury, I used the scratch wound model.  Unlike the 
transwell assay which relies on chemotaxis, the scratch wound assay is a wound healing model.  
In the transwell assay, cells are seeded onto one side of a transwell chamber and allowed to 
migrate to the opposite side in response to a chemotactic signal.  By counting the number of cells 
on the opposite side, migration is determined. In the scratch wound model however, a single 
scratch is made through the astrocyte monolayer.  In response to this injury, cells release factors 
into the extracellular environment to induce migration of adjacent cells.   
Retinal and optic nerve astrocytes were isolated as previously described in Chapter 2.  
Confluent primary astrocytes were passaged with 0.25% trypsin/2.21 mM EDTA and seeded 
onto cover glass chambers (ThermoScientific, Rochester, NY) coated with 0.01 mg/mL poly-D-
lysine.  Once confluent, astrocytes were serum-starved in 0.5% FBS overnight.  A single scratch 
with a 1 mL pipet tip was then made through the astrocyte monolayer, and cultures were washed 
three times with serum-free DMEM/F-12 to remove debris (Figure 3.1).  Cultures were then 
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incubated in astrocyte media plus 0.5% FBS in addition to pharmacological agents.  The 
following TRPV1-specific agonists were applied immediately following the scratch:  capsaicin 
(CAP; Sigma-Aldrich, St. Louis, MO, 100 pM-10 µM in ethanol) and resiniferatoxin (RTX; 
Thermo Fisher Scientific, Wilmington, DE, 100 pM-10 μM in ethanol). The following TRPV1-
specific antagonists were applied 15 minutes prior to scratch: capsazepine (CPZ; Tocris 
Bioscience, Bristol, UK, 1 μM-10 µM in ethanol) and 5’-iodo resiniferatoxin (IRTX; Tocris 
Bioscience, Bristol, UK, 300 nM-3 µM in ethanol).  The following calcium chelators were used: 
ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA, Sigma-Aldrich, St. 
Louis, MO, 100 µM-1 mM in water) and BAPTA-AM (Life Technologies, Grand Island, NY, 1 
μM-10 µM in dimethyl sulfoxide).  BAPTA was applied 15 minutes prior to scratch, while 
EGTA was added immediately after.  Differential interference contrast (DIC) images were taken 
on an inverted Nikon Eclipse Ti microscope at 6 to 12 hour intervals post-scratch to monitor 
wound closure.  A minimum of five images per well were taken, and each treatment was 
performed in triplicate.  Images were taken until the wound for one or more treatments reached 
70-100% closure, typically 24 to 48 hours post-wound.  
  
 79 
 
 
Figure 3.1. The scratch wound assay of injury-induced migration.  (A) A schematic of the assay 
where a wound is made through the astrocyte cell layer with a pipet tip is shown.  In response to 
the injury, astrocytes on either side of the injury would migrate over time to close the wound.  
(B) DIC images illustrate this assay in live astrocyte cultures.    
 
Quantification of proliferation in scratch wound assay 
To quantify proliferation, astrocyte cultures were fixed in 4% paraformaldehyde for 20 
minutes following scratch injury and treatment with TRPV1 pharmacological agents.  Cells were 
then placed in primary antibody for Ki-67 (ThermoScientific, Rochester, NY, 1:200) overnight at 
4˚C, followed by incubation in the appropriate DyLight-conjugated secondary antibodies 
(Jackson Immunoresearch, West Grove, PA 1:150).  Staining with 4',6-diamidino-2-phenylindole 
(DAPI; Life Technologies, Grand Island, NY, 1:100) in water was also performed to visualize 
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nuclei.  Confocal images were taken using an Olympus FV-1000 inverted microscope.  Cells 
positive for Ki-67 and DAPI were counted with ImageJ (Schneider et al., 2012).  Five images per 
replicate were taken, and each treatment condition had at least three replicates.  The amount of 
proliferation is represented as percent Ki-67-positive cells per total DAPI-positive cells in a field.   
 
Quantification of astrocyte migration 
To quantify astrocyte migration, DIC images for a given treatment were analyzed in 
blinded fashion to determine the area of the wound at each time point. Briefly, using ImageJ 
(Schneider et al., 2012) a rectangle was drawn over the cell-free area of the image, which was 
defined as the area that was minimally 95% free of astrocyte processes. This “cell-free” area was 
verified post-hoc by measuring total astrocyte cytoplasmic area and comparing it to any residual 
cytoplasmic area within the cell-free area.  Across all scratch wounds and conditions examined, 
this cell free area excluded 97.8 ± 1.8% of the astrocyte processes calculated by cytoplasmic 
area.  Although a 1 mL pipet tip was used to make the scratch wound in all assays, variations in 
tip diameter resulted in a range of initial cell-free areas within each preparation. To control for 
this variability, I restricted my analysis to scratch wound preparations with initial cell-free areas 
within the standard deviation of vehicle astrocytes for that assay.  Excluding preparations that 
fell outside the standard deviation left 10 to 15 images for analysis.  Rarely, a preparation 
required 1-2 additional rectangles to account for partial wound closure or asymmetric closure. In 
these cases, the areas of the rectangles were summed for total astrocyte-free area. 
Next, I graphed the cell-free area at each time point, and linear regression was then 
performed to determine the best-fitting line for cell-free area over time. The slope of each line 
and its associated error was considered the rate of migration.  These were compared between 
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treatments to determine significance using GraphPad Prism (GraphPad Software, Inc., La Jolla, 
CA). For each treatment, I calculated average cell-free area ± standard error of the mean (SEM) 
versus time post-scratch; this is shown in my figures along with the best-fitting regression line. 
 
Statistical analysis  
 Data is presented as mean ± standard error of the mean (SEM) for each treatment.  
Statistical analysis and p-values for comparing mean cell-free areas were obtained using one-way 
ANOVA with Bonferroni’s Multiple Comparison Test or t-tests for data meeting criteria for 
normalcy or using non-parametric rank statistics for data failing normalcy using SigmaPlot 11.0 
for Windows (Systat Software Inc., Chicago, IL) or GraphPad Prism (GraphPad Software, Inc., 
La Jolla, CA). 
 
3.3 Results 
Proliferation in scratch wound assay is reduced with low serum conditions 
In response to injury, astrocytes can also proliferate in the scratch wound assay (Liang et 
al., 2007).  In order to reduce astrocyte proliferation, I performed the scratch wound assay in low 
serum (0.5%) conditions.  To verify reduced proliferation in low serum conditions, I measured 
proliferation in astrocyte cultures following scratch injury under normal (10%) and low (0.5%) 
serum conditions.  Proliferation was examined by immunolabeling for Ki-67, which recognizes a 
nuclear antigen found in dividing cells but is absent in quiescent cells (Figure 3.2A; Scholzen 
and Gerdes, 2000).  Incubation in 0.5% serum reduced proliferation compared to 10% serum in 
both naïve (1.63 ± 0.63% vs. 17.98 ± 1.67% respectively; p < 0.001) and 24 hours after injury 
(5.68 ± 1.48% vs. 16.90 ± 2.42%, respectively; p = 0.005) conditions.  In normal 10% serum 
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conditions, scratch injury did not change the amount of proliferation compared to naive 
unscratched astrocytes (17.98 ± 1.67% vs. 16.90 ± 2.42%; Figure 3.2B).  Under low serum 
(0.5%) conditions, proliferation increased from 1.63 ± 0.63% to 5.68 ± 1.48% following scratch 
injury, although this was not significant (p = 0.918).  The average total number of cells was 
similar for naïve (96.00 ± 10.26 vs 116.95 ± 12.33 cells) and scratched (52.35 ± 3.63 vs 56.85 ± 
5.54 cells) under low and normal serum conditions, respectively (p > 0.262; Figure 3.2C).  The 
reduction in the number of cells following scratch was due to the lower concentration of cells at 
the leading edges. 
 
 
Figure 3.2. Proliferation in scratch wound model.  (A) Confocal micrographs show naïve 
astrocytes and injured astrocytes cultured under normal (10%) and low (0.5%) serum conditions 
that have been immunolabeled for Ki-67 (red) and DAPI (blue).  Scale: 50 µm.  (B) Bar graph 
shows the percent of Ki-67 positive cells for each treatment condition. * p ≤ 0.005 vs. 10% 
serum (n=4). (C)  Bar graph shows the total number of nuclei for each treatment. 
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TRPV1 agonism has modest effects on astrocyte migration 
Next, to determine if pharmacological activation of TRPV1 would affect migration, I 
treated astrocytes immediately following scratch with the specific agonists CAP or RTX 
(Caterina et al., 2000; Caterina et al., 1997; Raisinghani et al., 2005; Szallasi and Blumberg, 
1989).  Addition of CAP at the concentrations tested had no effect on cell morphology compared 
to vehicle throughout the duration of the experiment (Figure 3.3).  At 24 hours following injury, 
CAP-treated astrocytes had processes and morphologies similar to vehicle, and no cell 
detachment was observed (Figure 3.3B and 3.3C). 
Representative images show that scratch injury induces a wound through the astrocyte 
cell layer (Figure 3.4A and 3.4B).  Astrocyte migration to reduce the cell-free area following 
scratch wound was similar for vehicle and CAP-treated cells at the time points measured (Figure 
3.4A and 3.4B).  Initial wound areas for vehicle treated cells in the CAP experiments averaged 
6.49 ± 0.338 x10
5
 μm2 (Figure 3.4C).  Preparations treated with CAP with an initial wound area 
that did not fall within the standard deviation of vehicle were excluded from analysis, leaving at 
least 14 independent images per time point for analysis.  At 24 hours post-injury, treatment with 
100 nM, 1 µM and 10 µM CAP induced closure of 74 ± 4.21%, 64 ± 5.77% and 46 ± 4.60% 
respectively, compared to 62 ± 6.34% closure with vehicle (Figure 3.4C).  This difference in 
percent closure was not significant (p ≥ 0.097).  In terms of migration rate following CAP 
treatment (Figure 3.4D), a range of concentrations from 100 pM to 1 μM showed non-significant 
accelerations of 8-23% (p ≥ 0.26).  This trend towards acceleration was reversed at the highest 
concentration (10 μM), which resulted in a non-significant trend toward a reduced migration rate 
(~ 9%) compared to vehicle (p = 0.66).  
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To confirm the results with CAP and further assess TRPV1’s role in injury-induced 
migration, I tested the effects of RTX, another TRPV1 agonist.  Much like CAP treatment, cell 
morphology was not affected by the addition of RTX at the concentrations tested when compared 
to vehicle (Figure 3.5).  Again, representative DIC images show that scratch injury induces a 
wound that is reduced over time as the cells migrate for both vehicle and RTX (Figure 3.6A and 
3.6B).  Initial wound areas for vehicle averaged 8.60 ± 0.45 x10
5
 µm
2
 (Figure 3.6C).  All 
preparations treated with RTX had initial wound areas that fell within the standard deviation of 
the vehicle, therefore no preparations were excluded from analysis.  Treatment with 100 pM or 1 
nm RTX induced closure of 59 ± 4.05% and 52 ± 3.32%, similar to the 52 ± 5.05% closure with 
vehicle (p ≥ 0.289; Figure 3.6C).  As with CAP, the highest concentration of RTX used (10μM) 
appeared to reduce closure to 38 ± 1.74% at 24 h (p = 0.056). When comparing migration rates, 
treatment with 100 pM or 1 μM RTX accelerated migration 26% and 11% relative to vehicle, 
respectively (p ≥ 0.268; Figure 3.6D).  Migration rates for 1, 10 and 100 nM RTX were similar 
to vehicle (p > 0.823).  Despite a near 30% average reduction in migration rate when 10 μM 
RTX was applied, this effect was not significant (p = 0.186).   
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Figure 3.3.  Cell morphologies following CAP treatment.  In response to injury, cells at the 
leading edge migrate in the scratch wound assay (A).  DIC micrograph shows live, vehicle-
treated cells at 24 hours following injury. High magnification images were captured at the 
leading edge (solid box; B).  Morphologies are shown for cells treated with vehicle and multiple 
concentrations of CAP (C).  Scale: 50 µm for B, 20 µm for C.    
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Figure 3.4.  Effects of CAP on astrocyte migration.  DIC micrographs show astrocytes treated 
with (A) vehicle and (B) 100 nM CAP at 0, 12 and 24 hours following scratch injury.  Dotted 
boxes indicate the cell-free area. Scale bar: 100 µm.  (C) Scatter plots with the best-fit linear 
regression line show the change in area over time for astrocytes treated with vehicle, 100 nM, 1 
µM and 10 µM CAP.  (D) Bar graphs show the relative migration rate (or the slope of the best-fit 
linear regression line) for vehicle and multiple concentrations of CAP.  
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Figure 3.5. Cell morphologies following RTX treatment.  In response to injury, cells at the 
leading edge migrate in the scratch wound assay (A).  DIC micrograph shows live, vehicle-
treated cells at 24 hours following injury. High magnification images were captured at the 
leading edge (solid box; B).  Morphologies are shown for cells treated with vehicle and multiple 
concentrations of RTX (C).  Scale: 50 µm for B, 20 µm for C.    
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Figure 3.6.  Effects of RTX on astrocyte migration.  DIC micrographs show astrocytes treated 
with (A) vehicle and (B) 1 nM RTX at 0, 12 and 24 hours following scratch injury.  Dotted 
boxes indicate the cell-free area.  Scale bar: 100 µm.  (C) Scatter plots with the best-fit linear 
regression line show the change in area over time for astrocytes treated with vehicle, 100 pM, 1 
nM and 10 µM RTX.  (D) Bar graphs show the relative migration rate (or the slope of the best-fit 
linear regression line) for vehicle and multiple concentrations of RTX.  
  
 89 
 
Effects of TRPV1 agonists on astrocyte proliferation  
Although proliferation following scratch injury was low, averaging only 5.68% in 0.5% 
serum conditions (Figure 3.2), I also immunolabeled for Ki-67 to test whether proliferation was 
affected by addition of CAP and RTX.  Representative confocal micrographs show that Ki-67 
and DAPI labeled nuclei in both vehicle and CAP treated astrocytes (Figure 3.7A).  Similar 
labeling was observed following RTX treatment (data not shown).  The percentage of Ki-67 
positive cells averaged 5.91 ± 1.76 to 13.07 ± 2.41 % in CAP-treated cells and was similar to 
vehicle (7.93 ± 2.41%; p > 0.075; Figure 3.7B). Quantification of the percentage of Ki-67 
positive cells following RTX treatment shows that proliferation is similar for both 100 pM and 1 
nM RTX when compared to vehicle (p ≥ 0.572).  Addition of 10 µM RTX however, reduced 
proliferation from 7.33 ± 1.13% to 3.75 ± 0.59% compared to vehicle (p = 0.03; Figure 3.7C).  
The average number of total nuclei for CAP treated cells ranged from 24.36 ± 1.73 to 42.81 ± 
4.32, and was similar to the vehicle average of 38.00 ± 1.66 cells (p = 0.295; data not shown).  
The same was true for RTX-treated cells (p > 0.125). 
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Figure 3.7.  Effects of TRPV1 agonists on astrocyte proliferation following injury. (A) Confocal 
micrographs show vehicle- and 10 pM CAP-treated astrocytes immunolabeled for Ki-67 (red) 
and DAPI (blue) following scratch.  (B) Bar graph shows the percent of Ki-67 positive cells for 
vehicle and multiple concentrations of CAP. (C) Bar graph shows the percent of Ki-67 positive 
cells for vehicle and different RTX concentrations.  * p = 0.03 vs. vehicle.  
 
Antagonism of TRPV1 reduces retinal astrocyte migration  
 In addition to activating TRPV1 and measuring migration, I also treated isolated retinal 
astrocytes with the TRPV1-specific antagonists CPZ or IRTX 15 minutes prior to the scratch to 
discern whether blocking channel activation would influence injury-induced migration 
(Seabrook et al., 2002; Wahl et al., 2001; Walpole et al., 1994).   
 Addition of CPZ did not affect cell morphology compared to vehicle throughout the 
duration of the experiment (Figure 3.8). Figure 3.9 shows representative images of CPZ-treated 
astrocytes following scratch wound.  In the vehicle group, the initial cell-free area was reduced at 
36 hours by astrocytes migrating from the edges (Figure 3.9A). Treatment with 10 μM CPZ 
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reduced wound closure, resulting in a considerably larger cell-free area at 36 hours compared to 
vehicle (Figure 3.9B).  All preparations treated with CPZ had initial wound areas that were 
within the standard deviation of the vehicle, therefore no preparations were excluded from 
analysis.  For the vehicle group in the CPZ experiments, an initial wound area of 9.4 ± 0.09 x10
5
 
μm2 was reduced 75 ± 3.13% at 36 hours following injury (Figure 3.9C).  While treatment with 1 
μM CPZ resulted in similar closure at 36 hours (77 ± 4.87%, p = 0.65), both 5 and 10 μM CPZ 
significantly reduced closure to 44 ± 3.41% and 38 ± 3.10% (p ≤ 0.001), respectively. 
Accordingly, the rate of astrocyte migration also differed with increasing concentrations of CPZ 
(Figure 3.9D). Compared to vehicle, 5 and 10 μM CPZ reduced migration rate by 41% and 44%, 
respectively (p ≤ 0.006).  This effect was dose-dependent as the 15% reduction with 1 μM CPZ 
was not significant (p = 0.064).   
To further determine the effects of inhibiting TRPV1, I tested the effects of a second 
antagonist, IRTX on astrocyte migration. The addition of IRTX at various concentrations did not 
affect cell morphology compared to vehicle (Figure 3.8).  Like with 5 and 10 µM CPZ, treatment 
with 3 µM IRTX reduced migration, resulting in a larger cell-free area over time compared to 
vehicle (Figure 3.10A and 3.10B). All preparations treated with IRTX had initial wound areas 
that fell within the standard deviation of the vehicle, therefore no preparations were excluded 
from analysis.  Vehicle-treated cells had an initial wound area that averaged 12.54 ± 0.31 μm2 
x10
5
 and showed a closure of 76 ± 2.93% at 36 hours after injury.  Treatment with 300 nM or 1 
μM IRTX had no effect on wound closure compared to vehicle (67 ± 4.16% and 75 ± 4.02% 
respectively, p > 0.08), while 3 μM IRTX significantly reduced closure to 52 ± 2.23% of initial 
wound area (p ≤ 0.001; Figure 3.10C).  Similarly, while 300 nM and 1 μM had little effect on 
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migration rate compared to vehicle (p ≥ 0.687), 3 μM IRTX significantly reduced the rate by 
28% again illustrating a dose-dependent effect (p = 0.035; Figure 3.10D).  
 
 
Figure 3.8.  Cell morphologies following CPZ and IRTX treatments.  In response to injury, cells 
at the leading edge migrate in the scratch wound assay (A).  DIC micrograph shows live, vehicle-
treated cells at 24 hours following injury. High magnification images were captured at the 
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leading edge (solid box; B).  Morphologies are shown for cells treated with vehicle and multiple 
concentrations of CPZ or IRTX (C).  Scale: 50 µm for B, 20 µm for C.    
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Figure 3.9.  Effects of CPZ on astrocyte migration.  DIC micrographs show astrocytes treated 
with (A) vehicle and (B) 10 µM CPZ at 0, 12 and 36 hours following scratch injury.  Dotted 
boxes indicate the cell-free area. Scale bar: 100 µm. (C) Scatter plots with the best-fit linear 
regression line show the change in area over time for astrocytes treated with vehicle, 1, 5 and 10 
µM CPZ.  (D) Bar graphs show the relative migration rate (or the slope of the best-fit linear 
regression line) for vehicle and CPZ. * p ≤ 0.006 vs. vehicle.   
  
 95 
 
 
Figure 3.10.  Effects of IRTX on astrocyte migration.  DIC micrographs show astrocytes treated 
with (A) vehicle and (B) 3 µM RTX at 0, 12 and 36 hours following scratch injury.  Dotted 
boxes indicate the cell-free area.  Scale bar: 100 µm. (C) Scatter plots with the best-fit linear 
regression line show the change in area over time for astrocytes treated with vehicle, 300 nM, 1 
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and 3 µM RTX.  (D) Bar graphs show the relative migration rate (or the slope of the best-fit 
linear regression line) for vehicle and IRTX. * p = 0.035 vs. vehicle. 
 
Effects of TRPV1 antagonists on astrocyte proliferation 
  To further determine whether TRPV1 affects injury-induced proliferation, I tested 
whether the addition of the antagonists CPZ and IRTX influenced astrocyte proliferation 
following scratch injury.  Again, Ki-67 immunolabeling was present in the nucleus of both 
vehicle and CPZ-treated cells (Figure 3.11A), as well as in IRTX-treated cells (data not shown). 
Quantification of the number of cells positive for Ki-67 normalized to total nuclei indicated that 
proliferation averaged 7.70 ± 1.38% for vehicle in the CPZ experiments (Figure 3.11B). 
Addition of CPZ reduced proliferation to 3.31 ± 0.51% for 5 µM and to 1.73 ± 0.96% for 10 µM 
CPZ.  This reduced proliferation in response to 10 µM CPZ was significant compared to vehicle 
(p < 0.02; Figure 3.11B).  Similarly, addition of 3 µM IRTX reduced the percent of Ki-67 
positive cells relative to vehicle (1.11 ± 0.92% vs. 3.60 ± 0.71% respectively), but this reduction 
was not significant (p > 0.09; Figure 3.11C).  Total number of nuclei was similar to vehicle 
controls for all concentrations of CPZ (p > 0.48) and IRTX (p > 0.07; data not shown).        
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Figure 3.11.  Effects of TRPV1 antagonists on astrocyte proliferation following injury. (A) 
Confocal micrographs show vehicle- and 10 µM CPZ-treated astrocytes that have been 
immunolabeled for Ki-67 (red) and DAPI (blue) following scratch injury.  (B) Bar graph 
showing the percent of Ki-67 positive cells for vehicle and 5 and 10 µM CPZ. *p < 0.02 
compared to vehicle.  (C) Bar graph showing the percent of Ki-67 positive cells for vehicle and 3 
µM IRTX. 
 
Genetic knockout of TRPV1 slightly reduces retinal astrocyte migration 
 To complement my pharmacological experiments, I next examined whether genetic 
deletion of TRPV1 affected astrocyte migration in the scratch wound model.  To this end, I used 
optic nerve astrocytes isolated from C57 wild-type and TRPV1-/- mice at one month of age.  For 
the characterization, purity and genotyping of these astrocytes, see Chapter 2. 
 Similar to the prior experiments in retinal astrocytes, scratch injury induced a wound 
through the astrocyte cell layer that closed over time as migration occurred.  Representative 
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images show that C57 wild-type and TRPV1-/- astrocytes have similar morphologies after injury 
(Figure 3.12).  The change in cell-free area following injury was also similar (Figure 3.13A and 
3.13B).  Initial areas for C57 astrocytes averaged 10.54 ± 0.92 x10
5
 µm
2
.  Like with the 
pharmacological experiments, initial areas for TRPV1-/- astrocytes that were not within the 
standard deviation of C57 astrocytes were excluded, leaving at least ten images per time point for 
each replicate ( n= 9 animals for C57 and 10 for TRPV1-/-). Wound closure was similar between 
C57 and TRPV-/- astrocytes (80 ± 6.37% versus 78 ± 7.16%, respectively; p=0.90) following 
scratch injury (Figure 3.13C).  Although migration rate was reduced by 14% in TRPV1-/- 
astrocytes compared to C57, this reduction was not significant (p > 0.39; Figure 3.13D).   
 
 
Figure 3.12.  Comparison of cell morphologies in C57 and TRPV1-/- astrocytes.  DIC 
micrographs show live astrocytes from C57 and TRPV1-/- optic nerves at 24 hours following 
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scratch injury (A). High magnification images were captured at the leading edge (dotted lines).  
High magnification images are shown for C57 and TRPV1-/- (B).  Scale: 20 µm.    
 
 
Figure 3.13.  Injury-induced migration in TRPV1-/- astrocytes.  DIC micrographs show 
astrocytes from (A) C57 wild-type and (B) TRPV1-/- optic nerves at 0, 12 and 24 hours 
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following scratch injury.  Dotted boxes indicate the cell-free area. Scale bar: 100 µm.  (C) 
Scatter plots with the best-fit linear regression line show the change in area over time for C57 
and TRPV1-/- astrocytes.  (D) Bar graphs show the relative migration rate (or the slope of the 
best-fit linear regression line) for C57 and TRPV1-/- astrocytes.  
 
Chelation of extracellular calcium reduces astrocyte migration 
Given that calcium is a key regulator of cytoskeletal reorganization and cell motility 
(Conklin et al., 2005; Easley et al., 2008; Lee et al., 1999; Martini and Valdeolmillos, 2010), I 
next determined the effects of calcium on injury-induced astrocyte migration by using EGTA or 
BAPTA-AM to chelate extracellular and intracellular calcium, respectively.   Higher 
concentration of EGTA (10 mM) or BAPTA (10 µM) lead to cell rounding and detachment in 
my cultures, therefore lower concentrations were used in the scratch wound assay (Figure 3.14C 
and 3.14D). Astrocyte morphology was not affected by EGTA compared to vehicle at the 
concentrations tested (Figure 3.14B and 3.14C).   
Representative images of astrocytes treated with vehicle and 1 mM EGTA are shown in 
Figure 3.10.  As before, scratch injury induces a wound that becomes smaller as vehicle-treated 
astrocytes migrate (Figure 3.14A).  Addition of 1 mM EGTA reduced migration, resulting in a 
larger cell-free area at 48 hours compared to control (Figure 3.14B). Initial wound areas in 
vehicle treated cells averaged 7.1 ± 0.31 x10
5
 μm2 (Figure 3.14C).  Preparations treated with 
EGTA with initial wound sizes that did not fall within the standard deviation of vehicle areas 
were excluded from analysis, leaving at least 10 independent images per time point for analysis.  
For the vehicle group, the initial wound area was reduced 65 ± 7.67% at 48 h following injury 
(Figure 3.14C). Treatment with 100 µM EGTA led to 71 ± 6.32% closure after 48 h (p = 0.29), 
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while 1 mM EGTA resulted in 40 ± 9.31% closure (p = 0.052).   Although the reduced percent 
wound closure did not significantly differ with EGTA treatment, the 35% reduction in migration 
rate for 1 mM EGTA was significant compared to vehicle (p = 0.048; Figure 3.14D). The modest 
increase in rate with 100 μM EGTA (9%) was not significant (p = 0.48).  
Next, I tested if chelation of intracellular calcium with BAPTA-AM affected migration. 
BAPTA-AM treatment did not affect astrocyte morphology when compared to vehicle at the 
concentrations used (Figure 3.14B and 3.14D).  Scratch injury induced cells to migrate to close 
the wound over time, resulting in a smaller cell-free are that was similar for vehicle and 10 µM 
BAPTA-AM at 36 hours (Figure 3.16A and 3.16B).  Vehicle-treated cells had initial wound 
areas that averaged 8.3 ± 0.20 x10
5
 μm2 (Figure 3.16C).  All preparations treated with BAPTA-
AM had initial wound areas that fell within the standard deviation of the vehicle; therefore no 
preparations were excluded from analysis.  In contrast to EGTA, chelation of intracellular Ca
2+
 
with 1 μM or 10 μM BAPTA-AM had little effect on migration with 65 ± 3.62% and 70 ± 6.63% 
closure respectively, at 36 hours compared to 73 ± 3.94% for vehicle (p ≥ 0.106; Figure 3.16C). 
Accordingly, migration rate following BAPTA-AM treatment was also similar to vehicle (p ≥ 
0.53; Figure 3.16D).  
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Figure 3.14.  Astrocyte morphologies following addition of calcium chelators.  In response to 
injury, cells at the leading edge migrate in the scratch wound assay (A).  High magnification 
images were captured at the leading edge (dotted line) at 24 hours for vehicle EGTA and vehicle 
BAPTA cells (B).  Morphologies are shown for cells treated with vehicle and multiple 
concentrations of EGTA (C) or BAPTA (D).  Scale: 50 µm for B, 20 µm for C and D.    
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Figure 3.15.   Effects of EGTA on astrocyte migration.  DIC micrographs show astrocytes 
treated with (A) vehicle and (B) 1 mM EGTA at 0, 12 and 48 hours following scratch injury.  
Dotted boxes indicate the cell-free area. Scale bar: 100 µm.  (C) Scatter plots with the best-fit 
linear regression line show the change in area over time for vehicle, 100 µM and 1 mM EGTA-
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treated astrocytes.  (D) Bar graphs show the relative migration rate (or the slope of the best-fit 
linear regression line) for vehicle and EGTA. *p = 0.048 vs. vehicle.  
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Figure 3.16.  Effects of BAPTA-AM on astrocyte migration.  DIC micrographs show astrocytes 
treated with (A) vehicle and (B) 10 µM BAPTA-AM at 0, 12 and 36 hours following scratch 
injury.  Dotted boxes indicate the cell-free area. Scale bar: 100 µm.  (C) Scatter plots with the 
best-fit linear regression line show the change in area over time for astrocytes treated with 
vehicle, 1 µM and 10 µM BAPTA-AM.  (D) Bar graphs show the relative migration rate (or the 
slope of the best-fit linear regression line) for vehicle and BAPTA-AM.  
 
3.4 Discussion 
 This chapter discusses the contribution of TRPV1 to astrocyte migration using the scratch 
wound model.  Although astrocytes can also proliferate in response to injury, this was reduced 
with low serum conditions (Figure 3.2).  TRPV1 pharmacological agents also affected 
proliferation compared to vehicle, but only at the highest concentrations tested (Figure 3.7 and 
3.11).  For migration, TRPV1 agonism with CAP and RTX had modest effects on motility 
(Figure 3.4 and 3.6) while antagonism of TRPV1 with CPZ and IRTX significantly reduced 
migration (Figure 3.9 and 3.10).  Astrocytes from TRPV1-/- mice, however, showed minimal 
changes in migration relative to C57 wild-type astrocytes (Figure 3.13).  This process is partly 
dependent on extracellular calcium as chelation of extracellular, but not intracellular, calcium 
reduced motility (Figure 3.15 and 3.16)  
Several groups have shown that TRPV1 contributes to cell migration. In hepatoblastoma 
cells, Waning et al. showed that although CAP alone did not increase cell migration, it did 
enhance migration in response to hepatocyte growth factor, an effect that was inhibited by the 
TRPV1 antagonist CPZ (Waning et al., 2007). Yang et al. showed that TRPV1 mediated 
migration of corneal epithelial cells after scratch wound injury (Yang et al., 2010b). While CPZ 
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alone did not affect migration, it did prevent the CAP-induced increase in migration (Yang et al., 
2010b). Similarly, in pulmonary arterial smooth muscle cells, TRPV1 activation increased 
migration, which was blocked by CPZ (Martin et al., 2012).  I found that, in our retinal 
astrocytes, agonism with either CAP or RTX had little effect on migration following injury 
(Figure 3.4 and 3.6)  However, TRPV1 antagonism with CPZ or IRTX slowed migration and 
reduced wound closure over time (Figure 3.9 and 3.10).  Together, these data suggest TRPV1 
may be activated by the injury itself, and that further activation by agonists is not possible.  This 
endogenous activation could be mediated by other factors present in the wound milieu. Possible 
candidates include the endocannabinoids, such as anandamide, which are produced and released 
by astrocytes and can also influence their migration (Song and Zhong, 2000; Walter et al., 2002). 
Although CAP and RTX did not significantly affect migration rate, high concentrations 
(10µM) modestly reduced motility.  This could be a result of TRPV1 desensitization, which can 
occur following vanilloid-induced activation.  There are two types of desensitization: acute, 
which is a reduced response following a continuous application of drug, or tachyphylaxis, which 
is a reduced response after repeated applications of drug.  Although acute desensitization 
represents a fast response, both types can share common signaling molecules.  Desensitization of 
TRPV1 depends on calcium, as chelation of extracellular or intracellular calcium can attenuate 
both types of desensitization (Koplas et al., 1997).  Multiple proteins are involved in TRPV1 
desensitization including the kinases PKA, PKC, CaMKII, and the phosphatase calcineurin 
(Bonnington and McNaughton, 2003; Mandadi et al., 2004; Mohapatra and Nau, 2003, 2005).  
Other proteins involved include ATP, calmodulin and phosphatidylinositol 4,5-bisphosphate 
(Lau et al., 2012; Liu et al., 2005).  Following activation, TRPV1 can also be internalized 
through a clathrin- and dynamin-independent pathway that leads to degradation of the receptor in 
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lysosomes (Sanz-Salvador et al., 2012).  In addition to internalization, TRPV1 can also undergo 
a conformational change that affects agonist binding, although the precise structural changes that 
occur are currently unknown (Vyklicky et al., 2008; Yang et al., 2014).  For example, [
3
H]RTX 
displays reduced binding to desensitized TRPV1 (Jung et al., 2004).  In the scratch wound 
experiments, 10 µM CAP and 10 µM RTX caused a modest decrease in migration, suggesting 
that at these higher concentrations, TRPV1 might be desensitized and its activity reduced so that 
the observed changes in migration were similar to treatment with antagonists.    
Consistent with results from in vitro studies, in vivo models of cellular migration have 
also implicated TRPV1.  For example, intradermal injection of capsaicin increased migration of 
dendritic cells into the draining lymph nodes, an effect that was abolished in TRPV1-/- mice 
(Basu and Srivastava, 2005).  In vivo migration and proliferation of corneal epithelial cells were 
also reduced in TRPV1-/- mice, thus reducing corneal healing following epithelial debridement 
(Sumioka et al., 2014).  We induced scratch injury in optic nerve astrocytes isolated from 
TRPV1-/- mice, but observed only modest changes in migration compared to C57 wild-type 
optic nerve astrocytes (Figure 3.9).  This suggests genetic compensation may be occurring.  In 
addition to TRPV1, other TRPV channels have been shown to mediate migration, including 
TRPV4 and members of the TRPM and TRPC families, all of which are expressed by astrocytes 
(Beskina et al., 2007; Fiorio Pla and Gkika, 2013; Malarkey et al., 2008; Martin et al., 2012; 
Shirakawa et al., 2010).   
Additionally, although CPZ and IRTX are well-characterized TRPV1 antagonists and 
have been used to study TRPV1-mediated effects, the antagonists might be binding to other 
channels or receptors.  CPZ for example, can also bind nicotinic acetylcholine receptors, TRPM8 
and voltage-gated calcium channels (Docherty et al., 1997; Liu and Simon, 1997; Mustafa and 
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Oriowo, 2005).  In TRPV1-/- mice, [
3
H]RTX binding is still seen throughout the CNS especially 
in the spinal cord, dorsal root ganglia and hypothalamus and indicates nonspecific binding in 
these regions (Roberts et al., 2004).  Since IRTX is an analog of RTX, nonspecific binding of 
IRTX could be present as well.   
It is also possible that the difference in astrocyte population used in my assays could 
contribute to the results.  The cells in the pharmacological experiments were isolated from post-
natal, rat retina while the TRPV1-/- astrocytes were derived from adult, mouse optic nerves.  
Although retinal and optic nerve astrocytes both come from the same pool of progenitors and 
migrate from the brain during development, they are subtypes of astrocyte that express different 
genes and might have different functions as well (Hochstim et al., 2008; Ling et al., 1989; Ye 
and Hernandez, 1995).  Optic nerve astrocytes have been shown to migrate in response to injury 
especially in glaucoma, while less is known about retinal astrocytes (Miao et al., 2010; Tezel et 
al., 2001a).  Repeating the pharmacological studies in optic nerve astrocytes isolated from young 
adult wild-type mice would help us better understand any inherent differences between these two 
astrocyte populations.   
Migration can be modulated by calcium, and in my scratch wound experiments, chelation 
of extracellular but not intracellular calcium reduces migration (Figure 3.10 and 3.11). One 
reason for this could be the buffering effect of BAPTA, and the concentrations of BAPTA used 
might not be sufficient to buffer against the increases in calcium.  It is conceivable that a 
concentration higher than 10 M might be required to sufficiently chelate the injury-induced 
increases in calcium, However, the assay used does not allow for much higher concentrations as 
seen by the cell rounding and detachment observed when 50 M BAPTA was used (Figure 
3.14D).  The influx of calcium may also induce changes in membrane potential that might 
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activate voltage-gated ion channels, including calcium channels to mediate migration (Akerman, 
1978; Matsuda et al., 1982).  When extracellular calcium is chelated with EGTA, this calcium 
influx is reduced.  Since less calcium is entering the cell, this might reduce migration in a 
process similar to the addition of TRPV1 antagonists.  Additionally, it is possible that TRPV1 
may be tethered to or near the plasma membrane by scaffold proteins in order to bring signaling 
partners in closer proximity to the channel. For example, TRPV1 can bind to AKAP, an A-kinase 
anchoring protein that facilitates modulation by adenylyl cyclase and PKA, PKC and calcineurin 
phosphorylation to regulate the channel (Jeske et al., 2008; Jeske et al., 2009b; Zhang et al., 
2008).  Disruption of this signaling complex can impair sensitization of TRPV1 by inflammatory 
mediators such as forskolin, prostaglandin E2 and bradykinin (Efendiev et al., 2013; Schnizler et 
al., 2008; Zhang et al., 2008).  The formation of this complex at the plasma membrane might also 
bring various signaling proteins closer to the influx of calcium, and allow calcium to activate 
other proteins before chelation by BAPTA.  Chelation of extracellular calcium by EGTA would 
reduce calcium influx and the subsequent signaling pathways.  
 Calcium levels and EGTA can also affect other proteins involved in migration.  For 
example, chelation of calcium with 4 mM EGTA translocates E-cadherin from adhesion sites to 
the cytosol and thereby reducing cell attachment (Nakagawa et al., 2001).  In addition to 
cadherins, calcium also regulates integrin-mediated cell adhesion.  For example, increased 
intracellular calcium increases affinity of 4 integrin for ligands such as vascular cell adhesion 
molecule-1 (Hyduk et al., 2007).  Chelation of calcium with EGTA and Quin-2 on the other 
hand, inhibits β1 integrin activation and reduces adhesion of granulocytes to fibronectin (Rowin 
et al., 1998).  This suggests that chelation of calcium with EGTA might also reduce adhesion of 
retinal astrocytes to slow cell migration in my experiments. 
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While addition of the TRPV1 agonist CAP did not have a significant effect on 
proliferation following scratch injury, application of the highest concentration of RTX (10 µM) 
significantly reduced proliferation (Figure 3.5).  In general, TRPV1 antagonists also reduced 
astrocyte proliferation, but only 10 µM CPZ was significantly reduced compared to vehicle.  
This indicates that TRPV1 might be mediating multiple aspects of astrocyte reactivity following 
injury.  Addition of 10 µM CPZ reduced both migration and proliferation, and although IRTX 
reduced migration, the decrease in proliferation was not significant (Figure 3.9, 3.10 and 3.11).  
A similar trend occurred for 10 µM RTX – proliferation was reduced but the decrease in 
migration rate was not significant (Figure 3.6 and 3.7).  This suggests a possible correlation 
between reduced migration and reduced proliferation might exist and warrants further analysis. 
Although the scratch wound assay is an assay to determine changes in migration, proliferation 
can be tested further with other assays. One such assay utilizes bromodeoxyuridine (BrdU), an 
analog of thymidine to label dividing cells. Labeled BrdU is incorporated into the DNA of 
dividing cells in place of thymidine, and assessing the extent of BrdU labeling shows the amount 
of proliferation.  Since BrdU labeling requires active DNA synthesis, it is commonly used to 
measure proliferation in living cells or tissue (Rothaeusler and Baumgarth, 2007).  On the other 
hand, Ki-67 labels an antigen that is found only in dividing cells undergoing mitosis (Scholzen 
and Gerdes, 2000).  Therefore, Ki-67 labeling does not require active DNA synthesis, and cells 
can be fixed, permeabilized and then labeled for Ki-67.    
TRPV1 has been shown to modulate proliferation in other studies.  Proliferation of 
corneal epithelial cells is reduced in TRPV1-/- mice compared to wild-type following epithelial 
debridement (Sumioka et al., 2014).  In the spared nerve injury model of neuropathic pain, 
microglia increase proliferation following injury.  Although the TRPV1 agonist RTX did not 
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significantly affect migration following injury compared to vehicle, RTX did increase microglial 
proliferation under basal, uninjured conditions (Suter et al., 2009).  In MCF-7 breast cancer cells, 
TRPV1 overexpression does not affect proliferation compared to wild-type (Wu et al., 2014).  
However, increasing concentrations of CAP increases proliferation in the LNCaP prostate cancer 
cell line, but reduces proliferation in the PC-3 prostate cancer line (Malagarie-Cazenave et al., 
2009; Sanchez et al., 2006).   
The effects of TRPV1 on proliferation could be mediated through an influx of calcium as 
calcium has been linked to cell division and cell cycle regulation.  Calcium channel inhibitors 
like mibefradil, amlodipine, diltiazem and verapamil can reduce proliferation (Panner and 
Wurster, 2006; Taylor and Simpson, 1992).  Also, knockdown of TRPC1 and TRPC6 can block 
entry into the G1 and G2/M phase of the cell cycle respectively in other cell systems (Cai et al., 
2009; Kuang et al., 2012).  Calcium channels can interact with cell cycle proteins as well.  For 
example, cyclin-dependent kinase 1/cyclin B directly interacts with and phosphorylates IP3 
receptors in the endoplasmic reticulum (Malathi et al., 2005).  In addition, chelation of calcium 
with EGTA or addition of calcineurin inhibitors decreases fibroblast growth factor-induced 
expression of cyclin A and E (Tomono et al., 1998).  
Increased migration as well as proliferation is a stress response of reactive astrocytes, and 
is found in multiple types of injury and diseases including glial scar formation, metastasis of 
gliomas, glaucoma and age-related macular degeneration (Demuth and Berens, 2004; Ramirez et 
al., 2001; Tezel et al., 2001a; Yuan and He, 2013).  Reactive astrocytes can be both beneficial 
and detrimental to neuronal survival.  They can secrete neurotrophic factors to aid neuronal 
survival and repair the blood-brain barrier but they can also release cytokines and impede axon 
regeneration.  A better understanding of the mechanisms and signaling pathways that underlie 
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astrocyte migration can potentially lead to novel therapeutic interventions to target scar 
formation and gliosis in neurodegenerative diseases.  It might allow us to temper the detrimental 
effects associated with gliosis, while retaining the benefits and promoting CNS re 
 * Portions of this chapter have been published previously in Ho KW, Lambert WS and Calkins DJ.  
Activation of the TRPV1 cation channel contributes to stress-induced astrocyte migration (2014) Glia 
62(9):1435-51. 
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CHAPTER IV 
 
THE CONTRIBUTION OF THE TRPV1 CHANNEL TO INJURY-INDUCED CALCIUM 
INFLUX* 
 
4.1 Introduction 
Calcium is an important regulator of many cellular functions in both neuronal and non-
neuronal cell types.  For example, calcium can mediate muscle contraction, neurotransmitter and 
gliotransmitter release, and cell-cell communication in astrocytes (Berchtold et al., 2000; 
Catterall and Few, 2008; Newman, 2001; Volterra et al., 2014).  Calcium activates signaling 
molecules like PKA, PKC, calmodulin, CaMKII, and calcineurin to trigger downstream cascades 
and changes in cellular function (Crabtree, 2001; Dunn et al., 2009; Griffith, 2004; Luo and 
Weinstein, 1993).  Additionally, calcium regulates cytoskeletal dynamics that can drive cell 
migration and intermediate filament expression (Rodnight et al., 1997; Wei et al., 2012).  In 
astrocytes, calcium mediates the release of gliotransmitters to modulate synaptic transmission 
(Volterra et al., 2014).  Elevations in calcium also mediate intercellular communication in 
astrocytes through the propagation of calcium waves (Newman, 2001). While calcium is an 
important signaling component that regulates many aspects of astrocyte function under 
physiological conditions, it also plays a role in reactive gliosis following injury. For example, the 
injury milieu can contain factors such as glutamate, ATP, endothelin and cytokines that increase 
intracellular calcium (Cornell-Bell et al., 1990; Goldman et al., 1991; Guthrie et al., 1999; 
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Holliday and Gruol, 1993; Koller et al., 1996).  Mechanical injury or stretch can also increase 
astrocyte intracellular calcium levels (Charles et al., 1991; Rzigalinski et al., 1998).  
Astrocytes, like most cells, express a variety of receptors and channels that regulate 
calcium homeostasis and contribute to calcium increases following injury.  These include G-
protein coupled receptors, such as metabotropic glutamate receptors, as well as voltage-gated 
calcium channels (Bradley and Challiss, 2012; Latour et al., 2003).  Ligand-gated channels like 
the purinergic P2X receptors can also regulate calcium levels (Fumagalli et al., 2003).  In 
addition to these receptors, astrocytes also express multiple calcium transporters including the 
plasma membrane Ca
2+
-ATPase and Na
+
/Ca
2+
 exchanger (Fresu et al., 1999; Goldman et al., 
1994).  Increases in cytoplasmic calcium can also occur through release from intracellular stores 
within the endoplasmic reticulum.  The IP3 receptor type 2 is the main channel that regulates 
intracellular calcium stores in astrocytes (Petravicz et al., 2008).  In addition to IP3 receptors, 
ryanodine receptors can also be found in the endoplasmic reticulum (Matyash et al., 2002; 
Turner et al., 2003).  Intracellular stores that become depleted can be replenished by store-
operated channels in the plasma membrane, such as ligand gated TRPC channels (Golovina, 
2005; Huang et al., 2006; Malarkey et al., 2008; Smyth et al., 2010; Yuan et al., 2007; Zeng et 
al., 2008).  Multiple isoforms of the TRPC family have been found in astrocytes (Beskina et al., 
2007; Grimaldi et al., 2003; Malarkey et al., 2008; Miyano et al., 2010; Shigetomi et al., 2012).   
 Another member of the TRP family expressed by astrocytes is TRPV1 (Chapter 2; Doly 
et al., 2004; Huang et al., 2010; Leonelli et al., 2010; Mannari et al., 2013).  TRPV1 activation 
increases intracellular calcium in a variety of cell types, including endothelial cells, corneal 
epithelial cells, bronchial epithelial cells, glioma cells and dorsal root ganglion neurons 
(Amantini et al., 2007; Chard et al., 1995; Himi et al., 2012; Reilly et al., 2005; Zhang et al., 
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2007).   In these cells, TRPV1 modulates cell adhesion, migration, cytokine release and 
apoptosis.  In neurons, TRPV1 can mediate the release of glutamate and substance P (Ferrini et 
al., 2007; Medvedeva et al., 2008).  Endogenous TRPV1 ligands include protons, 
endocannabinoids and arachidonate metabolites (Edwards et al., 2012; Rousseau et al., 2005; 
Ryu et al., 2007); however, TRPV1 can also be activated in response to injury.  For instance, in 
retinal ganglion cells and microglia TRPV1 is activated in response to elevated hydrostatic 
pressure and can increase intracellular calcium (Sappington and Calkins, 2008; Sappington et al., 
2009).  Elevated hydrostatic pressure can also increase calcium in cultured optic nerve head 
astrocytes, an effect that was attenuated with ruthenium red, a non-specific TRP channel 
inhibitor (Mandal et al., 2010).  In Chapter 3, I showed that astrocytes migrate in response to 
injury, and that this effect is to some extent, mediated by TRPV1 and is dependent on 
extracellular calcium. As a next step, this chapter will examine calcium dynamics following 
TRPV1 activation in primary cultured astrocytes under physiological conditions and following 
scratch wound injury.  Because TRPV1 antagonism reduced injury-induced astrocyte migration, 
I will also examine the effect of TRPV1 antagonists on calcium influx following injury. 
 
4.2 Methods 
Calcium imaging 
Primary retinal and optic nerve astrocytes were isolated and prepared as previously 
described in Chapter 2.  Once confluent, astrocytes were plated onto 8-well cover glass chambers 
(ThermoScientific, Rochester, NY) coated with 0.01 mg/mL poly-D-lysine. Intracellular calcium 
was monitored with the fluorescent indicator, fura-2 AM (Molecular Probes, Eugene, OR).  
Upon binding calcium, fura-2 increases fluorescence at 340 nm and decreases fluorescence at 
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380 nm.  Therefore, a smaller 340/380 ratio indicates low calcium levels while a larger 340/380 
ratio shows high calcium levels (Levkovitch-Verbin, 2004).  Astrocyte cultures were loaded with 
5 μM fura-2 AM for 30 minutes at 37˚C, rinsed and incubated in DMEM/F12 minus phenol-red 
with the appropriate pharmacological reagents.  Cultures were then placed onto a Nikon Eclipse 
Ti inverted microscope for imaging.  The cells were excited at the 340 and 380 nm wavelengths, 
and emission was collected at 510 nm at 3 second intervals with a Roper Scientific black and 
white camera (Photometrics, Tucson, AZ).  A baseline recording of approximately 30 seconds 
was taken.  To test for pharmacological effects, 100 L of media was replaced with an 
equivalent volume containing the appropriate reagents to achieve the concentrations indicated.  
For scratch wound experiments, a 10 μL pipet tip was used to make a scratch through the 
astrocyte monolayer.  Each experiment had at least 4 replicates, and at least 8 C57 and TRPV1-/- 
mice were used. 
 
Quantification of calcium imaging 
 Image analysis was done with NIS Elements software (Nikon, Melville, NY).  Regions of 
interest were drawn at 50, 100, 200 and 400 μm from the edge of the scratch injury (≥ 6 regions 
per distance), and the 340/380 fluorescence ratio was determined over time for each region 
(Figure 4.1).  Ratios acquired during the scratch and 5 seconds prior to and after injury were 
excluded due to artifacts in the extracellular environment.  Basal calcium levels were determined 
by averaging the ratios taken prior to scratch injury for each replicate.  Time-to-peak 
measurements were calculated based on the time after injury required to reach maximum ratios 
for each treatment. 
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Figure 4.1.  Calcium imaging quantification and analysis.  Astrocytes were loaded with fura-2 
AM, and then scratched.  Regions of interest were drawn at 50, 100, 200 and 400 µm (solid 
lines) from the wound edge (dotted line).  The scale shows 340/380 nm ratio from low (violet-
blue) to high (orange-red) calcium levels. Scale: 100 µm. 
 
Statistical analysis  
 Data for calcium levels is presented as mean ± SEM  for each treatment.  Statistical 
analysis and p-values for comparing calcium levels were obtained using ANOVA or t-tests for 
data meeting criteria for normalcy or using non-parametric rank statistics for data failing 
normalcy using SigmaPlot 11.0 for Windows (Systat Software Inc., Chicago, IL) or GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA). 
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4.3 Results 
Effects of TRPV1 agonists on physiological calcium levels in astrocytes 
Since TRPV1 is a calcium-selective ion channel, I first tested if activation of TRPV1 
with CAP and RTX changed calcium levels in astrocytes under physiological conditions. 
Fluorescent micrographs of astrocytes loaded with fura-2 are shown in Figure 4.2.  Fura-2 ratios 
appeared similar between the four basal conditions.  Addition of 1 µM CAP or 100 nM and 1 
µM RTX (Figure 4.2) did not appear to change calcium levels compared to vehicle at 10 and 60 
seconds following drug application as fura-2 ratios remained similar between the four treatments.  
The change in calcium over time following treatment is quantified in Figure 4.3.  Following the 
addition of CAP to the astrocyte culture, there was a drop in the 340/380 ratio that appeared to 
indicate calcium reduction.  However, the change in ratio following application was similar for 
both vehicle and 1M CAP, indicating that any changes measured in the fura-2 ratio were due to 
drug application artifacts rather than changes in calcium (Figure 4.3A).  Likewise, the change in 
calcium ratio was similar for vehicle and 1 M RTX (Figure 4.3B), indicating this concentration 
of TRPV1 agonist had no impact under physiological conditions.  However, addition of 100 nM 
RTX induced a slight increase in calcium over time.  By 145-170 seconds following application, 
the average change in calcium levels for 100 nM RTX was 85.99 ± 4.40% greater than vehicle (p 
= 0.04; Figure 4.3B).  
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Figure 4.2.  Effects of CAP and RTX on basal astrocyte calcium levels.  Astrocytes were loaded 
with fura-2, and the scale shows 340/380 nm ratio from low (violet-blue) to high (orange-red) 
calcium levels. Fluorescent micrographs were captured under resting condition and at 10 and 60 
seconds following addition of vehicle, 1 µM CAP or 100 nM and 1 µM RTX.  Scale: 100 µm.   
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Figure 4.3.  Quantification of CAP and RTX on physiological calcium levels.  TRPV1 activation 
has modest effects on calcium levels under physiological conditions in astrocyte cultures.  
Calcium levels expressed as the 340/380 ratio are shown before and after addition of drug (time 
= 0 seconds) for cells treated with 1 µM CAP (A) or 100 nM and 1 µM RTX (B). * p = 0.04. 
 
Antagonism of TRPV1 reduces and slows calcium influx following injury  
 Although TRPV1 activation did not affect calcium levels under basal conditions, TRPV1 
may act as a stress response protein and increase intracellular calcium levels following injury.  
Since TRPV1 inhibition reduces astrocyte migration, I next wanted to determine if TRPV1 
modulates astrocyte calcium influx following scratch injury.  Figure 4.4 shows examples of 
astrocyte cultures loaded with fura-2 before and after scratch.  At 10 seconds following scratch 
wound, intracellular calcium increased throughout the culture, but especially near the leading 
edge (Figure 4.4B). Pre-treatment with the TRPV1-specific antagonists CPZ (10 μM; Figure 
4.4C) and IRTX (3 μM; Figure 4.4D) appeared to reduce this increase. 
I quantified the 340/380 nm calcium ratio over time at discrete distances from the 
scratch-wound edge (50, 100, 200 and 400 μm), both with and without the TRPV1 antagonists 
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(Figure 4.5).  Detailed quantification of the data shows that neither 10 μM CPZ nor 3 µM IRTX 
significantly influenced pre-scratch basal levels of calcium compared to vehicle (Figure 4.5 and 
4.6A).  Both TRPV1 antagonists did, however, slow the time to peak calcium levels following 
scratch wound (Figure 4.5 and 4.6B).  Compared to vehicle-treated astrocytes, 3 µM IRTX 
slowed the time to peak by over three-fold at 50, 100 and 200 µm from the scratch wound (p ≤ 
0.007). Treatment with 10 μM CPZ also slowed the time to peak more than two-fold at 100 µm 
from the wound (p = 0.025). The same trend of slower time to peak by CPZ was also seen at 50 
μm and 200 μm, but this was not significant (p ≥ 0.063).  At 400 μm from the scratch, the times 
to peak for the antagonists did not differ significantly from vehicle.  
In addition to slowing the time to peak, treatment with 3 µM IRTX also reduced the 
overall magnitude of calcium influx following scratch compared to vehicle at all four distances 
from the wound that were quantified (Figure 4.6C). In the time interval 5-30 seconds following 
scratch, IRTX reduced the change in calcium ratio by 55-80% at all distances from the injury site 
(p ≤ 0.04).  The decrease in calcium influx following injury with IRTX was also observed at 
subsequent intervals (40-70 seconds and 75-105 seconds) following injury, although the 
reductions were not significant (p ≥ 0.062; Figure 4.6C). Treatment with CPZ, while generally 
slowing the time to peak (Figure 4.6B), had little effect on the magnitude of the change in 
calcium following scratch (p ≥ 0.39; Figure 4.6C).   
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Figure 4.4.  Injury-induced calcium changes with addition of TRPV1 antagonists.  Scratch injury 
increases intracellular calcium in astrocytes.  Fluorescent image of astrocytes loaded with the 
calcium indicator, fura-2 AM shows modest basal intracellular levels. The scale shows 340/380 
nm ratio from low (violet-blue) to high (orange-red) basal calcium levels (A). Immediately 
following scratch wound (10 seconds), vehicle astrocytes (B) demonstrate increased intracellular 
calcium especially near the leading edge (dotted line); 10 μM CPZ (C) and 3 μM IRTX (D) 
appear to reduce this increase. Scale: 100 μm. 
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Figure 4.5.  Real time calcium changes following injury and with TRPV1 antagonism.  Levels of 
astrocyte intracellular calcium are expressed as the 340/380 nm fluorescence ratio before and 
following scratch injury (time = 0 seconds) for cells treated with vehicle, 10 μM CPZ and 3 μM 
IRTX.  Measurements were taken at 50, 100, 200 and 400 μm from the scratch leading edge.  
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Figure 4.6.  Quantification of calcium dynamics with TRPV1 antagonism.  Fura-2 AM 340/380 
ratio prior to scratch wound shows astrocytes treated with vehicle, 10 μM CPZ and 3 μM IRTX 
have similar basal levels of intracellular calcium (A).  Bar charts show time to reach peak 
340/380 calcium ratio following scratch injury for each treatment at 50, 100, 200 and 400 μm 
from the leading edge of the wound (B). Significance compared to vehicle:  *, p ≤ 0.007 for 
IRTX; #, p = 0.025 for CPZ.  Data show the average difference between scratch and basal 
340/380 calcium ratio determined for time intervals 5-35, 40-70, and 75-105 seconds post-
  
 125 
 
scratch at each distance from the injury (C). Significance compared to vehicle:  *, p ≤ 0.04.  All 
data: mean ± SEM.       
 
Effects of TRPV1knockout on intracellular calcium influx with injury 
 Scratch injury induced a rise in intracellular calcium that was reduced with TRPV1 
antagonism.  Next, I wanted to determine if TRPV1-/- astrocytes exhibit a change in calcium 
with scratch injury.  Optic nerve astrocytes from TRPV1-/- and C57 mice were loaded with fura-
2.  Genotype did not appear to affect basal levels of calcium (Figure 4.7A and B).  Scratch injury 
induced an increase in calcium that was highest at the leading edge and dissipated with 
increasing distance for both C57 and TRPV1-/- astrocytes (Figure 4.7C and D).    
    Detailed analysis of calcium imaging shows that C57 and TRPV1-/- astrocytes had 
similar basal levels of calcium (Figure 4.8 and 4.9A).  The time to reach peak calcium increased 
for both C57 and TRPV1-/- as distance from the scratch injury increased (Figure 4.8 and 4.9B).   
Although there was a trend towards a shorter time to peak for TRPV1-/- astrocytes compared to 
C57, this was not significant (p ≥ 0.210).  The change in calcium following scratch injury was 
also similar between C57 and TRPV1-/- astrocytes at the distances and time intervals tested 
(Figure 4.8 and 4.9C).  
 
 
 
  
 126 
 
 
Figure 4.7.  Calcium changes in C57 and TRPV1-/- astrocytes following injury.  Fluorescent 
micrographs show basal levels of calcium for astrocytes from C57 (A) and TRPV1-/- optic 
nerves (B).  The scale shows 340/380 nm ratio from low (violet-blue) to high (orange-red) 
calcium levels.  Scratch injury induced an increase in calcium at the leading edge (dotted line) 
for both C57 (C) and TRPV1-/- (D) astrocytes.  Scale 100 µm. 
 
 
 
  
 127 
 
Figure 4.8.  Real time calcium dynamics in TRPV1-/- astrocytes following injury.  Calcium 
levels expressed as the 340/380 ratio are shown before and after scratch injury (time = 0 seconds) 
for C57 and TRPV1-/- astrocytes.  Measurements were taken at 50, 100, 200 and 400 µm from 
the injury site.   
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Figure 4.9.  Quantification of calcium changes in TRPV1-/- astrocytes following injury.  C57 
and TRPV1-/- astrocytes have similar basal levels of intracellular calcium (A).  Bar charts show 
time to reach peak 340/380 calcium ratio following scratch injury for both C57 and TRPV1-/- 
optic nerve astrocytes at 50, 100, 200 and 400 μm from the leading edge of the wound (B).   Data 
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show the average difference between scratch and basal 340/380 calcium ratio determined for 
time intervals 5-35, 40-70, and 75-105 seconds post-scratch at each distance from the injury for 
both genotypes (C). All data: mean ± SEM.       
 
Microtubule stabilization has modest effects on intracellular calcium influx with injury 
Scratch injury in astrocytes induces an increased intracellular calcium influx and cell 
migration, both of which were reduced with addition of TRPV1 antagonists (Figure 4.6, 3.6 and 
3.7).  One link between calcium and migration is changes in cytoskeletal dynamics, and TRPV 
channels are known to interact with the cytoskeleton.  Goswami et al. showed that TRPV4 can 
bind microtubules and stabilize them, and that taxol treatment to stabilize microtubules reduced 
calcium influx via TRPV4 (Goswami et al., 2010). Stabilization of microtubules with taxol also 
reduces the amplitude of calcium transients and calcium release from the sarcoplasmic reticulum, 
while disruption of microtubules can increase the amplitude of calcium transients and its decay 
in myocytes (Howarth et al., 1999; Kerfant et al., 2001).  Additionally, TRPV1 activation results 
in the disassembly of dynamic microtubules, thus contributing to cytoskeletal remodeling 
(Goswami et al., 2006). Given the link between TRPV channels, calcium and the cytoskeleton, I 
next determined whether addition of taxol to stabilize astrocyte microtubules affected calcium 
influx following injury. Initially, I based taxol concentrations on a published report that treated 
cultured primary astrocytes with 5 M taxol (Cvetkovic et al., 2004).  However, pilot studies 
using 5 and 50 M taxol in the scratch wound assay showed that these concentrations induced 
cell detachment (data not shown).  Therefore, a concentration of 500 nM taxol was used in the 
calcium imaging analysis.   
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 Similar to previous experiments, astrocytes were loaded with fura-2 to measure calcium 
levels.  Astrocytes treated with either vehicle or 500 nM taxol appeared to exhibit similar basal 
calcium levels (Figure 4.10A and B).  Scratch wound injury induced an increase in calcium that 
was highest at the wound edge for both vehicle and 500 nM taxol (Figure 4.10C and D). Detailed 
quantification showed that basal levels of calcium were similar in vehicle and 500 nM taxol 
treated cells (Figure 4.11 and 4.12A).  The time to peak for 500 nM taxol was also not 
significantly different from vehicle (p ≥ 0.181; Figure 4.11 and 4.12B).  Similar to the previous 
experiments, the change in calcium following injury was highest at 50 m from the wound edge 
and diminished with increasing distance (Figure 4.11 and 4.12C).  The injury-induced increase in 
calcium was sustained.  The calcium changes at 5-35, 40-70 and 75-105 seconds following injury 
were similar.  Although treatment with 500 nM taxol appears to reduce calcium influx compared 
to vehicle at 50 and 100 m from the injury site at the time intervals tested, this decrease was not 
significant (p > 0.07; Figure 4.12C).  As distance from the wound edge increased to 200 and 400 
µm, the changes in calcium were also similar between vehicle and 500 nM taxol (Figure 4.12C).   
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Figure 4.10.  Effects of taxol on astrocyte calcium influx after injury.  Fluorescent micrographs 
show basal levels of calcium for astrocytes from vehicle (A) and 500 nM taxol (B) treatments.  
The scale shows 340/380 nm ratio from low (violet-blue) to high (orange-red) calcium levels 
(A).   Scratch injury induced an increase in calcium at the leading edge (dotted line) for both 
vehicle (C) and 500 nM taxol (D).  Scale 100 µm.   
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Figure 4.11.  Real time calcium changes after injury and with taxol treatment. Calcium levels 
expressed as the 340/380 ratio are shown before and after scratch injury (time = 0 seconds) for 
astrocytes treated with vehicle and 500 nM taxol.  Measurements were taken at 50, 100, 200 and 
400 µm from the injury site.   
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Figure 4.12.  Quantification of calcium dynamics with addition of taxol.  Vehicle and 500 nM 
taxol treatments have similar basal levels of intracellular calcium (A).  Bar charts show time to 
reach peak 340/380 calcium ratio following scratch injury for both vehicle and 500 nM taxol at 
50, 100, 200 and 400 μm from the leading edge of the wound (B).   Data show the average 
difference between scratch and basal 340/380 calcium ratio determined for time intervals 5-35, 
40-70, and 75-105 seconds post-scratch at each distance from the injury for both treatments (C). 
All data: mean ± SEM.       
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4.4 Discussion 
 In a previous chapter, I demonstrated that TRPV1 modulation influenced astrocyte 
migration following injury. As TRPV1 can flux calcium, and calcium is an important mediator of 
cell migration, this chapter examined the calcium dynamics in astrocytes with TRPV1 
modulation and following injury.  TRPV1 is regarded as a calcium-preferring channel where 
activation contributes to an increase in intracellular calcium.  However, I found that addition of 
TRPV1 agonists CAP or RTX had only a modest effect on intracellular calcium compared to 
vehicle (Figure 4.2 and 4.3).  This was unexpected as activation of other members of the TRP 
family, including TRPA and TRPC, can increase intracellular calcium in astrocytes (Malarkey et 
al., 2008; Shigetomi et al., 2012).  Moreover, CAP and RTX have been shown to increase 
calcium in other cells types including retinal ganglion cells, microglia, dorsal root ganglion 
neurons, endothelial cells and dopaminergic neurons (Kim et al., 2005; Marshall et al., 2003; 
Sappington and Calkins, 2008; Sappington et al., 2009; Yang et al., 2010a).  Interestingly, in 
cortical astrocytes TRPV1 activation by low pH can induce a change in current that is mediated 
by sodium influx rather than calcium (Huang et al., 2010).  While TRPV1 exhibits a 10-fold 
higher selectivity for calcium versus sodium (Caterina and Julius, 2001), it is possible that 
activation of TRPV1 in retinal astrocytes by CAP or RTX under physiological conditions might 
induce an influx of sodium, rather than of calcium. This is a hypothesis that certainly warrants 
future examination. 
I found that in retinal astrocytes, scratch injury increases intracellular calcium (Figures 
4.4-4.6).  The antagonist CPZ had only modest effects on scratch-induced calcium elevations, 
which was significantly reduced with IRTX.  This could be due to a species-dependent 
difference in efficacy that has been observed for CPZ, as this antagonist only weakly inhibits 
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calcium currents in rat TRPV1 compared to human TRPV1 (McIntyre et al., 2001; Phillips et al., 
2004).  IRTX, however, does not have this selectivity and has far greater efficacy (Correll et al., 
2004). Similar differences in calcium
 
responses have been shown for TRPV1 agonists as well, 
emphasizing the complexity of TRPV subunit pharmacology. For example, Toth et al. found that 
there were qualitative differences in calcium influx when cells are treated with various TRPV1 
agonists (Toth et al., 2005).  In response to CAP, cells exhibited an immediate increase in 
calcium, but with RTX, there was minimal initial increase but a sharp subsequent increase, 
suggesting a latency in cellular responses to RTX.  Furthermore, higher concentrations of CAP 
increased the maximal amount of calcium influx, an effect not seen with RTX treatment. Rather, 
the number of cells that responded increased with higher RTX concentrations. A similar 
difference in calcium response to CAP and RTX has also been observed in dorsal root ganglion 
neurons.  Addition of RTX produced a prolonged increase in calcium compared to the sharp 
transient increase from CAP, even when the RTX concentration was 1000-fold less (Karai et al., 
2004). As CPZ and IRTX are analogs of CAP and RTX, respectively, it is possible the 
qualitative differences in calcium influx seen with the agonists might be extrapolated to the 
antagonists (Wahl et al., 2001; Weber et al., 2008).   
In the scratch wound experiments in Chapter 3, there was a greater reduction in migration 
with CPZ than IRTX.  The opposite was seen in the calcium imaging experiments in this chapter 
– IRTX induced a greater decrease in calcium compared to CPZ.  The complexity of the injury 
milieu and the different mechanisms of the antagonists might contribute to the effects seen in the 
migration and calcium experiments.  In addition to activation by CAP and RTX, TRPV1 can also 
be activated by a variety of other effectors, including pH, heat and endocannabinoids, which can 
be blocked by both CPZ and IRTX in various systems (Korolainen et al., 2005; Sarthy et al., 
  
 136 
 
1998; Seabrook et al., 2002; Tura et al., 2009). This suggests the presence of multiple binding 
sites for the antagonists in addition to the vanilloid binding sites. The ability of antagonists to 
inhibit these stimuli can also vary.  For example, CPZ can block pH activation in guinea pigs but 
not in rats (McIntyre et al., 2001; Sun et al., 2013).  
The environment of TRPV1 can also influence its activation and regulation.  For 
example, TRPV1 contains multiple phosphorylation sites for PKA, PKC and protein phosphatase 
2B that sensitize and desensitize the channel (Shibasaki et al., 2013). Addition of cyclosporin A, 
an inhibitor for protein phosphatase 2B, increases the potency of TRPV1 agonists 1.1-fold for 
RTX to as much as 7.8-fold for DA-5018.  The potency for capsaicin increased 2.1-fold. Similar 
to the agonists, cyclosporin A increased antagonist potencies from 1.1-fold to 2.5-fold (Bai and 
Lipski, 2010). This suggests that the signaling environment and phosphorylation state of TRPV1 
have profound effects on the channel’s sensitivity to ligands.  In the injury milieu, cross-talk 
between a variety of effectors, receptors, and signaling pathways could modulate the structure 
and state of TRPV1, potentially affecting the efficacy of TRPV1 pharmacological agents. 
Together, these differences could explain why CPZ had the greater inhibitory effect on 
migration, while IRTX had the more robust effect on intracellular calcium levels.  To further 
investigate this incongruity, I examined calcium changes in optic nerve astrocytes from C57 and 
TRPV1-/- mice following injury.  Like in the migration experiments however, TRPV1-/- did not 
significantly change calcium influx following injury compared to C57 wild-type.  One possible 
explanation for these results is that loss of TRPV1 might have been compensated during 
development by other calcium channels or other TRP channels, including TRPA1 and TRPC 
channels (Beskina et al., 2007; Grimaldi et al., 2003; Malarkey et al., 2008; Miyano et al., 2010; 
Shigetomi et al., 2012).  
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Calcium influx also can be influenced by cytoskeletal dynamics, and this chapter 
examined the effects of taxol, which stabilizes microtubules, on injury-induced calcium influx in 
astrocytes.  Calcium imaging analysis indicates that addition of 500 nM taxol did not 
significantly affect calcium dynamics (Figure 4.10-4.12), even though microtubules can gate 
channels and modulate calcium influx.  Microtubule stabilization with taxol reduces the 
amplitude of calcium transients and calcium release in myocytes, while disruption of 
microtubules with colchicine can increase the amplitude of calcium transients and hasten its 
decay (Howarth et al., 1999; Kerfant et al., 2001).  Microtubules can also influence the kinetics 
of calcium channels.  Taxol can increase the probability of being in the open state and prolong 
the average open time of L-type calcium channels, while colchicine has the opposite effects and 
increases the closed state probability (Galli and DeFelice, 1994).  However, taxol [10 to 100 µM] 
decreases the activity of voltage-gated calcium channels, while microtubule depolymerization 
induced by offchicine and vinblastine increases the current amplitude, which indicates greater 
channel activity (Unno et al., 1999).  In my experiments, concentrations greater than 5 µM 
induced cell detachment (data not shown). Testing higher concentrations of taxol without 
disrupting cellular morphology might have induced a significant change in calcium following 
injury, and this is a possible avenue for future experiments.  Since stabilization of microtubules 
with taxol had only modest effects on calcium influx (Figure 4.10-4.12), it would also be 
interesting to examine whether agents like nocodazole and colchicine that promote microtubule 
disassembly would change scratch-induced calcium entry.     
Like microtubules, the actin cytoskeleton can also mediate calcium transients.  Actin 
rather than microtubules mediates calcium influx in gingival fibroblast following stretch 
activation.  Addition of cytochalasin C to inhibit actin polymerization reduced calcium influx 
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while taxol did not change calcium levels compared to controls (Wu et al., 1999).  Cytochalasin 
C can also decrease agonist-induced calcium influx as well as alter the shape of the endoplasmic 
reticulum (Ribeiro et al., 1997).  Since addition of taxol did not significantly change calcium 
dynamics following scratch wound (Figure 4.10-4.12), one potential future experiment is to 
examine whether modulating actin assembly/disassembly affects astrocyte calcium levels 
following scratch injury.   
Calcium can activate multiple downstream signaling pathways that influence astrocyte 
function including migration, as chelation of extracellular calcium reduces astrocyte migration 
(Chapter 3).  Since TRPV1 is a calcium-selective ion channel and its inhibition reduces 
migration, this chapter examined the changes in calcium dynamics induced by TRPV1 
modulation.  Cytoskeletal changes are important driving forces behind migration, and these 
changes are mediated by multiple calcium-mediated pathways.  Together, these data (Chapter 3 
and 4) suggest TRPV1 mediates a calcium-dependent stress response that results in astrocyte 
migration following injury.  This response likely involves cytoskeletal changes, which is the 
focus of Chapter 5.   
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CHAPTER V 
 
TRPV1 IN CYTOSKELETAL REMODELING OF ASTROCYTES FOLLOWING INJURY* 
 
5.1 Introduction 
 The astrocyte cytoskeleton is comprised of three main types of filaments: actin, 
microtubules and intermediate filaments.  The cytoskeleton is important in not only providing the 
structural framework of the cell, but it also facilitates vesicular trafficking and regulates many 
aspects of astrocyte function including cell migration (Cotrina et al., 1998; Couchie et al., 1985; 
Eliasson et al., 1999; Etienne-Manneville, 2004, 2006; Goetschy et al., 1986; Goldstein and 
Yang, 2000; Herrmann et al., 2007; Johnson and Byerly, 1993; Lascola et al., 1998; Middeldorp 
and Hol, 2011; Nogales, 2000; Sorci et al., 2000). During migration, cell protrusion occurs at the 
front of the cell to form the filopodia, which is comprised of parallel actin fibers and 
lamellipodia, which is made up on of a dense actin meshwork.  In astrocytes however, the 
lamellopodia is limited and the cells form a leading edge that contains primarily microtubules 
rather than actin.  During astrocyte migration, a large density of microtubules assembles near the 
leading edge to protrude the cell (Etienne-Manneville, 2013). Depolymerization of microtubules 
can inhibit cell protrusion and formation of the leading edge (Etienne-Manneville, 2013).  Actin, 
however can also mediate protrusion in astrocytes, as inhibiting actin polymerization with 
cytochalasin affects membrane protrusion (Baorto et al., 1992). Generally, cell protrusion results 
from the forces generated from actin and microtubule polymerization.   
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In order to migrate, cells also need to contact the extracellular matrix to establish 
contractile forces to pull the cell.  This is mediated by the formation of stress fibers comprised of 
actin and myosin II to facilitate contraction, and focal adhesions that anchor stress fibers 
allowing the cell to adhere to the extracellular matrix (for review, see (Gardel et al., 2010). 
Although not directly a part of this contractility machinery, microtubules are involved in this 
process and can regulate signaling pathways, such as Rho that mediate contractility (Bershadsky 
et al., 1996; Liu et al., 1998).  For example, microtubule disruption increases stress fiber and 
focal adhesion formation resulting in greater contractility, while microtubule growth leads to 
focal adhesion disassembly (Bershadsky et al., 1996; Liu et al., 1998).  
Migration also requires that a cell establish polarity for both direction of migration and 
orientation of the cytoskeleton. Cells sense direction in response to a chemoattractant, and the 
cytoskeleton becomes polarized so that the protrusive and contractile forces are formed at the 
proper locations.  Microtubules are key in establishing polarity, as cells treated with nocodazole 
to inhibit microtubule polymerization lose polarity and lamellipodia formation (Omelchenko et 
al., 2002).  Polarity of microtubules is established by the MTOC which stabilizes the minus ends 
of microtubule filaments.  In astrocytes, the MTOC is located near the nucleus and reorients 
towards the direction of migration following scratch injury (Etienne-Manneville, 2006). 
   In addition to the cytoskeleton, cell migration is mediated by a variety of receptors, 
proteins and signaling pathways. One such protein is the Rho GTP-ase CDC42, which mediates 
process formation and polarity during migration.  Following injury, CDC42 accumulates at the 
leading edge via vesicular trafficking in astrocytes (Osmani et al., 2010).  CDC42 is essential for 
cell protrusion and establishing directionality and can target the proteins mPar6 and PKC to 
polarize the MTOC in astrocytes (Etienne-Manneville and Hall, 2001). Astrocytes at the leading 
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edge also increase expression and release of tenascin C, an extracellular matrix glycoprotein, 
following injury (Nishio et al., 2005).  Exogenous addition of tenascin C increases both astrocyte 
migration and proliferation, while blocking tenascin C induces morphological changes – 
astrocytes become flatter and wider rather than thin with processes (Nishio et al., 2003; Nishio et 
al., 2005).  Vinculin is a cytoskeletal protein involved in the formation of focal adhesions and 
helps link actin to the extracellular matrix.  Following endothelin-1 induced gliosis, reactive 
astrocytes increase vinculin protein (Egnaczyk et al., 2003).  Astrocytes treated with the cytokine 
TNF-α, however exhibited reduced levels of vinculin (van Strien et al., 2011).   
Calcium is a key regulator of the cytoskeletal reorganization that mediates cell motility.  
Indeed, calcium initiates many of the signaling cascades that contribute to actin remodeling, 
retraction of the trailing edge and turnover of adhesion molecules (Conklin et al., 2005; Easley et 
al., 2008; Lee et al., 1999; Martini and Valdeolmillos, 2010).  By modulating calcium levels, 
TRPV1 activation can lead to cytoskeletal rearrangement including disassembly of microtubules 
and reorganization of F-actin to drive changes in cell migration (Goswami et al., 2007; Han et 
al., 2007; Martin et al., 2012).  In a dorsal root ganglion cell line, TRPV1 expression is 
concentrated at filopodia tips where the channel mediates filopodia formation (Goswami and 
Hucho, 2007).  TRPV1 can mediate migration of pulmonary arterial smooth muscle cells through 
actin rearrangement (Martin et al., 2012).  As I have shown that TRPV1 activation can modulate 
astrocyte migration (Chapter 3) and that calcium influx via TRPV1 is involved in this process 
(Chapter 4), this chapter will examine the effects of TRPV1 on cytoskeletal dynamics in 
astrocytes following injury. 
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5.2 Methods 
Western blots 
Primary cell isolations and scratch wound were performed as described in Chapter II and 
III.  Western blotting was performed as described in Chapter II with the following modifications.   
Cells were grown on 6-well plates until confluent, and then serum starved in 0.5% FBS.  Cells 
were pre-incubated for 15 minutes with 5 μM CPZ prior to scratch.  Four parallel wounds with 
200 µL pipet tips were made through the astrocyte culture. Cells were washed and incubated 
with 5 μM CPZ in astrocyte media with 0.5% FBS.  Protein lysates were collected and 
concentrations were measured as previously described in Chapter II.  Western blots were 
performed with the following primary antibodies and concentrations: GFAP (EMD Millipore, 
Billerica, MA, 1:5000), GAPDH (Cell Signaling, Danvers, MA, 1:1000), actin (Sigma-Aldrich, 
St. Louis, MO, 1:2000), α-tubulin (Sigma-Aldrich, St. Louis, MO, 1:2000), tenascin C (Cell 
Signaling, Danvers, MA, 1:1000), Cdc42 (Santa Cruz, Dallas, TX, 1:500) and vinculin (Sigma-
Aldrich, St. Louis, MO, 1:2000).  Proteins were detected with the Li-Cor system as described in 
Chapter II. 
 
Immunocytochemistry 
The following modifications were made to the protocol for immunocytochemistry 
outlined in Chapter II.  Following scratch wound, retinal or optic nerve astrocytes were fixed in 
extraction buffer (1 mM EGTA, 1 mM MgCl2, 80 mM PIPES, 0.1% saponin, 3% 
paraformaldehyde) for cytoskeletal proteins (Howell et al., 2013) for 20 minutes at room 
temperature.  A test of different types of buffers showed that fixation in extraction buffer 
produced more intense cytoskeletal labeling than 4% paraformaldehyde with 1% glutaraldehyde, 
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while addition of 10% glycerol did not seem to produce a significant change (Figure 5.1).  
Primary antibodies used were anti-α-tubulin (Sigma-Aldrich, St. Louis, MO, 1:500; (Sorci et al., 
1998) and vinculin (Sigma-Aldrich, St. Louis, MO, 1:500).  Proteins were visualized with the 
appropriate DyLight-conjugated secondary antibodies (Jackson Immunoresearch, West Grove, 
PA 1:150).  Filamentous actin were labeled with Alexa Fluor 488-phalloidin (Life Technologies, 
Grand Island, NY, 1:150) in phosphate-buffered saline with 1% bovine serum albumin 
(Gionfriddo et al., 2009).  Staining with 4',6-diamidino-2-phenylindole (DAPI; Life 
Technologies, Grand Island, NY, 1:100) in water was also performed to visualize nuclei.  
Confocal images were taken as previously described and settings were kept constant for all 
treatments so that comparisons in fluorescence intensity could be made.  Measurements of cell 
size and intensity were done using ImageJ (Schneider et al., 2012). 
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Figure 5.1.   Effects of fixation on the preservation of the cytoskeleton.  Astrocytes were treated 
with vehicle or 10 µM CAP for 10 minutes (A) and 24 hours (B).  Cells were then fixed in 
extraction buffer (left), extraction buffer with 10% glycerol (center) or 4% paraformaldehyde 
with 1% glutaraldehyde (right) and then labeled for actin (green), -tubulin (red) and DAPI 
(blue) to observe cytoskeletal arrangement.     
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5.3 Results 
Effects of TRPV1antagonism on levels of proteins involved in migration  
Since TRPV1 can influence both migration and intracellular calcium in retinal astrocytes, 
I hypothesized that the channel also plays a role in the expression and localization of cytoskeletal 
components after injury.  I collected protein from cultures containing injured astrocytes at 12 
hours after scratch and naïve unscratched astrocytes and then performed Western blot analysis 
for cytoskeletal proteins and migration-related proteins (Figure 5.2).  I chose this time point 
based on the divergence of closure progression in our antagonist migration assays (Chapter 3) 
and on literature showing peak expression of GFAP and tenascin C secretion at 12 hours 
following scratch injury (Gao et al., 2013; Nishio et al., 2005). Vehicle treatment following 
scratch injury produced a slight non-significant increase in expression of the cytoskeletal 
components, α-tubulin, actin and GFAP, about 5- 13% compared to unscratched naïve astrocytes 
(p ≥ 0.147).  Similarly, the expression of proteins involved in focal adhesion and migration — 
tenascin C, Cdc42 and vinculin — was modestly increased 10-20% following scratch (p ≥ 
0.206).  Treatment with 5 μM CPZ reduced the expression of cytoskeletal and migration-related 
proteins 3-18% compared to vehicle (p ≥ 0.224), with the exception of GFAP which remained 
slightly elevated.   
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Figure 5.2.  Effects of TRPV1 antagonism on levels of cytoskeletal and migration-related 
proteins following injury.  Western blots (A) and quantification (B) demonstrates a trend towards 
increased expression of cytoskeletal proteins (-tubulin, actin and GFAP) and migration-related 
proteins (tenascin C, CDC42 and vinculin) in cultured astrocytes 12 hours after scratch injury for 
vehicle treatments compared to naïve.  Treatment with 5 μM CPZ had modest effects on 
expression of cytoskeletal and migration-related proteins compared to vehicle. 
 
Effects of TRPV1 antagonism on cell area and cytoskeletal components 
 Although multiple scratches were made through the astrocyte monolayer, protein lysates 
were collected from cells at both the leading edge and farther away from the injury site.  This 
might have minimized the changes in protein expression measured by Western blotting, so I used 
confocal microscopy to specifically examine cytoskeletal changes occurring in cells at the 
leading edge.  To determine if there are cytoskeletal changes in astrocytes located at the leading 
edge compared to cells farther from the injury site, I used confocal microscopy to visualize 
astrocytes at 36 hours following scratch wound with and without the addition of 5 and 10 µM 
CPZ (Figure 5.3).  Low magnification (10X) images show that astrocytes at the leading edge 
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display a distribution of F-actin and α-tubulin that was qualitatively similar to cells farther away 
from the wound edge for vehicle (Figure 5.3).  A similar distribution of cytoskeletal filaments is 
also seen in cultures treated with CPZ.  Treatment with 5 and 10 µM CPZ, however resulted in a 
larger cell-free area compared to vehicle, indicating that TRPV1 antagonists reduced the rate of 
migration as shown in Chapter III.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  Actin and tubulin expression with increasing distance from the injury. Confocal 
micrographs (10X) show astrocytes at 36 hours following injury for vehicle (A), 5 µM CPZ (B) 
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and 10 µM CPZ (C) and labeled for actin (green), a-tubulin (red) and DAPI (blue).  Dotted boxes 
indicate cell free area.   
 
Higher magnification (40X) images at the leading edge of the scratch injury reveal 
unique localization patterns for α-tubulin and F-actin (Figure 5.4). At 36 hours post-scratch, 
immunolabeling for α-tubulin in vehicle-treated cells appeared concentrated in the perinuclear 
region, with microtubules extending into astrocyte processes (Figure 5.4A and 5.4B, red).  F-
actin microfilaments distributed throughout the cytoplasm in parallel arrays that extended out 
into astrocyte processes (Figure 5.4A and 5.4B, green).  There was little co-localization between 
α-tubulin and F-actin.  Treatment with 10 μM CPZ appeared to reduce the size of the astrocytes, 
though the pattern of F-actin and α-tubulin labeling was similar to vehicle-treated cells (Figure 
5.4A).  Astrocytes treated with 3 μM IRTX did not appear to contract (Figure 5.4B), but both F-
actin and α-tubulin labeling appeared more intense with more extensive co-localization. When 
quantified in Figure 5.4C, addition of 5 and 10 μM CPZ reduced astrocyte cytoplasmic area by 
42% and 29%, respectively, relative to vehicle (p ≤ 0.003).  Although 3 μM IRTX also reduced 
cell area 12% relative to vehicle-treated cells, this was not significant (p = 0.20).  Levels of α-
tubulin were reduced by 17% with 10 μM CPZ (p = 0.006, Figure 5.4D), while IRTX had no 
significant effect (p = 0.078). In contrast, F-actin intensities were similar for CPZ compared to 
vehicle (p ≥ 0.11), but increased 26% for 3 μM IRTX (Figure 5.4D; p < 0.0001).   
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Figure 5.4.  Effects of TRPV1 antagonism on cell area and -tubulin and F-actin intensity.  
Confocal images (40X) show astrocytes near the leading edge 36 hours following scratch wound 
labeled for F-actin (green), -tubulin (red) and DAPI (blue) for vehicle and 10 µM CPZ 
treatments (A). Astrocytes treated with 3 µM IRTX after scratch injury have increased co-
localization of F-actin and a-tubulin (arrows; B).  Bar graph shows average astrocyte cytoplasmic 
area (C) normalized to vehicle for 5 and 10 µM CPZ and 3 µM IRTX treatments 36 hours post-
injury. *p < 0.003 compared with vehicle (n=51 cells). Bar graphs show the relative intensities of 
-tubulin (D) and F-actin (E) normalized to vehicle for CPZ and IRTX treatments. *p <  0.006 
compared with vehicle for -tubulin (n=51 cells); *p < 0.0001 compared with vehicle for F-actin 
(n = 84 cells).  All data: mean ± SEM. 
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Antagonism, but not agonism, of TRPV1 affects α-tubulin rearrangement following injury 
To better understand the changes in the subcellular localization of cytoskeletal proteins 
during injury-induced migration, I captured higher magnification (80X) confocal micrographs of 
α-tubulin in astrocytes at the leading edge of the scratch wound following treatment with TRPV1 
agonists or antagonists. Astrocytes treated with vehicle and immunolabeled for α-tubulin show 
clearly defined microtubules that radiate out from the MTOC near the nucleus and extend into 
cell processes at the leading edge (asterisk; Figure 5.5A).  This rearrangement of the MTOC 
toward the leading edge establishes cell polarity and directs migration toward the cell-free area 
(Robel et al., 2011a).  Higher magnification (240X) shows tubulin localization is most intense in 
processes extending toward the leading edge (Figure 5.5B). Cells treated with 1 nM CAP or 10 
nM RTX had a tubulin arrangement similar to that of vehicle with microtubules radiating from 
the MTOC that extend into the astrocyte processes.  A range of concentrations for TRPV1 
agonists was used to observe possible effects on α-tubulin and representative results are shown. 
(Figure 5.5).   
A comparable distribution of α-tubulin was observed in scratched astrocytes treated with 
vehicle in the antagonist experiments.  Representative images of cells treated with vehicle or 
antagonists at the leading edge are shown in Figure 5.6.  Again, microtubules radiated out from 
the MTOC and extended into astrocyte processes, thus directing cell migration to close the 
wound area. In cells treated with CPZ, microtubules are clearly defined near the MTOC, which is 
oriented toward the leading edge similar to what is observed in vehicle-treated cells (Figure 
5.6A). However, microtubules in individual processes near the leading edge appear less intense 
in CPZ-treated cells (Figure 5.6A).  Higher magnification (240X) of cells treated with 5 μM CPZ 
shows that closer to the edge of individual processes (dotted line, Figure 5.6B;) microtubules 
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appear less defined and take on a fragmented appearance that is exacerbated with a higher dose 
of CPZ (10 μM). Astrocytes treated with 3 μM IRTX had clearly defined microtubules extending 
from the MTOC into processes (Figure 5.6). The retraction and fragmentation observed with 
CPZ treatment was not observed in IRTX-treated cells. 
 
 
Figure 5.5.   Agonism of TRPV1 and subcellular localization of -tubulin. High magnification 
(80X) confocal images show astrocytes labeled for -tubulin (red) near the leading edge (*) of 
the wound after scratch injury (A). High magnification (240X) views of boxed areas are shown 
in B. Cells were scratched in the presence of vehicle, 1 nM CAP or 10 nM RTX and then fixed in 
an extraction buffer for cytoskeletal proteins before labeling. 
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Figure 5.6.  Antagonism of TRPV1 and retraction of -tubulin.  High magnification (80X) 
confocal images show astrocytes labeled for -tubulin (red) near the leading edge (*) of the 
wound after scratch injury (A).  High magnification (240X) views of boxed areas are shown in 
B.  Cells were scratched in the presence of vehicle, 5 µM or 10 µM CPZ, or 3 µM IRTX. Dotted 
lines represent cell edge. 
 
Antagonism, but not agonism, of TRPV1 affects actin rearrangement following injury 
In addition to tubulin, I also examined actin rearrangement at the leading edge following 
injury with and without TRPV1 modulation.  Labeling for F-actin in vehicle-treated astrocytes 
shows intense localization at filopodia extending toward the leading edge and cell periphery 
(Figure 5.7 and 5.8).  This reorganization of actin filaments following injury provides the 
contractile force necessary to drive cell migration (Le Clainche and Carlier, 2008).  A range of 
concentrations for TRPV1 agonists were used and representative figures are shown.  Addition of 
1 µM CAP had a modest effect on actin rearrangement (Figure 5.7), similar to the result seen 
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with tubulin.  Actin is localized throughout the cell and extended into the astrocyte processes.  A 
result similar to CAP treatment was obtained with 10 nM RTX.  Cells treated with RTX 
exhibited extensive actin expression throughout the soma and also in astrocyte processes (Figure 
5.7).   
In the antagonist experiments, injured astrocytes treated with vehicle demonstrated 
intense actin expression throughout the cell, especially in the cell periphery, that extended into 
the astrocyte processes.  Representative images of cells treated with vehicle and antagonists at 
the leading edge are shown in Figure 5.8.  In cells treated with CPZ, actin intensity appeared 
reduced, especially its localization to the leading edge (Figure 5.8A).  Higher magnification 
(240X) images of cells treated with 5 µM CPZ indicate that compared to vehicle, actin 
expression and intensity in astrocytes processes is reduced, which is exacerbated with 10 µM 
CPZ (dotted line, Figure 5.8B).  In cells treated with IRTX, F-actin intensity appeared similar to 
vehicle and extended into astrocyte processes but localization was more perinuclear and less 
pronounced near the cell periphery (Figure 5.8).  Together, these results indicate that with injury, 
TRPV1 activation is associated with moderate cytoskeletal remodeling in astrocytes at the 
leading edge.  
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Figure 5.7.  Agonism of TRPV1 and the subcellular localization of actin. High magnification 
(80X) confocal images show astrocytes labeled for actin (green) near the leading edge (*) of the 
wound after scratch injury (A). High magnification (240X) views of boxed areas are shown in B. 
Cells were scratched in the presence of vehicle, 1 nM CAP or 10 nM RTX. 
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Figure 5.8. Antagonism of TRPV1 and retraction of actin.  High magnification (80X) confocal 
images show astrocytes labeled for actin (green) near the leading edge (*) of the wound (A). 
High magnification (240X) views of boxed areas are shown in B.  Cells were scratched in the 
presence of vehicle, 5 µM or 10 µM CPZ, or 3 µM IRTX and then fixed in an extraction buffer 
for cytoskeletal proteins before labeling. Dotted lines represent the cell edge. 
 
Knockout of TRPV1 has modest effects on cytoskeletal rearrangement following injury 
 To complement the pharmacological experiments, I next determined whether knockout of 
TRPV1 affected cytoskeletal rearrangement in optic nerve astrocytes 24 hours following scratch 
injury.  Although these astrocytes were isolated from optic nerves and the astrocytes used in the 
pharmacological experiments were isolated from retina, both cell populations exhibited a similar 
tubulin orientation following injury.  Astrocytes from C57 mice displayed an intense distribution 
of microtubules radiating from the MTOC and extending into the leading edge of astrocytes 
(Figure 5.9A).  Higher magnification (240X) images of the leading edge (Figure 5.9B, C) show 
microtubules extending out to the edges of the processes.    Following scratch injury, -tubulin 
distribution in TRPV1-/- astrocytes resembled that observed in C57 astrocytes (Figure 5.9).  
Microtubules appeared less intense in TRPV1-/- astrocytes, yet there did not appear to be 
retraction or fragmentation within the astrocyte processes as seen with CPZ treatment (Figure 5.6 
and Figure 5.9).  Next, I determined whether TRPV1 knockout affected actin rearrangement in 
astrocytes following injury (Figure 5.10).  Actin filaments in C57 wild-type astrocytes at 24 
hours post-scratch were localized throughout the cell and extended into astrocyte processes 
(Figure 5.10).  Again, actin distribution in C57 optic nerve astrocytes was comparable to that 
observed in retinal astrocytes (Figures 5.8 and 5.10).  Actin intensity appeared diminished in 
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TRPV1-/- astrocytes (Figure 5.10), although actin did not appear to retract at the leading edge as 
it did with CPZ treatment (Figure 5.8).  
 
 
Figure 5.9.  Effects of TRPV1 knockout on the subcellular localization of -tubulin. High 
magnification (80X) confocal images show astrocytes labeled for -tubulin (red) near the 
leading edge (*) of the wound (A). High magnification (240X) views of boxed areas are shown 
(B and C).  
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Figure 5.10. Effects of TRPV1 knockout on the localization of actin. High magnification (80X) 
confocal images show astrocytes labeled for actin (green) near the leading edge (*) of the wound 
after scratch (A). High magnification (240X) views of boxed areas are shown (B and C).  
 
Antagonism of TRPV1 reduces the number of focal adhesions 
 Focal adhesions link the cytoskeleton of a cell to the extracellular matrix to help mediate 
adhesion.  Since focal adhesion formation can be modulated by calcium, I next determined 
whether injury and TRPV1 modulation affected expression of vinculin, a protein present in the 
focal adhesion complex. In naïve (unscratched) retinal astrocytes that are confluent, vinculin 
expression is punctate and distributed within the cell body and along cell edges (Figure 5.11).  
Following injury in astrocytes treated with vehicle, vinculin appeared to distribute more toward 
the cell periphery or along cell-to-cell borders.  Vinculin distribution appeared similar in RTX-
treated cells.  However, in injured astrocytes treated with IRTX, vinculin expression was 
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diminished.  These results suggest that TRPV1 antagonism might reduce focal adhesion 
expression in astrocytes following injury.       
 
 
Figure 5.11.  Effects of TRPV1 on vinculin expression following injury.  Naïve astrocytes or 
injured astrocytes at 24 to 36 hours treated with vehicle, 1 µM IRTX or 1 µM RTX were labeled 
for vinculin (green) and DAPI (blue). 
 
5.4 Discussion 
 This chapter examined the role of TRPV1 in modulating cytoskeletal rearrangement in 
astrocytes following injury. Antagonism of TRPV1 induced moderate cytoskeletal rearrangement 
– CPZ reduced astrocyte cell area and decreased α-tubulin levels, while IRTX increased actin 
levels (Figure 5.4).  Addition of CPZ also resulted in actin and tubulin retraction within astrocyte 
processes, an effect not seen with IRTX treatment (Figures 5.6 and 5.8).  Treatment with the 
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TRPV1 agonists only had minimal effects on actin and tubulin subcellular rearrangement 
(Figures 5.5 and 5.7).  Cytoskeletal rearrangement following injury was similar in optic nerve 
astrocytes from C57 mice compared to rat retinal astrocytes (Figures 5.5 to 5.10).  Knockout of 
TRPV1 only slightly reduced actin intensity compared to C57 astrocytes (Figure 5.9 and 5.10).  
Finally, preliminary results suggest that IRTX might also reduce focal adhesion formation in 
astrocytes following injury (Figure 5.11). 
 TRPV1 is a cation channel with a high calcium permeability, and calcium regulates 
multiple downstream signaling cascades that influence cytoskeletal remodeling (Ridley et al., 
2003).  It is not surprising therefore, that TRPV1 has been shown to modulate cytoskeletal 
rearrangement in various systems. For example, activation of TRPV1 by capsaicin can lead to 
cytoskeletal remodeling involving rearrangement of F-actin and tubulin networks (Goswami et 
al., 2006; Martin et al., 2012).  The C-terminus of TRPV1 can bind both tubulin dimers and 
polymerized microtubules in a calcium-mediated manner (Goswami et al., 2004).  In a 
submandibular gland cell line, capsaicin induces cytoskeletal rearrangement by decreasing the 
amount of actin and increasing the space between each filament (Cong et al., 2013).  In 
pulmonary smooth muscle cells and neutrophils, however, capsaicin increased actin levels but 
had no significant effect on the tubulin cytoskeleton (Martin et al., 2012; Wang et al., 2005a).  
TRPV1 also localizes to the tips of filopodia and induces filopodia formation and microtubule 
disassembly in a dorsal root ganglia cell line (Goswami et al., 2006; Goswami and Hucho, 2007).  
Inhibition of TRPV1 following scratch-wound increased F-actin levels but decreased α-tubulin in 
migrating astrocytes (Figure 5.4).  Higher magnification images of astrocytes at the leading edge 
following TRPV1 antagonism showed microtubule fragmentation and retraction from the cell 
edge (Figure 5.6 and 5.8) suggesting TRPV1 modulates cytoskeletal rearrangement and 
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subcellular localization after injury.  Although actin intensity might be diminished in TRPV1-/- 
astrocytes, there was no apparent microtubule or actin retraction following scratch injury (Figure 
5.9 and 5.10).  This might be due to genetic or developmental compensation, or through 
pathways not mediated by TRPV1.  The lack of discernable cytoskeletal changes between C57 
and TRPV1-/- suggests that TRPV1 might only have a modest role in the development of the 
cytoskeleton.    
 Although the focus of this chapter is on modulation of actin and microtubule proteins by 
TRPV1, there is some evidence that TRPV1 might also modulate intermediate filaments.  In 
pulmonary arterial smooth muscle cells, the network of vimentin filaments localized to the 
perinuclear region and density was increased with capsaicin (Martin et al., 2012).   Following 
induction of inflammatory and neuropathic pain, GFAP expression was significantly reduced in 
TRPV1-/- animals (Chen et al., 2009).   TRPV1 activation with capsaicin can also increase 
GFAP expression in the retina (Leonelli et al., 2010).  This suggests that TPRV1 might also 
modulate intermediate filament rearrangement.  Although changes in GFAP levels were not 
observed with Western blots (Figure 5.2), there might be changes in the spatial distribution and 
organization of intermediate filaments that were not detected.  One possible experiment is to use 
high magnification imaging to observe changes in the distribution of intermediate filaments 
following scratch injury and whether this is affected with TRPV1 pharmacological agents.  CPZ 
induced retraction of actin and tubulin from astrocyte processes even though changes in the 
levels were not observed with Western blots (Figure 5.2).  This suggests that although total 
GFAP levels were not affected by injury or CPZ, there might be changes in the spatial 
distribution of GFAP within the cell following injury.       
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In order for a cell to migrate, it must form cell protrusions, establish directionality, and 
contact and adhere to the extracellular matrix.  I examined the expression of CDC42, a protein 
that mediates protrusion formation and polarity, in injured astrocytes with and without TRPV1 
modulation.  Scratch injury did not significantly affect total levels of CDC42 (Figure 5.2).  
Future experiments, however, could examine CDC42 localization and active state rather than 
protein levels.  Following scratch injury, GFP-tagged CDC42 localizes to the leading edge of 
astrocytes (Osmani et al., 2010).  It would be interesting to determine whether a similar change 
in CDC42 localization is observed in my astrocyte cultures and if this is mediated by TRPV1.  
High magnification imaging would be useful in elucidating changes in CDC42 localization 
following injury and with TRPV1 modulation.  CDC42 is a Rho GTPase that is active when 
bound by GTP and inactive when bound by GDP (Etienne-Manneville and Hall, 2002).  CDC42 
activity can be analyzed by precipitating GTP-bound CDC42 and then immunoblotting to 
determine levels.  One possible future direction would be to determine changes in levels of GTP-
bound CDC42 following scratch injury or with TRPV1 modulation.    
Tenascin C is an extracellular matrix glycoprotein that mediates cell adhesion. 
Expression of this protein is increased in astrocytes following injury, although I did not observe 
this in my western blot (Figure 5.2).  Again, high magnification imaging of tenascin C within the 
cell following scratch injury and with TRPV1 modulation may better determine the role of this 
protein in injury-induced migration.  Tenascin C can also bind fibronectin, an extracellular 
matrix protein (Ghert et al., 2001).  In trigeminal neurons, TRPV1 colocalizes with integrins, 
which bind fibronectin to regulate cell adhesion (Jeske et al., 2009a). Fibronectin has been 
shown to activate src kinase to phosphorylate and increase expression of TRPV1 at the plasma 
membrane (Jeske et al., 2009a). TRPV1 contains multiple phosphorylation sites and is highly 
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regulated by phosphorylation.  My data suggests antagonism of TRPV1 might reduce expression 
of vinculin, suggesting TRPV1 may mediate changes in cell adhesion (Figure 5.11).  Since 
TRPV1 phosphorylation can influence expression at the plasma membrane and TRPV1 
colocalizes with integrins, it would be interesting to observe whether there are changes in 
TRPV1 phosphorylation following injury and whether this affects integrin expression and 
localization, thereby affecting focal adhesion formation.   
TRPV1 could mediate cytoskeletal changes during migration via proteins and pathways 
that are activated by calcium.  One such protein is calpain, a calcium-dependent protease. 
Calpains can cleave focal adhesion kinase and talin, a protein that links the actin cytoskeleton to 
focal adhesions to regulate cell adhesion (Chan et al., 2010; Franco et al., 2004).  Calpain 
activation can also lead to focal adhesion turnover and disassembly to promote cell detachment 
from the extracellular matrix (Ramirez et al., 2001). Inhibitors of calpains reduce cell migration 
by stabilizing focal adhesions and reducing the rate of cell detachment from the extracellular 
matrix (Bhatt et al., 2002; Huttenlocher et al., 1997).  TRPV1 modulation of calpain activity in 
injury-induced gliosis to facilitate migration is quite possible, as calpain-mediated adhesion can 
be influenced by localized calcium entry through TRPM7, another member of the TRP family 
(Su et al., 2006).  In my experiments, antagonism of TRPV1 might reduce expression of 
vinculin, a protein present in the focal adhesion complex, suggesting that TRPV1 might also be 
mediating cell adhesion (Figure 5.11).  Astrocytes express calpains, and levels increase in 
reactive astrocytes (Konig et al., 2003; Li et al., 1996; Shields et al., 1998).  Since calpains are 
known to modulate focal adhesion dynamics, TRPV1 activation and the subsequent increase in 
calcium might lead to calpain activation to regulate vinculin expression.  One possible 
experiment would be to determine if calpain expression and activity is increased following 
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scratch injury and whether this is modulated by TRPV1.  Expression could be observed with 
immunolabeling or Western blots, and calpain activity can be determined by the production of 
calpain cleavage products.   It would also be interesting to determine whether calpain inhibitors 
affect vinculin expression following scratch injury.  
 This chapter examines the cytoskeletal changes that occur following scratch injury and 
with TRPV1 modulation.  Although the levels of various proteins involved in migration were not 
significantly changed, the spatial localization and orientation of the cytoskeleton was altered 
with TRPV1 inhibition.  Addition of TRPV1 antagonists induced retraction of actin and tubulin 
from astrocyte processes as well as reduced the presence of focal adhesions.  This suggests that 
TRPV1-mediated changes in cytoskeletal dynamics might contribute to reduced astrocyte 
migration after injury. 
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CHAPTER VI 
 
DISCUSSION AND CONCLUSION 
 
 6.1 Discussion 
 Motility is one component of the astrocyte stress response and a functional consequence 
of reactivity.  In order for a cell to migrate effectively, a convergence of signaling pathways 
occurs to mediate aspects of migration including protrusion of the leading edge, cell contraction 
and adhesion.  Calcium serves as an important signaling regulator of migration by modulating 
cytoskeletal rearrangement and focal adhesion dynamics.  Because calcium is an essential second 
messenger under both physiological and pathophysiological conditions, astrocytes express 
multiple channels and receptors including TRPV1 to regulate calcium levels.      
 Our lab has found that TRPV1 is an important component of the intrinsic stress response 
of RGCs.  Although the channel is also expressed in retinal astrocytes, its function there is 
unknown.  The purpose of this dissertation was to elucidate the role of TRPV1 in modulating an 
aspect of the astrocyte stress response – migration and the mechanisms that contribute to this 
phenomenon.  Since relatively little is known regarding the role of TRPV1 in astrocytes, Chapter 
II provided a detailed characterization of TRPV1 expression in retinal and optic nerve astrocytes.  
Although TRPV1 is expressed throughout mouse and rat astrocytes in the retina, its expression in 
the optic nerve is species-dependent and ranged from diffuse to punctate.  With the expression of 
TRPV1 in astrocytes established, the purpose of Chapter III was to elucidate the contribution of 
TRPV1 to astrocyte migration.  Using the scratch wound model, I found that antagonism of 
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TRPV1 reduced astrocyte migration while agonism had minimal effect.  This suggests a possible 
ceiling effect and that the scratch itself or the injury milieu might be activating TRPV1.  Injury-
induced astrocyte migration was dependent on extracellular calcium. Since calcium is important 
in migration and TRPV1 is a channel with a high calcium conductance, calcium dynamics in 
astrocytes were examined in Chapter IV.  While TRPV1 had modest effects on astrocyte calcium 
influx under physiological conditions, injury induced an increase in intracellular calcium that 
was attenuated with TRPV1 antagonism but not microtubule stabilization.  Calcium is also an 
important regulator of cytoskeletal rearrangement; therefore Chapter V examined the effects of 
TRPV1 modulation on cytoskeletal dynamics following injury.  TRPV1 antagonism caused 
retraction of actin and tubulin from the leading edge, while agonism had minimal effects. 
 One observation that is prevalent throughout this dissertation is the disparate effects of 
CPZ and IRTX, both well-characterized TRPV1 antagonists.  While CPZ and IRTX both 
reduced migration, IRTX caused a greater reduction in calcium influx and CPZ induced more 
cytoskeletal retraction from the leading edge.  Possible explanations for these differences 
between the two antagonists have been discussed in Chapter IV.  In addition, although TRPV1 
has a high selectivity for calcium, TRPV1 has been shown to mediate sodium influx in cortical 
astrocytes (Huang et al., 2010).  It is possible that the events downstream of CPZ treatment 
might be mediated by an influx of sodium. Unlike calcium, sodium is not widely regarded as an 
important second messenger but has been shown to mediate migration.  Blocking or down-
regulation of voltage-gated sodium channels by tetrodotoxin or siRNA respectively, can reduce 
migration of aortic smooth muscle cells (Meguro et al., 2009).  The sodium-hydrogen 
transporter, NHE1 is localized to the lamellopodia in fibroblasts, where it mediates cytoskeletal 
anchoring, polarity and focal adhesion dynamics (Denker and Barber, 2002).  This suggests that 
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sodium influx can mediate migration.  The modest change in calcium as well as the greater 
cytoskeletal retraction observed in retinal astrocytes with CPZ addition might due to an influx of 
sodium, and warrants further analysis. Furthermore, sodium is important in establishing 
membrane potential.  Influx of sodium would depolarize the cell to activate voltage-gated 
channels including ones that are selective for calcium. Moreover, although CPZ has been used 
extensively to study TRPV1 function and TRPV1-mediated effects on migration, CPZ has been 
shown to have non-TRPV1 mediated effects.  CPZ can also bind voltage-gated calcium channels, 
TRPM8 and nicotinic acetylcholine receptors (Docherty et al., 1997; Malkia et al., 2009).        
 In addition to the differential effects of TRPV1 antagonists, another prevalent result 
throughout the dissertation is the modest effects observed with TRPV1-/- astrocytes.  Astrocytes 
from TRPV1-/- mice were isolated to supplement the pharmacological experiments.  Unlike 
astrocytes in the presence of TRPV1 antagonists, TRPV1-/- astrocytes did not exhibit changes in 
migration, calcium or cytoskeletal retraction following injury when compared to wild-type 
astrocytes.  This might be due to genetic compensation by other channels.   For example, 
astrocytes express other TRP channels, including members of the TRPC family that mediate 
calcium influx  (Verkhratsky et al., 2014).   Also, the cultures used in the pharmacological and 
knockout experiments were fundamentally different.  The pharmacological experiments utilized 
astrocytes isolated from post-natal rat retinas while the knockout experiments used astrocytes 
from young adult mouse optic nerves.  Although both pools of cells are astrocytes, inherent 
differences exist between the two populations (see Chapter II discussion).  One interesting 
avenue of investigation would be to determine the functional differences between retinal and 
optic nerve astrocytes.  For example, the TRPV1 pharmacological experiments can be repeated 
with rat optic nerve astrocytes.  TRPV1 antagonists reduced migration and calcium influx and 
167 
 
caused cytoskeletal retraction in rat retinal astrocytes.  It would be interesting to determine if the 
same results are observed in rat optic nerve astrocytes.  A similar approach can be taken with 
mouse retinal astrocytes.  Alternatively, inducible knockouts of TRPV1 or siRNA-mediated 
TRPV1 knockdown can be used to overcome potential genetic compensation.  It is also possible 
that TRPV1 might only have a modest role in astrocytes, and the effects seen are mediated by 
other channels or receptors.              
 Despite the points described above, the results presented in this dissertation suggest a role 
for TRPV1 in modulating astrocyte migration via calcium influx and cytoskeletal dynamics 
following injury (Figure 6.1).  Following scratch injury, TRPV1 is activated, most likely by 
endogenous activators within the injury milieu like endocannabinoids or pH changes.  This 
induces an influx of calcium that leads to a relocalization of actin and tubulin within the cells.  
Other mediators of migration like tenascin C, CDC42 and vinculin can relocalize to the leading 
edge.  Ultimately, these events drive cell migration.     
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Figure 6.1.  Intracellular changes that occur to modulate cell migration.  Following injury, 
TRPV1 channels open to increase intracellular calcium.  Calcium mediates cytoskeletal 
rearrangement and localization of migration proteins to influence motility.   
 
6.2 Conclusion 
Astrocyte migration can be modulated by TRPV1, a channel known for sensing 
extracellular stimuli and mediating cellular responses.  Previous studies by our lab have shown 
that in a model of optic neuropathy, TRPV1 is neuroprotective in RGCs.  Astrocyte reactivity 
and neuronal loss underlie many neurodegenerative diseases, and extensive communication 
exists between the two cell types.  Since TRPV1 mediates stress responses in both RGCs and 
astrocytes, modulating TRPV1 activity might serve as a viable therapeutic option to target both 
neuronal and glial functions in disease.  Reducing glial reactivity and migration while increasing 
neuronal survival could significantly improve outcomes in neurodegenerative diseases.   
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